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Abstract 
 
Renal ischaemia-reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) 
which is in turn the leading cause of morbidity and mortality in hospitalized patients. The 
principle aim of this thesis was to evaluate potential new therapies that might afford 
protection against IRI in both in vitro and in vivo settings.  
 
Recent evidence suggests that nitrite (NO2
-) may play an important role in protecting the 
myocardium from IRI. Our initial work into the role of NO2
- in an in vitro model of renal 
IRI in proximal tubular epithelial cells provided evidence that NO2
- can prevent 
apoptosis and preserve cell viability. This lead to an in vivo study where high NO2
- 
concentrations (50 mg/L) were given orally to rats for 7 days prior to inducing renal IRI 
but no beneficial effects of this treatment were observed.  
 
Another potential treatment identified was thiamine (vitamin B1) and this, like NO2
-was 
investigated to see if it had the potential to protect rats from AKI injury. It has been 
previously recognized that in renal IRI the high energy phosphate ATP is found to be 
severely depleted whilst is is known that thiamine can play a pivotal role in generating 
ATP. Furthermore, thiamine has previously been demonstrated to protect against 
myocardial ischaemic injury and has the ability to reduce myocardial infarct size. In 
vitro, thiamine was found to reduce the degree of apoptosis in cultured HK-2 cells 
caused by ischaemia whilst in vivo it afforded protection against AKI caused by renal IRI 
by anti-apoptotic, anti-inflammatory and anti-oxidant mechanisms.  
 
  
16 
 
Finally, a study into the possible therapeutic role of gene therapy with bone 
morphogenic protein 7 (BMP-7) in renal IRI was undertaken. Previous work has 
established that i.v. BMP-7 is able to protect against renal IRI but it has also been 
associated with ectopic bone formation at the site of injection. Therefore another 
method to increase circulating BMP-7 was sought. We initially found that BMP-7 gene 
therapy could attenuate apoptosis and preserves cell viability in an in vitro model of 
renal IRI. However, whilst in vivo gene therapy with electroporation of BMP-7 plasmid 
DNA increased BMP-7 expression in mice serum 2 days post electroporation, it was 
unable to protect the animals against IRI induced AKI. In rats the direct injection of 
naked DNA BMP-7 plasmid systematic 2 days prior to renal IRI was able to upregulate 
BMP-7 expression 4 days later in kidney tissue. Despite this it was unable to afford 
protection against renal IRI. 
Apoptosis and necrosis play a crucial role in the pathogenesis of renal IRI induced AKI. 
In this thesis we investigated the role of three putative therapeutic agents and their role 
in apoptosis and necrosis in vitro in PTECs and in vivo against renal IRI induced AKI. All 
three therapeutic drugs were able to attenuate apoptosis in PTECs but were unable to 
protect against necrosis, whilst against renal IRI induced AKI only thiamine was found to 
be protective. Thiamine appears to hold the most promise and more work needs to be 
undertaken so that its potential benefit in AKI can be realised.  
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1.1: Acute kidney injury (AKI) 
 
Acute Kidney Injury (AKI) was previously known as Acute Renal Failure (ARF) (Webb 
and Dobb, 2007) and is characterized by a rapid reduction in kidney function resulting in 
a failure to maintain fluid, electrolyte and acid-base homoeostasis and is typically 
diagnosed by an accumulation of end products of nitrogen metabolism (urea and 
creatinine) or decreased urine output, or both. This complex condition can be due to (i) 
pre-renal AKI (in around 55% of cases), involving diseases that can cause renal 
hypoperfusion leading to renal dysfunction without renal parenchymal damage (ii) 
intrinsic AKI (40%), including disease that directly insults the renal parenchyma; and 
(iii) post-renal AKI (5%), resulting from diseases associated with urinary tract 
obstruction (Brady, 1998).The major cause of intrinsic AKI is acute tubular necrosis 
(ATN) which is caused by ischaemic injury or a toxic insult to the kidney caused by 
varied distinct pathomechanisms (Webb and Dobb, 2007).It results in severe and 
persistent hypoperfusion of the kidneys (as seen in pre-renal AKI).  
 
AKI is a common, harmful, and life threatening condition which may be treatable if 
detected early. A minor reduction in the kidney function has a detrimental effect on the 
prognosis of AKI (Chertow et al., 1998). It is clinically important to detect and treat AKI 
as this may improve outcomes. Recently two similar deﬁnitions of AKI based on serum 
creatinine and urine output (RIFLE and AKIN) have been proposed and validated. 
Firstly, the Acute Dialysis Quality Initiative Group (Bellomo et al., 2004) has classified 
AKI according to the severity and duration of degree of acute renal dysfunction. This 
classification of AKI is known as RIFLE criteria (Table 1).  
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Table 1: AKI classification according to RIFLE category (Bellomo et al., 2004) 
RIFLE 
Category 
 
Serum creatinine 
 or GFR criteria 
Urine output (UO) 
criteria  
Risk  
(R) 
Increased creatinine x 1.5  
or GFR decrease > 25% 
 
UO < 0.5 mL/kg/h  6 h 
 
Injury  
(I) 
Increased creatinine x 2 
or GFR decrease > 50% 
 
UO < 0.5 mL/kg/h  12 h 
 
Failure  
(F) 
Increased creatinine x 3 
or GFR decrease > 75%            
or an absolute serum creatinine  354 
mol/L with an acute rise of at least 44 
mol/L  
 
UO < 0.3 mL/kg/h  24 h 
or anuria  12 h 
 
Loss 
(L) 
Persistent ARF = complete loss of renal 
function > 4 weeks 
 
 
 
ESRD 
(E) 
Complete loss of renal function > 3 
months 
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Secondly, the Acute Kidney Injury Network (AKIN) group (Mehta et al., 2007) has 
proposed rectifications to the RIFLE criteria. They are as follows in Table 2: 
 
Table 2: AKIN criteria (Mehta et al., 2007). 
Stage 1 Increase in serum creatinine  26.2 mol/L          
or increase to  150 – 199% (1.5 – 1.9 
fold) from baseline 
 
UO<0.5 mL/kg/h  6 h 
Stage 2 Increase in serum creatinine to 200 – 
299% (>2 – 2.9 fold) from baseline 
 
UO<0.5 mL/kg/h 12 h 
 
Stage 3 Increase in serum creatinine to  300% ( 
3-fold) from baseline or serum creatinine  
354 mol/L with an acute rise of at least 
44 mol/L or initiation of RRT 
UO<0.3 mL/kg/h 24 h 
or anuria  12 h 
 
 
Multiple studies have shown the validity of both RIFLE and AKIN criteria to identify the 
groups of hospitalised patients that have an increased risk of death and/or need for 
renal replacement therapy (RRT) (Hoste et al., 2006, Uchino et al., 2006, Ostermann 
and Chang, 2007, Bagshaw et al., 2008, Joannidis et al., 2009, Thakar et al., 2009). 
One study has directly compared RIFLE criteria with and without the AKIN modiﬁcation 
(Joannidis et al., 2009) and showed that AKI classiﬁed by either criterion was 
associated with similarly increased hospital mortality rates. Surprisingly, the two sets of 
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AKI criteria detected diverse patients. The RIFLE criteria did not detect 9% of patients 
that were detected by AKIN criteria. Likewise, the AKIN criteria missed 26.9% of the 
patients detected by RIFLE criteria. Most of the cases found by RIFLE criteria and 
missed by AKIN included 30% RIFLE-Injury(R-I) and 18% RIFLE-Failure (R-F). While 
the patients detected by AKIN and missed by RIFLE were 90% in stage 1. Mortality rate 
of patient detected by RIFLE and missed by AKIN was R-I group 37% and R-F group 
41%, but mortality rate of patients detected by AKIN stage 1 and missed by RIFLE was 
twice high when compared with patients without AKI. This analysis therefore identified 
the importance of using both sets of criteria for the diagnosis and staging of AKI 
(Joannidis et al., 2009, John, 2012, Citerio et al., 2013). 
 
The loss of tubular epithelial cells, a dilated and flattened epithelium, and the presence 
of Tamm-Horsfall protein-rich casts are the main histological findings in ischaemic AKI. 
This may be caused by IRI of the kidney due to kidney transplantation (Aydin et al., 
2007), sepsis (Ahlstrom et al., 2006, Ronco et al., 2008), cardiopulmonary (Mangano et 
al., 1998) and aortic bypass surgery (Kazmers et al., 1997). AKI is very common in 
critically ill patients and all other hospital based patients and is often secondary to extra 
renal events and is the leading cause of morbidity and mortality in all hospitalised 
patients (Bonventre, 1993). Furthermore, research indicates that hospitalised patients 
who develop AKI have a poor prognosis with mortality ranging from 10% to 80% (Hou et 
al., 1983, Shusterman et al., 1987). It has now been recognised that even a very small 
rise in serum creatinine in a variety of clinical settings is associated with a likely 
outcome of AKI (Praught and Shlipak, 2005). Multiple studies show that the population 
incidence of AKI in the UK ranges from 172 per million population (pmp) per year from 
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early data up to 486-630 pmp/year identified more recently (Feest et al., 1993, Stevens 
et al., 2001, Hegarty et al., 2005). Furthermore, the mortality rate is around 50% in 
patients with AKI and multiple organ failure and if RRT is required the mortality reaches 
around 80% (Liano et al., 1998). The mortality rate is further enhanced by severe 
complications of AKI such as sepsis, bleeding and respiratory failure (Levy et al., 1996). 
A Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) 
study involving patients with multi-organ dysfunction or failure indicates that the all-
cause mortality by day 60 after admission was 51% - 54% (Palevsky et al., 2008). A 
recent study involving 2,901 patients from 17 Finnish Intensive Care Units (ICU) 
showed an AKI incidence rate of nearly 40%. Hypovolemia, diuretics, artiﬁcial colloids 
and CKD were identiﬁed as major independent risk facts for developing AKI in ICU. This 
study further showed that the reversibility of AKI is highly dependent on its stage at 
presentation. There is 30% resolution on the following day for AKI stage 1 and 87% AKI 
persistence in patients with stage 3 (Nisula et al., 2013, Citerio et al., 2013). Despite 
recent advances in our understanding of AKI and its pathogenesis the therapeutic 
options for such patients are very limited.  
 
Research has been conducted in order to identify novel early biomarkers for AKI such 
as serum neutrophil gelatinase associated lipocalin (NGAL), IL-18, cystatin-c and KIM-
1. NGAL is an iron-transporting protein (Bao et al., 2010) that is produced in the kidney 
distal nephron and many other tissues and organs and is normally filtered and 
reabsorbed by the proximal tubule. Iron has been proposed to play an important role in 
protecting the proximal tubule from injury. Studies suggest that intravenous (i.v) 
administration of purified recombinant NGAL results in uptake by proximal tubular cells 
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where it enhances proliferation, attenuates apoptosis and provides significant functional 
and pathological protection in murine models of renal IRI (Mishra et al., 2004, Mori et 
al., 2005, Bonventre and Yang, 2011, Citerio et al., 2013). NGAL as a maker has been 
shown to be able to help in detecting the occurrence of AKI after 48 h, before any 
significant increase of serum creatinine was seen and has also indicated the 
requirement of RRT in critically ill patients (Cruz et al., 2010). Its main drawback as a 
marker is the influence of systemic inflammation and the resulting increase in serum 
NGAL concentrations even in the absence of AKI (Martensson et al., 2010). Further 
research shows that NGAL does not seem to be effective as an early marker in critically 
ill patients suffering from contrast-induced AKI (Valette et al., 2013). 
 
Urinary NGAL was once considered to be a reliable parameter for detecting AKI with 
sepsis (Bagshaw et al., 2010) but research conducted on 100 patients with systemic 
inflammation and the lowest stage of AKI found a lack of specificity for AKI prediction 
and a very weak link with RRT requirement (Glassford et al., 2013, Citerio et al., 2013). 
Urinary NGAL monomeric form is derived from neutrophils and renal tubular cells whilst 
NGAL homodimer is generated only by neutrophils whilst NGAL heterodimer is 
produced in the renal tubular cells only. Unfortunately there is currently no test available 
to evaluate heterodimer NGAL thereby limiting its diagnostic potential (Glassford et al., 
2013, Citerio et al., 2013).  
 
KIM-1 is a phosphatidylserine receptor in the proximal tubule that recognizes and 
directs apoptotic cells to lysosomes in proximal tubular cells. Furthermore, in the 
proximal tubular cells KIM-1 mediates the phagocytosis of necrotic cells and oxidized 
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lipoproteins (Bonventre and Yang, 2011). Recent studies demonstrate that KIM-1 
facilitates the clearance of apoptotic debris from the tubular lumen and may play an 
important role in limiting the immune reaction by phagocytosis of apoptotic bodies. This 
might be a mechanism for limiting the pro-inflammatory response (Ichimura et al., 2008, 
Citerio et al., 2013, Bonventre and Yang, 2011). Research suggest that the ectodomain 
of KIM-1 can shed into the urine of human and rodent kidneys with renal injury and can 
serves as a biomarker for the early diagnosis of AKI in humans and rodents (Bonventre 
and Yang, 2002, Bonventre and Yang, 2011). However, despite all these new 
biomarkers currently under study for the early detection of AKI, serum creatinine is still 
considered clinically as a biomarker for AKI diagnosis (Praught and Shlipak, 2005, 
Khwaja, 2012). 
 
The management of AKI is dependent on the identification and treatment of the 
underlying cause. This routinely includes the avoidance of substances that are toxic to 
the kidneys known as nephrotoxins. These include non-steroidal anti-inflammatory 
drugs (NSAIDs) such as ibuprofen, iodinated contrast media and antibiotics such as 
gentamicin. Although there is a significant amount of experimental research carried out 
on AKI with drugs like dexamethasone (Kumar et al., 2009), furosemide (Cantarovich et 
al., 2004), low dose dopamine (Bellomo et al., 2000), theophylline (Ix et al., 2004), 
erythropoietin (Patel et al., 2004), haemoxygenase inducer (Takahashi et al., 2004, 
Sikorski et al., 2004), hepatocyte growth factor (Nagano et al., 2004) and pyrrolidine 
dithiocarbamate (Chatterjee et al., 2003a) but none is documented as being an effective 
treatment for AKI. Stem cell therapy is a novel approach and research indicates that 
bone marrow stem cells have the ability to repair ischaemic renal tubular injury but the 
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clinical implementation of this procedure will take time (Kale et al., 2003).  
 
Briefly, there is an urgent need for novel specific strategies with respect to prevention, 
early identification and treatment of established AKI in order to significantly improve the 
dismal outcome of this clinical syndrome.  
 
1.2: Renal ischaemia reperfusion injury: 
 
1.2.1 Pathophysiology and basic mechanism 
 
One of the leading causes of AKI is renal ischaemia reperfusion injury (IRI). Renal IRI is 
caused by any impairment in the delivery of oxygen and nutrient to the kidney and any 
impairment in the removal of waste product from the kidney. Evidence suggests that in 
renal IRI there is a severe reduction in oxygen supply to tissue compared to its demand 
and accumulation of waste product of metabolism. Due to this imbalance the tubular 
epithelial cells progress to apoptosis and necrosis with organ functioning impairment of 
water and electrolytes balance and reduced excretion of waste products of metabolism. 
There are many known pathophysiological mechanisms that contribute to renal IRI 
(Bonventre and Yang, 2011).  
 
Normally, when there is a fall in renal perfusion pressure the kidneys maintain a 
relatively constant normal blood flow and GFR, even when the mean arterial pressure is 
as low as 80 mmHg. This property of the kidneys is known as autoregulation. This is 
achieved by the production of prostaglandins which cause a decrease in afferent 
arteriolar resistance and angiotensin II leading to an increase in efferent glomerular 
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arteriolar resistance (Abuelo, 2007). However, when renal perfusion pressure is very 
low, autoregulation is lost and afferent arteriolar constricts due to vasoconstrictors which 
leads to a significant decrease in renal blood flow and GFR, causing pre-renal 
azotaemia. This results in a decrease in blood flow and perfusion pressure in the post-
glomerular capillary bed which perfuses the renal tubules. With increasing severity and 
duration ischaemia causes structural and functional tubular injury and alteration in the 
microcirculation leading to the clinical syndrome of AKI. Co-morbid conditions such as 
hypertension, diabetes mellitus, CKD, atherosclerosis and NSAIDS cause an impaired 
afferent arteriolar vasodilatory response. Sepsis, hypercalcaemia, radiocontrast agent, 
calcineurin inhibitors can cause afferent arteriolar vasoconstriction as a primary 
response and angiotensin converting enzyme or angiotensin receptor blockers are 
associated with inability to increase efferent arteriolar resistance. All of the above 
mentioned conditions are associated with increased risk of AKI, even with moderate 
hypoperfusion (Abuelo, 2007).  
 
During renal ischaemia there is tubular dysfunction and impaired salt reabsorption 
(Kwon et al., 1999, Abuelo, 2007) that leads to an increase in sodium delivery which 
enhances glomerular vasoconstriction and decreases glomerular filtration rate (GFR) 
through tubuloglomerular feedback (TGF) (Brezis and Rosen, 1995). When there is 
increase of distal delivery of solutes to the macula densa it results in feedback signals to 
the glomerulus to decrease GFR by afferent arteriole constriction. After renal ischaemic 
injury, tubular epithelial cell reabsorption of sodium is impaired, which results in 
increased distal delivery of NaCl and subsequent activation of TGF. This decreased 
renal blood flow and GFR result in oliguria and, in severe cases, anuria (Srichai et al., 
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2008).  
 
The kidneys receive 25% of the cardiac output, the outer medullary region of the kidney 
is very vulnerable because it receives <10% of the blood delivered to the kidney via the 
vasa recta; the majority of that flow being directed to the renal cortex. The partial 
pressure of oxygen in the renal cortex is about 50 mmHg whilst in contrast the outer 
medulla has a partial pressure of oxygen in the 10 to 20 mmHg range (Brezis and 
Rosen, 1995). Recent evidence suggests that the enhanced vasoconstriction that 
occurs with small vessel occlusion is due to endothelial-leukocyte interactions caused 
by enhanced expression of ICAM-1 on damaged endothelial cells and their counter 
receptors on leucocytes and the activation of the coagulation system. This leads to a 
local compromise of the microcirculation and regional ischaemia, especially in the outer 
medulla. Furthermore, arteriolar vasoconstriction reduces the tubular blood flow to the 
outer medulla and is reduced further by local oedema (Bonventre and Yang, 2011). 
During ischaemic AKI, there is tubular necrosis in the outer stripe of the outer medulla 
(the straight portion of proximal tubules) and marked congestion in the inner stripe of 
the outer medulla (Bonventre, 1993). Furthermore the outer medullary region contains 
the S3 segment of proximal tubules and the medullary thick ascending limb of the loop 
of Henlé (TAL) and both of these are sensitive to hypoxia, but their role in renal IRI 
induced renal is unclear.  
  
Some data (Srichai et al., 2008) suggest that TAL epithelial cells had a five-fold higher 
blood urea nitrogen and creatinine levels upon induction of apoptosis in genetically 
engineered mice that received targeted injury. This study identifies that there is loss of 
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urine concentrating ability in these animals that resemble clinical AKI. Furthermore, 
sodium is reabsorbed in the TAL, which plays an important role in the kidneys capacity 
to concentrate urine and is necessary for maintaining the counter-current exchange 
mechanism by generating a hypertonic medullary interstitial. This medullary 
concentration gradient is lost with the loss of Na-K-2Cl co-transport in the TAL and 
ultimately leads to an inability to concentrate urine even in the presence of vasopressin 
(Srichai et al., 2008). Renal IRI can be seen to mimic clinical AKI with effects on renal 
tubular cells, endothelial cells and haematological cells (Friedewald and Rabb, 2004). 
 
During ischaemia, there is reduction or cessation of the blood supply to the kidney that 
causes hypoxia or anoxia. This insult leads to a massive depletion of adenosine 
triphosphate (ATP) and causes the release of catecholamines such as adrenaline, 
noradrenaline and dopamine which enhance contractility to thereby increase the blood 
flow to the tissue at risk. This leads to intracellular accumulation of ions such as Ca2+, 
Na+ and Cl- with an influx of water that causes the swelling of cells, particularly in the 
endothelial cells. Simultaneously, there is loss of fluid from the intravascular space 
resulting in increased blood viscosity which is further enhanced by the leukocytes and 
all these factors may interfere with the restoration of the microcirculation during 
reperfusion leading to capillary obstruction (no-reflow phenomenon) (Ames et al., 1968, 
Hakan Parlakpinar, 2013). ATP depletion during ischaemia stimulates many critical 
alterations in structure, metabolism and tubular dynamics which can cause apoptotic or 
necrotic cell death (Wiegele et al., 1998). These include depletion of cellular energy 
stores, disruption of the actin cytoskeleton, accumulation of intracellular calcium, 
accumulation of hypoxanthine, and generation of reactive oxygen species (ROS). 
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Ischaemic AKI can be sub-lethal resulting in tubular dysfunction, or lethal, resulting in 
cell death (Edelstein et al., 1997). Furthermore, like tubular cells, endothelial cells may 
also experience similar consequences leading to cellular malformations and endothelial-
erythrocyte interactions which enhance erythrocyte sludging in the ascending vasa recta 
(Friedewald and Rabb, 2004). All of this results in a massive reduction in substrate and 
oxygen delivery (Friedewald and Rabb, 2004, Mason et al., 1989). In addition, there is 
endothelial dysfunction and recruitment of inflammatory cells (see section 1.3) during 
ischaemia induced microcirculatory alterations and there is upregulation of intracellular 
adhesion molecules-1 (ICAM-1) during reperfusion. Reperfusion is essential for the 
survival of ischaemic tissue as it removes toxic metabolites and restores energy. 
However, in the last few decades studies have shown that tissue damage is further 
enhanced by reperfusion (Lieberthal and Levine, 1996, Thadhani et al., 1996, Weight et 
al., 1996) and this phenomenon is known as reperfusion injury or the reflow paradox. 
This is associated with release of pro-inflammatory cytokine (TNF-α, IL-1β and 
generation of ROS), the upregulation of adhesion molecules (selectins, ICAM-1, β-
integrins) and adhesion of leucocytes to endothelial lining of microvasculature (Menger 
et al., 1999, Hakan Parlakpinar, 2013).  
 
1.2.2: Inflammation during renal IRI 
 
Inflammation plays a major role in the pathophysiology of AKI (Bonventre and Zuk, 
2004, Friedewald and Rabb, 2004). During experimental renal ischaemia, ischaemic 
injury results in functional and structural changes to the vascular endothelium and 
tubular epithelium. This leads to the infiltration of leukocytes, neutrophil, macrophages, 
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natural killer cell and lymphocytes into the damaged kidney. The injury forces tubular 
and endothelial cells to release inflammatory cytokines and chemokines which may 
enhance inflammation or decrease it. Adherent and infiltrating leucocytes are 
responsible for the tubular and epithelial injury which can be caused due to release of 
oxygen radicals and vasoconstrictors. Furthermore, endothelin release and decrease in 
NO contributes to enhance endothelial injury during inflammation (Akcay et al., 2009).  
 
There is evidence that suggests that the vascular endothelium is involved in the 
recruitment and migration of circulating inflammatory cells into the sites of inflammation 
(Umehara et al., 2001). Furthermore, anti-inflammatory therapies such as 
mycophenolate and alpha-melanocyte stimulating hormone (α-MSH, a known inhibitor 
of IL-8 and ICAM-1 induction) have protective effects that target the pro-inflammatory 
pathways that participate in the pathogenesis of AKI (Yalavarthy and Edelstein, 2008).  
 
During AKI, the renal tubular epithelium is a major site of cell injury and death. Many 
studies have demonstrated that renal tubular epithelial cells play a pro-inflammatory role 
in AKI. Interferon regulatory factor-1 (IRF-1) is a transcription factor which can activate 
pro-inflammatory genes such as interferons and chemokines. It is stimulated by ROS 
during ischaemic injury both in vitro and in vivo and is produced within the S3 region of 
proximal tubule cells (Akcay et al., 2009). Research conducted on transgenic knockouts 
of IRF-1 shows that the animals can attenuate the renal dysfunction, injury, and 
inflammation after acute ischaemia (Wang et al., 2009). Furthermore, the Rho kinase 
pathway can play a crucial role in the dedifferentiation of epithelial cells and the 
infiltration of inflammatory cells. Further experimental data provide evidence that 
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inhibition of Rho kinase with a renally targeted Y27632-lysozyme conjugate attenuates 
fibrogenesis, tubular damage and inflammation caused by IRI by attenuating KIM-1 and 
E- cathrin (Prakash et al., 2008, Akcay et al., 2009).  
 
It is recognized that cytokines are released by leukocytes and renal tubular cells into the 
injured kidney and play an important role in the initiation and extension of inflammation 
in AKI (Akcay et al., 2009). The pro-inflammatory cytokines/chemokines interferon- γ 
(IFN-γ), interleukin-2, -6, -10 (IL-2, -6, -10), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), transforming growth factor- β (TGF-β), chemokine ligand-1 (CXCL1), 
monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein-2 (MIP-
2) are increased in the kidney in ischaemic AKI (Rice et al., 2002, Albelda et al., 1994, 
Goes et al., 1995, Akcay et al., 2009). During inflammation, adhesion molecules are 
required for leukocyte adhesion to endothelial cells and leads to inflammation and an 
extension of the cellular injury (Fuggle and Koo, 1998). As mentioned above (1.2.1 
Pathophysiology and basic mechanism), ICAM-1 plays an important role in the 
pathophysiology of AKI (Molitoris and Marrs, 1999, Kelly et al., 1994) with both the 
administration of a monoclonal ICAM-1 antibody into wild-type mice and ICAM-1 
deficient mice being protected against renal ischaemic injury (Kelly et al., 1994, Kelly et 
al., 1996). 
Literature suggests that selectins and their ligands adhesion molecules that can play a 
significant role in the inflammatory response. P-selectin molecules are expressed as a 
response to the inflammatory stimulus in platelets and endothelial cells, L-selectin 
molecules are expressed in leukocytes and lymphocytes, and E-selectin is expressed in 
the endothelium (Akcay et al., 2009). Renal ischaemia can cause upregulation of 
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endothelial P-selectin but not L-selectin, with enhanced adhesion of neutrophils 
(Singbartl et al., 2001). CD147 (also known as Basigin or Bsg) is a membrane 
glycoprotein that belongs to the immunoglobulin superfamily and is a ligand for E-
selectin (Akcay et al., 2009) and is thought responsible for neutrophil recruitment in 
renal IRI (Kato et al., 2009). Research suggests that CD147-deficient mice when 
compared with wild-type mice have significant suppression of neutrophil infiltration in 
the kidney after renal IRI (Kato et al., 2009). 
 
Toll like receptors (TLRs) are a family of transmembrane receptors that are widely 
expressed on leukocytes and kidney epithelial cells and regulate innate and adaptive 
immune responses (Akcay et al., 2009). Renal proximal tubular epithelial cells (PTECs) 
express TLR-2 and -4. Data from experimental endotoxemia, ischaemic and 
nephrotoxic AKI suggest that the expression of TLR-2 and TLR-4 was reported to 
increase in these models (Arumugam et al., 2009, Akcay et al., 2009). Furthermore, that 
the inhibition of TLR-2,-4 and -9 is protective against the renal dysfunction caused by 
renal IRI (Shigeoka et al., 2007, Pulskens et al., 2008, Cunningham et al., 2004, 
Yasuda et al., 2008). 
 
During inflammation, the first step which leads to the movement of these cells from 
capillaries to damage and injured tissue is the neutrophils adherence to the vascular 
endothelium. Studies show that infiltrating neutrophils can release ROS after adherence 
and chemotaxis that can cause damage to the tubular cells (Linas et al., 1988, Akcay et 
al., 2009). Furthermore, many studies indicate that macrophages also contribute in 
inflammation by generating pro-inflammatory chemokines and cytokines such as IL-18 
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(Liew and McInnes, 2002, Kanai et al., 2001), IL-1α (Zaldivar et al., 2002), TNF-α, IL-1β, 
MCP-1, macrophage migration inhibitory factor (MIF) and NK-B (Nikolic-Paterson and 
Atkins, 2001). Resident dendritic cells (DCs) form a contiguous network throughout the 
kidney but their role in AKI remains unclear. Following renal IRI, resident DCs release 
similar cytokines and chemokines as macrophages (Akcay et al., 2009). 
 
1.2.3: Oxidative stress during renal IRI 
 
Oxidative stress plays a crucial role in the pathogenesis of many clinical diseases 
(Cross et al., 1987, Halliwell et al., 1992) such as cardiovascular diseases (McCord, 
1985, Jeroudi et al., 1994), liver diseases (Comporti, 1985, Poli et al., 1987), lung 
disease (Kalra et al., 1991, Ryrfeldt et al., 1993), gastrointestinal disorders (Otamiri and 
Sjodahl, 1991, Das and Banerjee, 1993), and AKI (Aragno et al., 2003). Oxidative stress 
can be defined as the tissue damage resulting from an imbalance between an 
excessive generation of oxidant compounds and insufficient antioxidant defence 
mechanisms (Kao et al., 2010). The generation of oxidative compounds plays a 
physiologically important part of defence mechanism against invading micro-organisms 
and malignant cells. It also plays a crucial role in tissue repair, healing and remodelling 
(Locatelli et al., 2003). 
 
Oxidative compounds such as ROS and reactive nitrogen species have unpaired 
valence shell electrons and are therefore unstable in nature and interact readily with 
adjacent molecules. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in 
particular has a major role in generation of ROS. ROS can be also generated by 
vascular and non-vascular enzymes (Kao et al., 2010). Evidence shows that xanthine 
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oxidase, lipoxygenase, uncoupled NOS and an impaired mitochondrial respiratory chain 
can all produce oxidative stress (Stocker and Keaney, 2004, Laursen et al., 2001). It is 
thought that the generation of a single ROS leads to the generation of several others 
through radical chain reactions. ROS is generated through a univalent reduction of 
molecular oxygen (O2)(Kao et al., 2010). 
 
Polymorphonuclear neutrophils and monocyte-macrophages are activated after 
exposure to a stimuli and as a result, increase their O2 consumption (‘respiratory burst’) 
(Locatelli et al., 2003). There is then a series of reactions. Firstly, O2 will be reduced to 
superoxide anion (O2
•−
) by the NADPH-oxidase enzyme system. Then O2
•−
 either by 
dismutation of O2
•−
 or by direct reduction of O2 will be converted into H2O2, which is 
highly unstable. Both O2
•−
 and H2O2 can play important role in the generation of more 
powerful oxidants. Increased production of all these oxidants inactivates nitric oxide 
(NO), resulting in reduced bioavailability of NO. These oxidants also lead to the 
formation of peroxynitrite (ONOO-), which is cytotoxic and is responsible for both 
increased platelet aggregation and vasoconstriction. O2
•−
 interacts with NO to form 
highly toxic nitrogen derivatives whereas H2O2 reacts with intracellular iron to form 
hydroxyl radicals (OH•) (Descamps-Latscha et al., 2001, Kao et al., 2010). These 
hydroxyl radicals then exert a pivotal effect in the degradation process of the cell 
membrane lipid, protein aggregation and DNA damage. H2O2 is also the substrate for 
myeloperoxidase (MPO) which produces chlorinated oxidants such as hypochlorous 
acid (HOCL), a potent oxidant, especially in molecules such as lipids, proteoglycans 
and other intracellular components (Kao et al., 2010). Recent studies have shown that 
oxidative stress and subclinical inflammation co-exist together. When released together 
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with pro-inflammatory cytokines, angiotensin II and advanced glycation end products 
(AGE), ROS release augments the whole ROS generation process (Davi et al., 2002, 
Kao et al., 2010). 
 
As free radicals have a very short half-life it is very difficult to evaluate oxidative stress 
in the clinical setting. Therefore oxidative stress is often determined by studying more 
stable marker molecules that have longer half-lives, from hours to weeks. These 
markers include malonyldialdehyde, advanced oxidation protein products, 4-
hydroxynonenal (HNE), advanced glycosylation end-products (AGE), 8-hydroxy-2′-
deoxyguanosine and dimethylarginine (Kao et al., 2010).  
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1.2.4: Apoptosis and necrosis 
 
During ischaemic AKI, renal tubular cells death is mediated by both apoptosis and 
necrosis, but the exact pathway is still unclear. Although, there is evidence of apoptosis 
occurs when ATP concentrations are reduced, it is known that prolonged ATP depletion 
leads to necrosis. Furthermore, apoptotic cells that are not removed from the site of 
injury may undergo a ‘secondary necrosis’.  
 
Necrosis was previously thought to be an uncontrolled cell death but evidence indicates 
that it can also occur via a transduction pathway and execution mechanisms. It can be 
morphologically characterised by cytoplasmic swelling and dilated organelle 
(endoplasmic reticulum, golgi apparatus and mitochondria), absence of chromatic 
condensation followed by the loss of cell membrane integrity and release of the cellular 
contents into the surrounding extracellular space (Kroemer et al., 2005, Vanden Berghe 
et al., 2010). This rapid metabolic collapse leads to early loss of plasma membrane 
integrity and the release of cytosolic contents including proteins such as lactate 
dehydrogenase (LDH) (Lieberthal et al., 1998a). LDH is an enzyme which catalyzes the 
conversion of lactate to pyruvate at a rate determined by positive feedback inhibition 
and is retained in the cytosol unless the cell membrane is compromised. Necrotic injury 
is often evaluated by quantifying the amount of LDH released into blood plasma 
(Breggia and Himmelfarb, 2008). Recent studies have focused on the fact that necrosis 
can occur through a mechanism called necroptosis or programmed necrosis (Degterev 
et al., 2005). This mechanism is activated upon stimulation by TNF-α, FasL, and TRAIL, 
the same ligands that activate apoptosis. Receptor interacting protein 1(RIP1) plays an 
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important role in necroptosis. RIP1 serine/threonine kinase activity is essential for 
necrotic death pathway but is not essential for NF-kB activation and apoptosis (Holler et 
al., 2000, Christofferson and Yuan, 2010). Another member of RIP1 family, RIP3, has 
been identified to play a crucial role in necroptosis (Cho et al., 2009, He et al., 2009). 
RIP3 expression sensitizes necroptosis insensitive cell lines to necroptosis. RIP1 and 3 
interact with their RIP homotypic interaction motif (RHIM) domains (Sun et al., 2002). 
RIP1 and 3 are 33% similar in kinase domain but inhibitor of necroptosis called as 
necrostatin-1(Nec-1) inhibits RIP1 only (Cho et al., 2009, Degterev et al., 2008). During 
death receptor induced apoptosis, RIP1 and RIP3 are cleaved by caspase-8, which 
suppress their anti-apoptotic and/or pro-necrotic properties (Lin et al., 1999, Feng et al., 
2007). Pathogen recognition receptors (PRRs) such as TLRs, the cytosolic NOD- like 
receptors (NLRs) and the RIG-I-like receptors (RLRs) can lead to necrotic cell death 
(Kalai et al., 2002, Ma et al., 2005). Extensive DNA damage causes hyperactivation of 
poly-(ADP-ribose) polymerase-1 (PARP-1) and causes necrosis (Jagtap and Szabo, 
2005). When there is moderate DNA damage PARP-1 repairs DNA but excessive 
PARP-1 activation causes depletion of NAD+ by catalyzing the hydrolysis of NAD+ into 
nicotinamide and poly(ADP ribose) (PAR), ultimately causing ATP depletion with 
permanent cellular energy failure and necrotic cell death. PARP-1 is mediated by 
activation of RIP1 and TNF receptor-associated factor-2 (TRAF2) (Xu et al., 2006). In 
execution of necrotic cell death many mediators are involved such as ROS, calcium 
(Ca2+), calpains, cathepsins, phospholipases and ceramide (Vanlangenakker et al., 
2008, Duprez et al., 2009). 
 
Apoptosis can be marked by the reduction of cellular volume (pyknosis), rounding-up of 
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the cell, chromatin condensation, retraction of pseudopodes, nuclear fragmentation 
(karyorrhexis), with no or little ultrastructural modifications of cytoplasmic organelles, 
plasma membrane blebbing (but maintenance of its integrity until the final stages of the 
process) and engulfment by resident phagocytes’ (Kroemer et al., 2005, Kroemer et al., 
2009). In apoptosis two main protein families are involved, the Bcl-2 family of protein, 
which control mitochondrial integrity and the cysteinyl aspartate-specific proteases or 
caspases, which mediate the execution phase of apoptosis (Youle and Strasser, 2008). 
 
At least 18 mammalian caspases have been identified and many of these can be split 
into apoptotic and inflammatory subfamilies of caspases. Apoptotic caspases can be 
further divided into initiator caspases: Caspase -2,-8,-9 and -10 and the executioner or 
effector caspases: caspase -3,-6 and -7 (Riedl and Shi, 2004). Caspases are cysteine 
proteases that can cleave after aspartate (Asp) residues in their substrates and 
irreversibly causes cell death (Chang and Yang, 2000). Caspases are inactive 
proenzymes and consist of an N-terminal prodomain of variable length, a large subunit 
(p20) and a small C- terminal subunit (p10). The long prodomain of initiator caspases 
contain protein: protein interaction motifs belonging to death domain superfamily, 
namely death effector domains (DEDs) and caspase activation and recruitment domains 
(CARDs)(Chang and Yang, 2000, Duprez et al., 2009).  
 
Caspases undergo proteolytic activation by pro-apoptotic stimuli that cause the auto 
activation of initiator caspases. Initiator caspases then triggers a self-amplifying 
cascade of downstream caspase activation (Riedl and Shi, 2004, Nicholson et al., 1995, 
Thornberry and Lazebnik, 1998) leading to the activation of caspase-3. Activation of 
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caspase-3 leads to cell death by proteolytic cleavage of broad spectrum of cellular 
target proteins (Chang and Yang, 2000). In mammalian cells, caspases can be 
activated by the extrinsic or intrinsic apoptotic pathway.  
 
The extrinsic pathway is induced by stimulation of death receptors belonging to TNFR 
family, such as TNFR, Fas and TRAIL-R. Death stimuli originated from outside of cell 
binds to an extracellular death ligand such as FasL, to its cell surface receptor Fas 
(Ashkenazi and Dixit, 1999). Cytosolic factors FADD and caspase-8 binds to these and 
form a complex known as death inducing signaling complex (DISC) which causes 
activation of caspase-8 (Thorburn, 2004) which leads to the activation of the 
executionary caspases as mentioned above and results in cell death.  
 
The intrinsic pathway is activated by various stimuli, such as DNA damage and 
cytotoxic insults and is mediated through the mitochondria. Proteins like cytochrome c, 
SMAC/DIABLO (second mitochondrial derived activator of caspases/direct inhibitor of 
apoptosis binding protein with low pI) and AIF (apoptosis inducing factor) are released 
from the inter-membrane space of mitochondria due to specific apoptotic stimuli and 
they then activate the intrinsic pathway. Cytochrome c binds and activates APAF1 
(apoptosis protease activating factor-1) which in turn binds to ATP/dATP leading to 
activation of caspase-9 (Green and Kroemer, 2004, Sanz et al., 2008). Caspase-9 then 
activates executioner caspases as mentioned above and causes cell death. 
 
Research shows that mitochondrial changes can be prevented in cells by anti-apoptotic 
members of the Bcl-2 family of proteins (Kaushal et al., 2004). Furthermore, there is 
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evidence that the Bcl-2 family may regulate activation of caspases through control of 
cytochrome c release from the mitochondria and by directly binding to APAF1, thus 
preventing the activation of pro-caspase-9 and subsequently caspase-3 (Gross et al., 
1999).  
 
The enzymatic activity of caspases is subject to inhibition by the conserved IAP 
(inhibitor of apoptosis) family of proteins (Deveraux and Reed, 1999, Hay, 2000). 
Literature suggest that there are eight distinct IAPs, such as XIAP, ML-IAP/Livin, c-IAP1 
and c-IAP2 (Ashhab et al., 2001, Kasof and Gomes, 2001, Vucic et al., 2000) have 
been identified in mammals, and they can target caspase-9 (initiator caspase), and they 
can also target caspase-3 and caspase-7 (the effector caspases). These IAP proteins 
do not inhibit other caspases, such as caspase-6 or -8 (Shi, 2002). Furthermore, 
release of pro-apoptotic proteins from mitochondria such as Smac/Diablo antagonizes 
the action of IAPS such as XIAP, cIAP1 and 2 (LaCasse et al., 2008). 
 
During AKI in clinical and animal models, apoptosis is the main cause of tubular cell 
death (Basile et al., 1997, Burns et al., 1998, Kishino et al., 2004, Iwata et al., 1994) and 
evidence from ischaemic AKI studies suggest that mitochondrial fragmentation 
contributes to both mitochondrial damage and apoptosis (Brooks et al., 2009)There is 
an urgent need of therapies which can prevent apoptosis and necrosis in the setting of 
AKI. 
  
  
42 
 
1.3: Nitrite and its role in ischaemic conditions: 
 
Nitrite (NO2
-) is naturally occurring component and is an oxidation product that has been 
shown to serve as an acute marker of NO flux/formation. Initially NO2
− was considered 
as being physiologically inert but it is now accepted that NO2
- represents a major 
storage form of NO in the blood and tissues which can be converted to NO and other 
reactive nitrogen species during hypoxia to maintain physiological signalling. Most of 
NO2
− is derived from the oxidation of NO Synthase (NOS)-generated NO. This is a one 
electron auto-oxidation of NO and is formed relatively slowly from NO2
− when compared 
to the two electron oxidation of NO to nitrate (NO3
−) by haem proteins in the blood and 
tissue. NO2
− formation is catalyzed by the multicopper oxidase ceruloplasmin in the 
plasma or by cytochrome c oxidase (COX) in tissues (Shiva, 2013).. NO2
- is also derived 
from reduction of salivary nitrate (NO3
-) by commensal bacteria in the mouth and 
gastrointestinal tract and 30 % NO2
- is derived from dietary sources like meat, 
vegetables and drinking water (Bryan et al., 2007, Shiva, 2013). NO2
- concentration in 
the plasma is very low at around 300-330 nmol/L in humans, 150-250 nmol/L in rats and 
400-500 nmol/L in mice (Kleinbongard et al., 2003). In tissues, NO2
- concentration is 
around 0.5 mol/L to 20 mol/L in rats (Bryan et al., 2004). 
 
In ischaemic conditions there is a lack of NO because NOS is unable to produce NO 
without oxygen being present and oxygen is deficient in ischaemia (Samouilov et al., 
1998). However, NO can be generated in ischaemic conditions but NOS inhibition does 
not affect it thereby indicating that there is an enzyme independent pathway of NO 
generation. NO might be formed by reduction of NO2
- to NO during ischaemia or 
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hypoxia by acidic disproportion, xanthine oxidoreductase (XOR) and 
deoxyhaemoglobulin (Zweier et al., 1995, Tripatara et al., 2007). Thus, NO2
- is an 
oxidative metabolite derived from NO and it can also be a source of NO generation in 
ischaemic conditions. NO has one unpaired electron and is a free radical species and 
can react with other free radicals like O2
•−
. Reaction with O2
•−
 can form ONOO-, which is 
cytotoxic (Beckman et al., 1990). NO rapidly forms nitrogen dioxide (NO2) in air. NO2 is 
a brown gas that can cause tissue damage (Moncada and Higgs, 1993) and reacts to 
forms dinitrogen, trinitrogen or tetraoxide, these react with water to give NO2
- and NO3
- 
(Ignarro et al., 1998). 
 
Research now shows that NO2
- can attenuate the formation of ROS by inhibiting 
mitochondrial complex-1 by S nitrosation during IRI and reduces damage associated 
with it. In IRI there is depletion of ATP formation, reduction in energy stores and the 
influx of oxygen during reperfusion causes ROS generation at complex I and III. 
Furthermore there is oxidation of proteins causing opening of mitochondrial 
permeablility transition pore and the release of cytochrome c to cause apoptosis. These 
events can be attenuated due to NO2
- dependent  S nitrosation of complex 1 which 
decreases cytochrome c release and inhibits opening of the permeability transition pore 
(PTP) ultimately reducing apoptosis and IRI (Shiva, 2013).  
 
As NO2
- mediated beneficial effects are dependent on NO it is necessary to understand 
how NO is functioning in physiological and pathological conditions. Literature suggest 
that NO is lipid soluble and there is a high concentration of NO at the cellular level 
(Ignarro et al. 1998). NO plays important physiological role in neurotransmission, 
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hormone secretion, immunity and inflammation (Kone, 1997, Bentz et al., 2000). It is 
also involved in pathological conditions like septic shock, atherosclerosis, hypertension, 
carcinogenesis and IRI (Bentz et al., 2000). NO plays an important role in kidney 
functions such as the regulation of glomerular and medullary haemodynamics, TGF 
response and Renin release by taking control of the extracellular fluid volume status 
(Kone, 1997). On the other hand, it can contribute in several common renal diseases 
like immune mediated glomerulo-nephritis, radio-contrast nephropathy, obstructive 
nephropathy, acute and chronic renal allograft and post-ischaemic renal failure (Kone, 
1997). 
 
NOS are enzymes which catalyse the oxidation in the L-arginine (L-arg) NO pathway 
(Beckman et al., 1990). There are three isoforms of NOS expressed in the kidney (a) 
neuronal NOS (nNOS or NOS-I) is found in epithelial cells of the macula densa (Mundel 
et al., 1992, Terada et al., 1992) and principal cells of collecting ducts (Wang et al., 
1998) (b) inducible NOS (iNOS or NOSII) is found in tubule epithelia including proximal 
tubule, TAL and distal convoluted tubule (Morrissey et al., 1994) and (c) endothelial 
NOS (eNOS or NOS-III) is expressed in renal vascular endothelial cells (Terada et al., 
1992) whilst  nNOS and eNOS are regulated by calcium and calmodulin (CaM) and 
iNOS is controlled by inflammatory stimuli such as lipo-polysacchride and cytokines but 
is not regulated by calcium (Xie et al., 1992, Forstermann et al., 1994). Data suggest 
that human neutrophils also express iNOS (Cedergren et al., 2003) whilst eNOS derived 
NO plays an important role in determining and maintaining normal renal function, such 
as proximal tubule function (Liang and Knox, 2000, Ortiz and Garvin, 2002) but that 
elevated levels cause proximal tubular injury (Liang and Knox, 2000).  
  
45 
 
 
During ischaemia eNOS activity is diminished because of its dependence on oxygen 
and the increasing acidosis (Giraldez et al., 1997). However, studies have recognised 
that there is NO generation from the endogenous NO2
- pool during ischaemia in heart, 
liver and kidney, which is NOS independent (Zweier et al., 1995, Webb et al., 2004, 
Duranski et al., 2005, Okamoto et al., 2005). Recently, NO2
- derived NO has been 
shown to play an important role in preventing myocardial infarction (MI) (Bryan et al., 
2007) and renal ischaemia by XOR (Tripatara et al., 2007). However, as far as we are 
aware, no study has looked at the role of oral/dietary high NO2
- in the setting of renal 
IRI.  
 
1.4: Thiamine and benfotiamine: 
 
Thiamine, also known as vitamin B1 is a vitamin of the B complex which is considered to 
play an important role in energy metabolism. It is a colourless compound and its 
structure contains an aminopyrimidine and thiazole ring with methyl and hydroxyethyl 
side chains linked by a methylene bridge (Lonsdale, 2006). Thiamine is soluble in water, 
methanol, and glycerol but it is insoluble in ether, acetone, benzene and chloroform. It is 
stable in acidic pH, but unstable in alkaline solutions (Tanphaichitr V, 1999, Mahan LK, 
2000). It has been suggested that the water soluble vitamins such as thiamine and 
folate are unrelated structurally and functionally but they may share properties that 
make them essential for normal cellular function, growth and development (Bukhari et 
al., 2010).  
 
Thiamine is found in many foods such as cereal grain, oatmeal, brown rice, cauliflower 
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and potatoes. Daily requirement of thiamine as described by the recommended daily 
allowance (RDA) is 1 to 1.5 mg (Lonsdale, 2004, Lonsdale, 2006). Thiamine is stored in 
the body in the liver, skeletal muscle, kidney, brain and heart and the human body can 
store 25 to 30 mg of thiamine. Furthermore, phosphatase and pyrophosphatase 
enzymes can release thiamine in the upper portion of small intestine. This process is 
carrier mediated at lower concentrations whilst at higher concentrations absorption of 
thiamine occurs via passive diffusion. In the jejunum and ileum thiamine is absorbed by 
active transport which is reduced by folic acid deficiency and alcohol consumption 
(Mahan LK, 2000). A decline in thiamine absorption occurs at intakes above 5 mg. 
Intestinal mucosal cells have thiamine pyrophosphokinase activity, but it remains 
uncertain whether this enzyme is linked to active absorption. 
 
Vitamin B1 is transported mainly in thiamine form and it turns into the phosphorylated 
active form after phosphorylation. There are 5 main phosphorylated forms of thiamine 
i.e. thiamine monophosphate, thiamine diphosphate (thiamine pyrophosphate, TPP), 
thiamine triphosphate, adenosine thiamine di and tri phosphates (Lonsdale, 2006). 
Thiamine present in the intestine is mostly in the pyrophosphorylated form TPP, but 
when thiamine arrives on the serosal side of the intestine it is often in the free form. 
 
TPP is a coenzyme (a cofactor loosely bound to enzyme) for many cellular processes 
such as transketolase (TK), pyruvate dehydrogase (PDH) and -ketoglutarate 
dehydogenase (-KGDH). All of these enzymes play crucial role in energy metabolism. 
TK is a cytosolic enzyme which is associated with the biosynthesis of deoxyribose and 
oxyribose (sugars) in the pentose phosphate pathway. Furthermore, mitochondrial PDH 
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and -KGDH enzymes play an important role in generating ATP. PDH links glycolysis to 
the citric acid cycle and -KGDH is the rate limiting enzyme step. In the nervous 
system, PDH is involved in production of acetylcholine, which is a neurotransmitter and 
leads to formation of myelin (Butterworth, 1999, Bettendorff and Wins, 2009). 
 
Thiamine in its active form of TPP is involved in many cellular processes and its 
deficiency causes fatal disease such as beri beri (polyneuritis) and cardiovascular 
diseases in humans (Lonsdale, 2006). One study has demonstrated that the treatment 
of diabetic rats with high doses of thiamine prevents diabetic retinopathy through the 
inhibition of AGE formation and other signalling or metabolic pathways (Hammes et al., 
2003) and another that it can ameliorate cardiomyocyte contractile dysfunction (Ceylan-
Isik et al., 2006). These effects of thiamine are due to its antioxidant properties 
(Hammes et al., 2003). Furthermore, thiamine has an important role in preventing 
hypoxic cardiac cell death (Shin et al., 2004). As mentioned earlier (Bonventre, 1993) 
there is a massive depletion of ATP in IRI and thiamine is known to play an important 
role in generation of ATP (Nozaki et al., 2009). As inflammation, oxidative stress and 
ROS play important role in the pathogenesis of renal IRI and thiamine can attenuate 
these, there is an obvious potential for thiamine to play a very important role in the renal 
IRI settings. 
 
Other thiamine derivatives have been identified such as allithiamine, sulbutiamine, 
prosultiamine, frusultiamine and the thiamine analog benfotiamine. These may possess 
better bioavailability as they are lipid soluble and therefore may cross cell membranes 
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easily in contrast to thiamine (Lonsdale, 2004, Volvert et al., 2008, Lonsdale, 2006). 
Benfotiamine (S-benzoylthiamine O-monophosphate) is a synthetic S-acyl derivative of 
thiamine and has an open thiazole ring compared to thiamine and it is this open thiazole 
ring that closes once the compound is absorbed, resulting in biological active thiamine. 
Furthermore, after oral administration benfotiamine is dephosphorylated to S-
benzoylthiamine by the ecto-alkaline phosphatase present in the brush borders of 
intestinal mucosal cells. The lipid soluble S-benzoylthiamine is absorbed and then 
diffuses by passively through the membranes of intestinal and endothelial cells and 
subsequently appears in the circulation. Most of the S-benzoylthiamine is captured by 
erythrocytes and is converted to free thiamine. Thioesterases hydrolyse the remaining 
to thiamine and benzoic acid in the liver. Benfotiamine is supposed to have 5-10 times 
better bioavailability than thiamine at similar dose (Balakumar et al., 2010) 
Benfotiamine should not be confused with a natural thiamine disulfide derivative called 
allithiamine which has a distinct pharmacological profile (Volvert et al., 2008). The 
primary use of this antioxidant is as an "anti-AGE" supplement. Research conducted 
with benfotiamine was found to lower AGE concentrations by 40% (Lin et al., 2000). At 
high doses, benfotiamine was shown to be an effective treatment for diabetic 
retinopathy, neuropathy and nephropathy. Supplementation of benfotiamine increases 
intracellular TPP levels (Balakumar et al., 2010), a cofactor of TK. This enzyme directs 
advanced glycation and lipoxidation end products (AGE's, ALE's) substrates to the 
pentose phosphate pathway, thus reducing tissue AGEs. Published data indicate that 
treatment with benfotiamine blocks three major pathways (the hexosamine pathway, the 
AGE product formation pathway and the diacylglycerol-protein kinase pathway) of 
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hyperglycaemic damage, probably by removal of glyceraldehyde 3-phosphate and 
fructose 6-phosphate through activation of the pentose phosphate enzyme 
transketolase (Hammes et al., 2003, Balakumar et al., 2010). 
Benfotiamine has been shown to reduce glucose toxicity (Berrone et al., 2006, Marchetti 
et al., 2006) and it can attenuate diabetes-induced cerebral oxidative damage (Wu and 
Ren, 2006). It has been suggested that benfotimaine can be protective against injury 
caused by ischaemia in the diabetic limbs of mice (Gadau et al., 2006) and can also 
alleviate cardiomyocyte contractile dysfunction in experimental diabetes mellitus 
(Ceylan-Isik et al., 2006). Several studies show that the administration of benfotiamine 
leads to higher thiamine blood levels than those achieved by the administration of 
water-soluble thiamine (Bitsch et al., 1991, Greb and Bitsch, 1998, Netzel et al., 2000). 
As thiamine and benfotiamine have shown to have anti-oxidant, anti-inflammatory and 
anti apoptotic properties and as these mechanisms play an important role in 
pathogenesis of renal IR we herein investigated the role of thiamine and benfotiamine in 
the setting of renal IRI in vivo and PTECs apoptosis in vitro. 
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1.5: Bone morphogenic protein-7: 
 
Bone morphogenic protein-7 (BMP-7) was previously known as osteogenic protein-1 
(OP-1) and is a member of the transforming growth factor-β (TGF-β) superfamily that is 
expressed widely in embryonic life and plays a critical role in renal development (Godin 
et al., 1999). BMP-7 null mutation mice lack normal kidneys and the administration of 
BMP-7 can promote nephrogenesis in isolated metanephric mesenchyme (Vukicevic et 
al., 1996). In the adult animal, BMP-7 expression subsides in other organs but remains 
high in the kidney BMP-7 RNA in the normal kidney is largely confined to the medullary 
tubules (tentatively identified as collecting tubules), peripheral glomerular cells 
(presumptive podocytes), and renal artery adventitial cells (Vukicevic et al., 1998, 
Simon et al., 1999). Furthermore, BMP-7 physiological functions in adult kidney are not 
known but its role in renal pathophysiology has been studied in detail. In a renal IRI 
model in the rat, BMP-7 expression falls in the medulla and cortex (Simon et al., 1999, 
Almanzar et al., 1998). Studies have shown that BMP-7 exogenous systemic 
administration in conditions like ureteral ligation (Hruska et al., 2000) and renal IRI 
(Vukicevic et al., 1998) has been shown to ameliorate renal injury.  
 
The TGF-β superfamily of proteins is the primary regulator of fibrosis whilst BMP-7 is 
thought to counteract its action. The TGF-β superfamily plays a role in a wide range of 
cellular processes. The ligands of it are regulated both outside and inside the cell. The 
list of ligands of TGF-β receptor include TGF-β1, β2, β3, activins, inhibins, BMPs and 
growth and differentiation factors (Shi and Massague, 2003, Miyazono et al., 2001, 
Patel and Dressler, 2005). These bind to receptor I and II on the cell surface. Type one 
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receptors are known as activin receptor like kinase or Alk of which there are 7 types. 
There are 5 type II receptors which are ligand specific (Samad et al., 2005). Upon 
binding of ligand, active type II activates the type I receptor by phophorylation and this 
causes phosphorylation of downstream signalling effectors called contraction of Sma 
and Mad (Mothers against decapentaplegic) known as Smad proteins (Patel and 
Dressler, 2005). 
 
BMPs activate Smad1, 5 and 8 whereas activins and TGF-β activates Smad2 and 3. 
These Smads interact with common Smad4 and this ensuing complex translocates to 
the nucleus in order to regulate target gene transcription. Smad6 and 7 negatively 
regulate BMPs and TGF- β mediated signalling. Smad signalling is terminated by 
ubiquitin mediated degradation (Wrighton et al., 2009, Patel and Dressler, 2005). Smad 
ubiquitin regulatory factor 1 (Smurf1) targets Smad1 and Smad5 for destruction (Zhu et 
al., 1999). Smurf2 targets Smad2 (Lo and Massague, 1999) and SCF-Roc1 degrades 
Smad3 (Fukuchi et al., 2001). Smurf1 with Smad7 targets TGF- β type 1 receptor for 
degradation (Ebisawa et al., 2001) and Smurf1 and Smad6 targets BMP type 1 receptor 
for degradation (Murakami et al., 2003). Inhibitors of BMP signalling include chordin, 
noggin, DAN (cerebrus), ectodin and gremlin (Garcia Abreu et al., 2002, Wilkinson et 
al., 2003, Balemans and Van Hul, 2002, Laurikkala et al., 2003). BMP type 1 receptors 
Alk3 and 6 are expressed on the developing nephron, including the tip and branching 
ureter, mesenchymal cells and early epithelial derivatives of mesenchyme (Martinez et 
al., 2001, Patel and Dressler, 2005). Smad1 and 5 are important mediators of BMP-7 
signalling in the adult kidney (Lin et al., 2005, Wang and Hirschberg, 2004). 
 
  
52 
 
BMP-7 has anti-inflammatory and cytoprotective effects on PTECs (Gould et al., 2002) 
and it is also able to prevent renal IRI (Vukicevic et al., 1998). Studies with gene therapy 
techniques using electroporation (EP) are being considered for tissue regeneration and 
repair (Ferber, 2001, Nishikawa and Huang, 2001) and are easy to handle, safe and 
cost efficient. An examination of the use of non-viral gene therapy (EP) with BMP-7 and 
its role in renal IRI is presented in this thesis.  
 
  
53 
 
1.6: Aim and hypothesis: 
 
The aim of this thesis was to prevent AKI using three distinct putative agents. Each 
treatment was to be assessed in vitro using a chemical model of ischaemia and in vitro 
using rodent renal IRI models. 
 
1.6.1 Nitrite study 
 
To investigate the possible beneficial role of oral NO2
- supplementation on the degree of 
rat kidney injury found secondary to renal IRI and to assess whether NO2
- can reduce 
apoptosis in PTECs. 
  
1.6.2 Thiamine study 
 
To investigate the possible beneficial role of oral thiamine supplementation upon rat 
kidney injury secondary to renal IRI, on PTECs and to see if thiamine and its lipid 
soluble analogue benfotiamine has anti-apoptotic, anti-oxidant and anti-inflammatory 
properties that can protect the rat kidney against renal IRI. 
 
1.6.3 BMP-7 in renal IRI study 
 
To investigate the possible role of non-viral gene therapy using hBMP-7 in the setting of 
renal IRI and to test if BMP-7 has anti-apoptotic properties that can prevent renal IRI 
and to further assess whether BMP-7 protein can reduce the degree of apoptosis in 
PTECs subjected to an in vitro model of IRI. 
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CHAPTER 2 
 
 
 
 
EFFECTS OF LOW AND 
HIGH DIETARY NITRITE 
ON AKI 
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2.1: Introduction 
 
Renal IRI is one of the principal causes of AKI (Liano and Pascual, 1998) and AKI 
remains a major cause of morbidity and mortality in hospitalized patients (Singri et al., 
2003). In addition, renal dysfunction develops in 5% of all general surgical patients and 
complicates the course of recovery in 15–25% of critically ill patients (Nash et al., 2002). 
Currently, the treatment of AKI is either symptomatic or dependent on RRT, so there is 
urgent need of new therapies to prevent AKI.  
 
Evidence suggests that the topical application of NO2
- directly onto the kidneys can 
prevent the damage and dysfunction caused by renal IRI (Tripatara et al., 2007). 
Furthermore, NO2
- has been shown to protect the liver and heart from damage caused 
by IRI (Duranski et al., 2005). Moreover, these studies demonstrate that the beneficial 
effects of NO2
- are related to its reduction to NO under ischaemic conditions. 
 
NOS enzyme play an important role in the generation of NO with three known isoforms 
with eNOS derived NO playing an important role in determining and maintaining aspects 
of normal renal function such as proximal tubule sodium reabsorption. However, 
elevated concentrations of NO can cause proximal tubule ischaemic injury (Liang and 
Knox, 2000). NO can therefore either attenuate or aggravate renal injury and this dual 
nature of NO depends on the site and the rate of NO production and the chemical fate 
of NO (Tripatara et al., 2007). Furthermore, there are multiple studies which indicate 
that iNOS inhibition or iNOS knockout mice can attenuate the proximal tubular injury 
caused by ischaemia, indicating that NO from iNOS contributes to renal injury 
(Chatterjee et al., 2002, Chatterjee et al., 2003b). Evidence also suggests that during 
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ischaemia or hypoxia, NO generated from sources other than NOS can play a vital role 
in mediating protective responses. Inorganic NO2
- which can be produced biologically 
via oxidation of NO or by consumption via diet, either directly or indirectly after reduction 
of NO3
- by the NO3
- reductases present in oral bacteria, with this process being one of 
the key sources of NO(Shiva et al., 2007).  
 
NO2
- can be found circulating and as the tissue storage form of NO. NO2
- is reduced to 
NO during hypoxia and acidosis by the enzymatic action of XOR and by haem proteins 
such as deoxyhaemoglobin, myoglobin, and tissue haem proteins (Basireddy et al., 
2006, Tripatara et al., 2007). 
 
As mentioned earlier, in an AKI setting the topical administration of NO2
- upon the 
kidneys has been shown to be beneficial (Tripatara et al., 2007). Conversely the 
systemic i.v. administration of NO2
- and NO3
- has been shown to be detrimental 
(Basireddy et al., 2006) but there is evidence to suggest that oral NO2
- (50 mg/L) given 
in the drinking water to mice for 7 days is able to prevent the myocardial damage 
caused by IRI (Bryan et al., 2007) indicating that dietary high NO2
- might play a crucial 
role in preventing renal IRI. As there is known to be a deficiency of NO during renal 
ischaemia we herein hypothesise that oral NO2
- may prevent the damage and 
dysfunction caused by renal IRI in rats through NO and may also prevent apoptosis in 
PTECs subjected to an in vitro model of IRI (using immortalised human kidney cells, 
HK-2). 
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2.2. Materials and methods 
 
2.2.1. Rat model of renal IRI  
 
This procedure was done as described previously by workers in our lab (Kumar et al., 
2009). Briefly, these studies were carried out on adult male Wistar rats (Charles River 
Ltd., Margate, UK) that weighed 250-400 g and received a standard diet and water ad 
libitum. The animals were cared for in accordance with the Home Office Guidance on 
the Operation of the Animals (Scientific Procedures) Act 1986, published by HMSO, 
London, UK. All rats were anesthetised with an i.p. injection of an anaesthetic cocktail 
consisting of ketamine and xylazine at a 2:1 ratio. Surgery was performed on a 
preheated mat to maintain body temperature at 37°C. Right and left kidneys were 
approached via lateral incisions on either flank respectively, and the renal pedicles were 
bilaterally clamped for 45 min with microaneurysm clamps followed by reperfusion for 24 
h.  
The time of ischaemia was chosen (45 min ischaemic phase) to obtain a reversible 
model of ischaemic AKI and to avoid animal mortality. The kidneys were observed for 
restoration of blood flow, as confirmed by returning to their original colour. Sham 
surgery consisted of the same surgical procedure except that clamps were not applied. 
Directly after closure of the abdomen all the rats were administered with 2 mL of normal 
saline (preheated to 37°C) i.p. At 24 h animals were sacrificed, blood samples were 
collected via a cardiac puncture and the kidneys were harvested. The kidneys were cut 
longitudinally into two halves and each half from respective kidneys were stored in 10% 
formalin for histological analysis or were immediately snap frozen in liquid N2 for further 
experiments. 
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2.2.2 Assessment of renal function 
 
Blood was collected into plain tubes and was allowed to clot. Centrifugation for 3 min at 
9000 g yielded the serum. The veterinary clinical pathologists, based at VETLAB 
(www.vetlab.co.uk), a division of IDEXX Laboratories, Sussex, UK; blinded to the 
treatment given, performed serum creatinine measurements which was used as a 
biochemical measure of kidney injury (Kumar et al., 2009).  
 
2.2.3 Experimental design 
 
The rats were divided into the following groups: IRI group: (i) Control rats were given 
standard diet and normal drinking water for 7 days prior to ischaemia. IRI high NO2
- 
group (ii) were given standard diet and NaNO2 50 mg/L in drinking water for 7 days prior 
to ischaemia. IRI low dietary NO2- group (iii) were given a low dietary NO2- chow for 7 
days with normal drinking water. Sham group (iv) were given normal water and standard 
diet. All rats underwent the same surgical procedures except arterial clamps were not 
applied in the sham group. 
 
2.2.4 Plasma NO2
-/NO3
- measurement by Griess assay 
 
Plasma NO2
- and NO3
- concentrations were measured as an indicator of NO levels. NO3
- 
in plasma was enzymatically converted to NO2
- using a protocol similar to that described 
previously (Chatterjee et al., 2002). Briefly, NO3
-  was stoichiometrically reduced to NO2
-  
by incubation of plasma (50 L) for 15 min at 37°C in the presence of NO3
-  reductase (1 
U/mL), -NADPH (50 mol/L) and FAD (50 mol/L) in a final volume of 80 L. When 
NO3
- reduction was complete, the unused -NADPH, which interferes with the 
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subsequent NO2
- determination, was oxidised by L-lactate dehydrogenase (100 U/mL) 
and sodium pyruvate (100 mmol/L) to a final reduction volume of 100 L and incubated 
for 5 min at 37°C. Subsequently, total NO2
- in the medium was assayed by adding 100 
L of Griess reagent (Reagent A+B 1:1) to each sample. Optical density at 550 nm was 
measured using a spectrophotometer (Dynex Jencons PLS Technologies Microplate 
Reader). Total NO2
- / NO3
- concentration for each sample was calculated by comparison 
of a standard solution of sodium nitrite (NaNO2) prepared in ultra pure water. 
 
2.2.5 HK-2 Cells 
 
The immortalised HK-2 cell line was originally established by transduction of a primary 
adult human PTEC line obtained from normal adult human renal cortex with human 
papilloma virus (HPV 16) E6/E7 genes (Ryan et al., 1994). At the molecular level, the 
E6 and E7 gene products bind to DNA regulatory proteins, the result of which is to 
facilitate cell proliferation. However, these changes do not equate to malignant 
transformation because the features of differentiation of the host cells remain preserved 
(positive for alkaline phosphatase, gamma glutamyltranspeptidase, leucine 
aminopaptidase, acid phosphatase, cystokeratin, 31 integrin and fibronectin) and their 
growth remains anchorage dependent and under the control of normal regulatory 
processes. They also retain functional characteristics of proximal tubular epithelium 
including sodium dependent/phlorizin sensitive sugar transport, adenylate cyclase 
responsiveness to parathyroid but not to anti-diuretic hormone. The cells are widely 
employed as a tool for studying injury and repair of the proximal tubular cell (Zager, 
1999, Handa, 2001, Iwata et al., 1995, Lee and Emala, 2002). Ham’s nutrient mixtures 
were originally developed to support growth of several clones of Chinese hamster ovary 
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(CHO) cells, as well as clones of HeLa and mouse L-cells. Ham’s F-12 DMEM has been 
used for the growth of primary rat hepatocytes and rat prostate epithelial cells. Ham’s F-
12 DMEM media (1:1) was used to grow and maintain HK-2 cell with 10 % fetal calf 
serum (FCS) and 1 % antibiotic in most of the work presented here unless specified. 
HK-2 cell cultures were re-constituted with fresh media every second day. Most 
experiments were performed on confluent HK-2 cells at passages 2 to 19 (after thawing 
frozen cell stocks of maximum 3-5 passage) that were cultured for 2 weeks. 
2.2.6 In vitro ischaemia reperfusion injury model 
 
A chemical model of IRI was induced in vitro according to the well-studied and 
extensively characterized model using a combination of antimycin A (a complex III 
inhibitor of mitochondrial electron transport) and 2-deoxyglucose (a non-metabolizable 
isomer of L-glucose) as described earlier (Kumar et al., 2009). Briefly, this is an in vitro 
model that chemically mimics renal IRI. HK-2 cells were seeded in a 6-well tissue 
culture plate and allowed to adhere for 20-24 h in an incubator at 37°C with 5% CO2 in 
humidified air. After the above incubation period, cells were 70 – 80% confluent and the 
culture medium was replaced with Hank’s Balanced Salt Solution (HBSS) (containing 
1.3 mmol/L Ca2+ and 0.8 mmol/L Mg2+) and were incubated with or without 50 mol/L 
antimycin A plus 10 mmol/L 2-deoxyglucose for 1 h to induce ischaemic injury. The in 
vitro reperfusion was achieved by incubating cells in Ham’s F-12 DMEM growth medium 
for 24 h. After 24 h cells were lifted by scrapping and centrifuged at 3000 g for 5 min. 
The supernatant was removed from the cells and the pellets were frozen at -200C. 
Pellets were then lysed with radio-immunoprecipitation assay (RIPA) buffer and 
centrifuged at 16000 g. Cell debris was then removed and further assays were 
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performed on the resulting cell lysates. 
 
2.2.7 Cell viability assay  
 
Cell viability was determined by using the Celltiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega, Southampton, UK) according to the manufacturer’s 
instructions. This cellular reduction involves the MTS tetrazolium compound being 
converted to formazan by the NADH and NADPH generated by the metabolically active 
cells. Hence, the amount of formazan formed, as monitored by absorbance, directly 
correlates with the metabolic activity of the cells.  
 
Briefly, 10,000 cells (in 100 l) were seeded in a 96 well tissue culture plate and 
incubated at 37oC in the cell culture incubator for 20-24 h and allowed to adhere and 
proliferate. The cells were treated according to the experiment protocol and 24 h later 
20 l of the yellow MTS solution was added into each well. The plate was incubated 
under the same conditions for up to 4 h and the absorbance was measured at 490 nm.  
 
2.2.8 Serum starvation model 
 
Serum Starvation was done as described previously (Kumar et al., 2009). Serum 
starvation can be used as an in vitro model to mimic ischaemia. In this study, HK-2 cells 
were seeded in a 6-well tissue culture plate and allowed to adhere for 20-24 h in an 
incubator at 37°C with 5% CO2 in humidified air.  After the above incubation period, 
when cells were 50 – 60% confluent the culture medium was replaced with fresh culture 
medium with 10% FCS for controls whilst for serum starved and treatment groups, no 
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FCS (with or without treatment) was provided for 24 h. After 24 h, cells were lifted by 
scrapping and centrifuged at 3000 g for 5 min. The supernatant was removed from the 
cells and the pellets were frozen at -200C. Pellets were then lysed with RIPA buffer, 
centrifuged at 16000 g. Cell debris was then removed and further assays were 
performed on the resulting cell lysates. 
 
2.2.9 Assessment of apoptosis 
 
2.2.9.1 Caspase activity  
 
The activity of caspase-3 was measured using the fluorometric substrate N-Acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) and N-Acetyl-Asp-Glu-Val-
Asp-al (Ac-DEVD-CHO) as inhibitor, as described previously by our laboratory (Allen et 
al., 2003, Kumar et al., 2009). The assay is based on the hydrolysis of Ac-DEVD-AMC 
by caspase-3, resulting in the release of the fluorescent 7-amino-4-methylcoumarin 
(AMC) moiety. The excitation and emission wavelengths used to determine AMC 
concentrations were 360 nm and 460 nm respectively.  
 
Briefly, the assay protocol is as follows. 10l of the samples (extracted protein for HK-2 
cells or kidney homogenates prepared in RIPA lysis buffer 50 mmol/L Tris HCl, pH 7.5, 
150 mmol/L NaCl, 50 mmol/L NaF, 0.5% deoxycholic acid, 1% NP-40, 1 mmol/L sodium 
orthovanadate, 0.1% SDS devoid of protease inhibitor cocktail) in duplicate were added 
to a black 96 well plate. 90 l of the prepared assay buffer (caspase assay buffer 
contains,100 mmol/L HEPES buffer pH 7.5 containing 325 mmol/L sucrose,1.8 mmol/L 
CHAPS, dithiothreitol 11.1 mmol/L, and purified water in appropriate concentration) was 
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added to the above samples. 2 l (50 mol/L) of the diluted caspase inhibitor was 
added to half of the wells with vehicle added to paired samples followed by incubation at 
37°C in the dark for 30 min. Subsequently, 2l (50 mol/L) of diluted substrate was 
added to all the wells followed by mixing on the shaker and incubating under the same 
conditions except for an hour instead of 30 min. The concentration of the AMC released 
can be calculated from the standard curve determined with defined AMC solutions from 
stock AMC. Fluorescence readings, obtained using a BMG Fluostar Galaxy plate reader 
(BMG Labtech Ltd, Aylesbury, Bucks, UK) from wells that contained inhibitor were 
subtracted from total fluorescence, and results were calculated as nmol AMC/min per 
mg protein. The activity of caspase-9 was determined in a similar manner using N-
Acetyl-Val-Glu-His-Asp-7-amido-4-methylcoumarin (Ac-VEHD-AMC) as the substrate 
and Ac-VEHD-CHO as the inhibitor. The activity of caspase-8 was determined by using 
the Acetyl-Ile-Glu-Thr-Asp-7-amido-4-methylcoumarin (Ac-IETD-AMC) as a substrate 
and Acetyl-Ile-Glu-Thr-Asp-Aldehyde Inhibitor (Ac-IETD-CHO) as inhibitor. 
2.2.10 In vitro reperfusion model 
 
The H2O2 was utilised to induce injury as an in vitro model that could mimic reperfusion 
injury in animals. H2O2 was given to cells when confluent at a dose of (500 mol/L) for 
2-4 h. After 2-4 h cells were lifted by scrapping and centrifuged at 3000 g for 5 min. 
Supernatants were collected and used for cytotoxicity assay. Cytotoxicity was then 
assessed by a cytotoxicity assay (LDH assay).  
 
2.2.11 LDH cytotoxicity assay  
 
Lactate dehydrogenase (LDH) release into the supernatant was assayed using a 
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commercial colourimetric method (Cytotoxicity Detection Kit; Roche Diagnostics). 
Results were expressed as a percentage of the total cellular LDH measured from cells 
lysed in 1% Triton-X100 and corrected with appropriate media controls and total lysate 
protein. 
 
2.2.12. Bicinchoninic (BCA) assay 
The protein concentrations were measured using a BCA assay (Perbio Science, 
Cramlington, UK) following the manufacturer’s instructions. The BCA Protein Assay 
combines the well-known reduction of Cu2+ to Cu1+ by protein in an alkaline medium 
with the highly sensitive and selective colorimetric detection of the cuprous cation (Cu1+) 
by bicinchoninic acid. In the first step, peptides containing three or more amino acid 
residues form a coloured chelate complex with cupric ions in an alkaline environment 
containing sodium potassium tartrate. In the second step of the colour development 
reaction, bicinchoninic acid (BCA) reacts with the reduced (cuprous) cation that was 
formed in step one. The intense purple-coloured reaction product results from the 
chelation of two molecules of BCA with one cuprous ion. The BCA/copper complex is 
water-soluble and exhibits a strong linear absorbance response at 562 nm with 
increasing protein concentrations.  
Cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in ice-cold 
modified RIPA lysis buffer without protease inhibitor. Insoluble material was removed by 
centrifugation at 12,000 g for 15 min at 40C. Clear 96 well plates were used. 25 µL of 
cell lysates and standards were added (standard range 25-2000 g/mL). BCA reagents 
A and B were mixed together at a ratio of 50:1 before use and 200 µL was added to 
every well. The plate was then sealed and incubated for 30 min in an oven at 370C. 
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Plates were read at 550 nm in a plate spectrophotometer (Dynex Jencons PLS 
Technologies Microplate Reader) 
2.2.13 Materials 
 
Unless stated otherwise, all compounds used in this study were purchased from Sigma 
Aldrich-Company Ltd (Poole, Dorset, UK). All solutions used were prepared using 
genetic grade water from ELGA process water, Marlow International, Marlow, UK. 
Thiopentone sodium (Intraval Sodium) was obtained from Rhone Merieux (Harlow, 
Essex, UK). 
 
2.2.14: Statistical analysis 
 
All values are reported as mean ± SDs. LDH assay, caspase assays, and MTS assays 
were performed. Each experiment was repeated 3 times in total. All multiple group 
comparisons were performed using ANOVA with a post-test according to Bonferroni. 
We have used an unpaired Student’s t test to compare the means of two different 
groups. All statistical analysis was performed using GraphPad Prism version 5 
(GraphPad Software, San Diego, CA). A P value of < 0.05 was considered significant. 
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2.3 Results 
 
2.3.1: Sodium nitrite (NaNO2) protects HK-2 cells against apoptosis 
caused by serum starvation (SS) 
 
Caspase-3 activity was significantly increased in SS treated HK-2 cells after 24 h when 
compared with control cells treated with 10% FCS whereas NaNO2 ( 50,100 & 500 
nmol/L) attenuated this increase ( see Figure 1). Although 100 nmol/L NaNO2 was 
found to be optimal for this effect there was also a significant reduction in caspase-3 
activity when using 50 nmol/L (Figure 1 and 2). Similar effects were seen when 
caspase-9 was measured whilst no caspase-8 activity was seen (Figure 3). 
Furthermore, this anti-apoptotic effect translated into preserved cell viability at several 
concentrations (Figure 4) 
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Figure 1: NaNO2 (50 nmol/L, 100 nmol/L and 500 nmol/L) protected HK-2 cells 
against apoptosis caused by SS. 
SS caused significant increase in apoptosis when compared to control FCS treated 
cultures. This increase was attenuated by NaNO2 at several concentrations. Apoptosis 
was measured by caspase-3 activity (nmol AMC/mg/min), n=3, ***= P<0.001. 
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Figure 2: NaNO2 protected HK-2 cells against SS induced apoptosis. 
SS of HK-2 cells for 24 h caused significant activation of caspase-3 activity compared to 
control (with serum) and this increase was attenuated by NaNO2 treatment (50 nmol/L), 
n=3, ***= P<0.001 
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Figure 3: NaNO2 protection against apoptosis was mediated via caspase-9 
(intrinsic mitochondrial pathway). 
HK-2 cells were incubated with NaNO2 at 50 nmol/L simultaneously with SS for 24 h. 
Caspase-9 activity was significantly increased in the SS group which was attenuated by 
NaNO2, n=3, ***= P<0.001. No caspase-8 activity was detected.  
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Figure 4: NaNO2 improves HK-2 cell viability caused by 24 h SS. 
Cell viability was significantly reduced in SS treated cells compared to control treated 
cells. NaNO2 significantly improves viability of HK-2 cells after SS for 24 h at several 
concentrations. The cell viability was determined by MTS assay and the absorbance, 
proportional to the number of viable cells was measured at 490 nm. n=8, ***= P<0.001. 
 
 
2.3.2 NaNO2 protects HK-2 cells against in vitro IRI induced apoptosis 
 
Caspase-3 activity was significantly increased in HK-2 cells treated with antimycin A (50 
µmol/L) and 2-deoxyglucose (10 mmol/L) with HBSS (antimycin A model, AA) when 
compared with control treated cells whereas, NaNO2 (100 nmol/L) attenuated this 
increase when given with or after in vitro ischaemia injury, but high NaNO2 (10 mol/L) 
given with or after in vitro ischaemia did not protect the cells from injury. This suggests 
that NO2
- can play a significant protective role in preventing apoptosis caused by our in 
vitro model of renal IRI (Figure 5). 
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Figure 5: NaNO2 protects HK-2 cells against cellular IRI-induced apoptosis. 
HK-2 cells were incubated with (50 mol/L) antimycin A plus (10 mmol/L) 2-
deoxyglucose in HBSS (AA) for 1 h to induce ischaemic injury in vitro. The in vitro 
reperfusion was achieved by incubating cells in DMEM growth medium with FCS 10% 
and antibiotic 1%. Cells were then left to incubate for 24 h in an incubator. Caspase-3 
activity was significantly increased in the AA group compared to control treated cells, 
this increase was significantly reduced by NaNO2 at 100 nmol/L when given with or after 
in vitro ischaemia. Although a 10 mol/L dose did afford some protection it was found 
not to be significant.  n=3, ***= P<0.001, *= P<0.05, NS= not significant. 
 
2.3.3 Effects of NaNO2 on HK-2 cell necrosis 
 
The LDH cytotoxicity assay showed a significant increase in LDH release in the H2O2 
treated group (500 mol/L in DMEM with 10% FCS and 1% antibiotic) when compared 
to the untreated control HK-2 cells (given H2O as a vehicle). However, this increase 
could not be abolished by NaNO2 supplementation (Figure 6).  
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Figure 6: NaNO2 does not attenuate necrosis caused by in vitro reperfusion 
model. 
HK-2 cells were given H2O2 (500 mol/L) for 2 h with or without NaNO2. LDH 
cytotoxicity assay was performed to assess necrosis. There was significant necrosis in 
the H2O2 group when compared to control HK-2 cells P <0.05. NaNO2 could not 
attenuate this significant increase. n=3, NS= not significant. 
 
 
2.2.4: Pre-treatment with NaNO2 does not prevent apoptosis at several 
doses 
 
Caspase-3 activity was significantly increased in SS treated HK-2 cells after 24 h when 
compared with control cells treated with 10% FCS (SS=348.2±73.5; control=199±60.3, 
P<0.05) whereas pre-treatment for 4 h prior to SS with several doses of NaNO2 did not  
attenuated this increase (Figure 7).  
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Figure 7: Pre-treatment with NaNO2 does not attenuate apoptosis caused by SS. 
HK-2 cells were cultured in 6 well plates for 24 h in incubator with DMEM , 1 % 
Antibiotic and 10 % FCS. When cells were confluent media in SS + pretreatment group 
(SS+ PT NaNO2) was added NaNO2 at several different doses for 4 h. After 4 h, media 
was removed and SS injury was induced by removing FCS from the media and cells 
were placed in incubator for 24 h. After 24 h, cells were scraped and caspase-3 assay 
was performed. The result provide evidence that there is significant apoptosis in SS 
group when compared to control HK-2 cells and pre-treatment with NaNO2 at several 
different doses cannot attenuate apoptosis caused by SS. n=3,  *= P<0.05, NS= not 
significant. 
 
2.2.5: Pre-treatment with NaNO2 does not preserve cell viability at 
several doses 
 
Cell viability was significantly decreased in antimycin treated HK-2 cells after 24 h when 
compared with control cells treated whereas pretreatment for 4 h before AA with several 
doses of NaNO2 did not preserve HK-2 cell viability (Figure 8).  
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Figure 8: Pre-treatment with NaNO2 did not preserve the HK-2 cell viability. 
HK-2 cells were cultured for 24 h. When cells were confluent HK-2 cells were pretreated 
with NaNO2 at several different doses for 4 h. Then media was removed and HK-2 cells 
were incubated with (50 mol/L) antimycin A plus (10 mmol/L) 2-deoxyglucose in HBSS 
(AA) for 1 h to induce ischaemic injury in vitro. The in vitro reperfusion was achieved by 
incubating cells in DMEM growth medium with FCS 10% and antibiotic 1%. Cells were 
then left to incubate for 24 h in an incubator. Cell viability was significantly decreased in 
the AA group compared to control treated cells, but pre-treatment with NaNO2 at several 
doses did not protect cell viability.  n=8, ***= P<0.001. 
 
2.3.6: Plasma NO2
-/NO3
-levels 
 
Plasma NO2
-/NO3
-concentrations were as expected significantly higher in the IRI+high 
NaNO2 treatment (50 mg/L) group when compared to IRI group (Figure 9). IRI group 
were fed upon a normal NO2
- diet. Although plasma NO2
-/NO3
- concentrations were 
increased in the high NaNO2 group there was no protection from injury seen against 
renal IRI. 
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Figure 9: Plasma NO2
-/NO3
- levels in high NaNO2 vs IRI group before renal 
ischaemia.                                
IRI rats were drinking normal water and IRI+ high NaNO2 were given NaNO2 at 50 mg/L 
in drinking water. Blood was collected prior to IRI to assess NO2
-/NO3
- levels in serum. 
The Griess assay was performed as shown previously (Chatterjee et al., 2002). The 
result of the Griess assay showed that plasma NO2
-/NO3
- levels were significantly higher 
in the high oral NaNO2 group when compared to the IRI group, n=4, ***= P<0.001 
 
2.3.7: Effect of NaNO2 on renal IRI in rats 
 
In comparison with sham animals, control animals (normal NO2
- diet) that were 
subjected to renal IRI (IRI group) had significant renal dysfunction at 24 h as suggested 
by a significant increase in serum creatinine concentration (Figure 10). However, pre-
treatment for 7 days with NaNO2 (50 mg/L) in the drinking water (IRI+high NO2
- 
treatment) with normal NO2
- chow or low NO2
- diet chow group (IRI+low NO2
- diet 1.38 
µg/L) with normal water prior to renal IRI neither attenuated nor worsened the 
deleterious effects of IRI. 
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Figure 10: Showing a significant difference in serum creatinine concentration 
between sham operated animals vs IRI+V, P <0.001. 
Sham rats and IRI received normal water and standard diet for 7 days. IRI+ high NaNO2 
received normal standard diet and NaNO2 was given in drinking water at a concentration 
of 50 mg/kg for 7 days. IRI+ low NO2
- diet group were given normal water and standard 
diet was replaced with special low NO2
- diet (1.38 g/L). IRI was performed on all rats 
leaving sham in which renal pedicle was not clamped. The results provide evidence that 
pre-treatment with high NaNO2
- or low NO2
- diet did not attenuate the increase in serum 
creatinine concentration when compared to IRI group, ***= P <0.001, n=9, NS = not 
significant. 
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2.4 Discussion 
 
The main findings of these experiments are that (a) NO2
- cannot abolish the damage 
and dysfunction caused by renal IRI at lower and higher dose in rats (b) NO2
- can 
protect human renal PTECs against apoptosis caused by in vitro IRI model and can 
preserve cell viability (c) pretreatment with NO2
- both in vivo and in vitro does not 
ameliorate the damage and dysfunction associated with renal IRI. Taken together, these 
observations suggest that oral NO2
- therapy is not protective against renal IRI. However, 
nitrite may prevent apoptosis and preserves cell viability if given at time of injury or post 
injury in PTECs. 
 
Investigators in our laboratory have previously demonstrated the beneficial effects of the 
topical application of NO2
- on rat kidneys when applied just before reperfusion in a renal 
IRI model through the XOR mechanisms (Tripatara et al., 2007). However, i.v. NO2
- has 
also been shown to be detrimental in renal IRI (Basireddy et al., 2006).The study 
presented here explores whether altering the oral NO2
- diet in rats (low and high) can 
prevent the damage and dysfunction caused by renal IRI. The results demonstrated that 
both the low and high NO2
- diets were unable to protect against renal IRI, this being in 
contrast to the beneficial effects seen in both cardiac and hepatic IRI (Duranski et al., 
2005). In a renal IRI model we have previously demonstrated beneficial effects of NO2
- 
but the mode of administration was topical upon the kidneys, the dosage was lower (60 
mol/L) and the ischaemia duration was different (60 min) (Tripatara et al., 2007). 
Previously, NO donors have been shown to be beneficial if given prior to the onset of 
ischaemia in IRI (Schulz et al., 2004, Lefer et al., 1993) but at high doses NO donors 
have been found to be harmful. Higher sustained generation of NO at concentrations 
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>300 nmol/L, which causes iNOS activation is known to be pro-apoptotic and leads to 
increased lipid peroxidation (Goligorsky et al., 2002).  
 
One of the likely reasons why NO2
- treatment has been seen to be detrimental can be 
that a too high a dose has been used, as most of the previous studies have 
demonstrated that nanomolar doses of NO2
- are beneficial in a number of organs and 
species (Lefer et al., 1993, Bolli, 2001, Lefer, 1995). However, in contrast to above 
mentioned studies our low dietary NO2
- group was not found to be protective against 
renal IRI. Furthermore, the NO2
- beneficial effects are dependent on its conversion to 
NO by XOR (Tripatara et al., 2007) and there is also evidence suggesting that XOR is 
associated with the generation of ROS and is detrimental to tissues (Tiravanti et al., 
2004). The NO protective effects are due to eNOS derived NO, which causes 
vasodilation and inhibits leukocyte adhesion and platelet aggregation (Raat et al., 2009, 
Tripatara et al., 2007). Damaging inflammatory effects are due to iNOS derived NO 
which forms ONOO- from the interaction of NO and O2
•−
 (Raat et al., 2009).  
 
As expected our results showed that plasma NO2
-/NO3
- concentrations were elevated 
before renal IRI in the high NO2
- treatment group and our results are in accordance with 
others work which shows that plasma NO2
-/NO3
- levels were significantly higher in rats 
at 30 min after i.v administration of NO2
- compared to control group (Basireddy et al., 
2006). Although, NO2
-/NO3
- levels were higher they were unable to see any beneficial 
effects of NO2
- via systemic administration. Their finding mimic our findings as we also 
did not find any beneficial effects of NO2
- via oral administration (Basireddy et al., 2006). 
However, contrary to our study, previous works demonstrates that plasma NO2
-/NO3
- 
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levels were surprisingly higher in renal IRI group after 6 h of reperfusion when 
compared to NO2
- treated group (Tripatara et al., 2007). Triptara further measured the 
levels of NO2
- derived NO in kidney homogenates under anaerobic conditions which 
showed that there was significant NO generated from NO2
- in NO2
- treated group during 
anaerobic conditions compared to IRI group (Tripatara et al., 2007). Further research is 
needed to understand whether pre-treatment of NO2
- contributes towards the generation 
of ONOO- as a by-product of O2
•−
 and NO which is normally seen where iNOS is 
activated (Raat et al., 2009). It will also be worthwhile to investigate the levels of NO2
- 
and NO during ischaemia with pretreatment of NO2
-. Furthermore, it might be of interest 
to perform nitrotyrosine staining on the kidney homogenates to assess whether 
pretreatment of NO2
- is contributing towards increased ONOO- formation and to perform 
western blot analysis to look at iNOS, eNOS and XOR expression in order to identify the 
possible mechanism. The findings of these in vivo experiments may be clinically 
relevant as pre-treatment of oral NO2
- by patients undergoing high risk procedures such 
aortic aneurysm surgery or coronary artery bypass graft would have been the natural 
strategy if pre-clinical data had shown any benefit. 
 
To summarise, the oral route of administration for NO2
- is unable to prevent renal IRI 
and the damage and dysfunction associated with it. To date, the effect of NO2
- upon 
apoptosis in PTECs have not been studied. The main finding of these in vitro 
experiments are that a direct cytoprotective effects of NO2
- upon PTECs occurred in 
both SS and simulated IRI models. Furthermore, this anti-apoptotic protection is 
mediated via the intrinsic pathway in the SS in vitro model. 
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NO2
- was also able to preserve cell viability in the SS model, but was not able to 
ameliorate the degree of necrosis caused by H2O2, in an in vitro reperfusion model. 
Although the relevance of SS induced apoptosis as an in vitro mimic of renal IRI 
remains controversial, our findings that NO2
- exerts a cytoprotective effects against the 
well established in vitro (simulated) cellular IRI model confirms its pro-survival role 
against IRI.  
 
Research indicates that intracellular ATP depletion and a decrease in tissue oxygen 
content with increase in intracellular calcium are the main features of renal IRI. In the 
above experiments, we produced ATP depletion mediated apoptotic cell death as an in 
vitro model of ischaemic or ATP depletion injury. This injury was achieved by a 
combination of metabolic inhibitors antimycin A and 2-deoxyglucose (Iwata et al., 1994). 
It has been demonstrated that this treatment produces approximately 90% ATP 
depletion compared to untreated cultures (Iwata et al., 1994). Our data suggest that 
NO2
- prevents apoptosis through the intrinsic pathway by reducing the caspase-9 
activity and preserves cell viability if given at lower doses in SS and in in vitro IRI model 
but pre-treatment with NO2
- seems to be of little or no therapeutic effect which confirms 
our in vivo data. It is possible that preloading with NO2
- both in vivo and in vitro is 
ineffective.  
 
In conclusion, our in vivo study demonstrates that pre-treatment with dietary NO2
- is not 
an effective treatment for AKI. Although in vitro it was found to reduce apoptosis and 
preserve cell viability if given at time of ischaemic injury.  Further research is needed to 
understand the NO2
- mechanism of action and role in AKI and renal tubular apoptosis. 
  
79 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
ROLE OF THIAMINE AND 
BENFOTIAMINE IN AKI 
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3.1: Introduction 
 
Renal IRI is a major cause of AKI (Liano and Pascual, 1998) and is a consequence of 
acute tubular injury initiated by a combination of ROS generation and ATP depletion 
(Bonventre, 1993). Thiamine has been previously shown to play an essential role in the 
scavenging of ROS and the regeneration of ATP (Nozaki et al., 2009, Natera et al., 
2011). Studies have shown that it reduces ischaemic myocardial damage and has 
marked cytoprotective effects against MI (Larrieu et al., 1987). Furthermore, thiamine 
has been shown to attenuate the degree of hypoxic/ischaemic cardiac cell death (Shin 
et al., 2004) and has been found to prevent incipient diabetic nephropathy at high doses 
(Babaei-Jadidi et al., 2003). Tissue thiamine deficiency is a major cause of delayed graft 
function during transplantation and its supplementation to the graft donor can prevent 
the delayed graft function (Klooster et al., 2007). Moreover, thiamine deficiency has 
been revealed to cause the oxidative stress that leads to the formation of ROS, lipid 
peroxidation and apoptosis in cardiac muscle and eventually leads to heart failure 
(Gioda et al., 2010). In a similar manner there is an increase in COX-2 expression in the 
brain of thiamine deficient rats which leads to the generation of ROS such as peroxide, 
O2
•−
 and cause neuronal cell death in vivo and in vitro (Pepicelli et al., 2002). 
 
In vitro studies using cultured neonatal rat cardiomyocytes have identified the 
cytoprotective role of thiamine by attenuating hypoxia-induced apoptosis with an 
inhibition of caspase-3 activation, PARP cleavage and DNA fragmentation. This 
cytoprotective effects could be abolished by anti-Hsp70 antibodies (Shin et al., 2004).  
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In many diseases, such as Wernicke’s encephalopathy (Victor et al., 1971), diabetic 
nephropathy (Babaei-Jadidi et al., 2003) and diabetic dyslipidaemia (Babaei-Jadidi et 
al., 2004) a high dose of thiamine is able to prevent known symptoms. Thiamine is 
transported across plasma membranes by high affinity carriers (Bettendorff and Wins, 
1994) but the rate of transport is generally very slow. Many of lipophilic thiamine 
derivatives have been synthesized which can diffuse easily through the plasma 
membrane with better bioavailability (Greb and Bitsch, 1998, Lonsdale, 2006). These 
lipophilic derivatives bypass the rate limiting transport system required by thiamine. 
These lipophilic derivatives can be converted to thiamine inside the cell by enzymatic or 
non-enzymatic processes (Volvert et al., 2008). Currently, two lipophilic disulphide 
derivatives are used as therapeutic agents: thiamine tetrahydrofurfuryl disulphide 
(fursultiamine) (Lonsdale, 2004, Volvert et al., 2008) and O-isobutyrylthiamine 
disulphide (sulbutiamine) (Van Reeth, 1999). Sulbutiamine is used as a symptomatic 
drug in treating asthenias (Van Reeth, 1999). Chronic treatment with sulbutiamine 
increases thiamine, ThMP, ThDP and ThTP levels in brain and peripheral tissues 
(Bettendorff et al., 1990).  
 
Benfotiamine is a third derivative with better bioavailability than thiamine. In contrast to 
other derivatives it is an S-acyl derivative and has been shown to protect against 
diabetic complication (Wu and Ren, 2006). Benfotiamine is able to prevent glucose 
toxicity (Berrone et al., 2006, Marchetti et al., 2006) and blocks three major pathways 
(the hexosamine pathway, the AGE formation pathway and the diacylglycerol-protein 
kinase pathway) of hyperglycaemic damage, by removing glyceraldehydes-3-phosphate 
and fructose-6-phosphate through the activation of transketolase enzyme which plays a 
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crucial role in pentose phosphate pathway (Hammes et al., 2003). Furthermore, 
benfotiamine has been shown to protect against ischaemia induced toe necrosis, 
improve hind limb perfusion and oxygenation and restore endothelium dependent 
vasodilation in streptozocin-induced diabetic mice models (Gadau et al., 2006).  
 
Benfotiamine has also been shown to improve the recovery from MI by reducing 
oxidative stress, correcting the impairment of adaptive pro-survival mechanism and 
moderating neurohormonal activation. This study identifies that benfotiamine improves 
myocardial perfusion, promotes reparative neovascularization in the infarcted heart, 
reduces oxidative stress and apoptosis and activates pro-survival signalling 
mechanisms, in the infarcted heart (Katare et al., 2010). Another study shows that 
benfotiamine protects against peritoneal and kidney damage associated with peritoneal 
dialysis. The study identifies that benfotiamine decreases glucose-induced tissue 
damage in a model of peritoneal dialysis in uraemic rats and treatment with 
benfotiamine decreased peritoneal fibrosis, markers of inflammation, and 
neovascularization, resulting in improved characteristics of peritoneal transport (Kihm et 
al., 2011). Furthermore, this study also shows that rats treated with benfotiamine 
exhibited a lower expression of advanced glycation end products (AGE) and their 
receptor in the peritoneum and the kidney, reduced glomerular and tubulointerstitial 
damage, and less albuminuria. Increased activity of transketolase in tissue and blood 
contributed to the protective effects of benfotiamine (Kihm et al., 2011). 
 
Studies have shown that the administration of benfotiamine leads to higher thiamine 
levels in blood compared to water soluble thiamine (Greb and Bitsch, 1998, Lonsdale, 
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2004). Another study has identified that benfotiamine is not as potent as previously 
thought compared to other lipophilic thiamine derivatives (Volvert et al., 2008). 
Furthermore, recent study suggests that there is downregulation of thiamine 
transporters in the CKD rats and it is suggestive of severe deficiency of thiamine in 
these rats (Bukhari et al., 2010). Similarly, recently published data shows that thiamine 
pyrophosphate can reduce the oxidative damage in renal IRI but they did not evaluated 
its effects on renal IRI (Altuner et al., 2013). Thiamine and benfotiamine have been 
shown to play a crucial role in preventing ischaemic damage in different models by 
reducing oxidative stress, inflammation and apoptosis whilst renal IRI is a consequence 
of oxidative stress, inflammation and apoptosis. The possible utility of both these 
compounds appear obvious so that the aim of this study was to investigate the effects of 
thiamine and benfotiamine upon the rat kidney (functional and histological) in a renal IRI 
model and to investigate if thiamine has anti-oxidant, anti-inflammatory and anti-
apoptotic effects.  
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3.2 Materials and methods 
 
3.2.1 Rat model of renal IRI 
 
The protocol was the same as described in chapter 2 (2.2.1 Rat model of renal IRI). 
Briefly, the procedure requires that the renal pedicles are bilaterally clamped for 45 min 
with microaneurysm clamps followed by reperfusion for 24 h with the time of ischaemia 
chosen to obtain a reversible model of ischaemic AKI and to avoid animal mortality. 
Sham surgery consisted of the same surgical procedure except that clamps were not 
applied.  
 
3.2.2 Assessment of renal function 
 
The protocol was as described earlier (2.2.2 Assessment of renal function). End-points 
examined include histological evaluation by both haematoxylin and eosin staining and 
TUNEL assay. IDEXX Laboratories, Sussex, UK, were blinded to the treatment given, 
performed serum creatinine measurements. 
 
3.2.3 Experimental design 
 
The study was divided into the following groups; 
 
(i)SHAM OPERATED RATS: The renal pedicle was not clamped but the remaining 
procedure was the same as for the IRI group and rats were gavaged once daily with 
saline for 3 days. 
 
(ii) IRI GROUP: Rats subjected to IRI of the kidney (IRI group) and were gavaged once 
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daily with saline for 3 days. 
 
(iii)THIAMINE GROUP: Rats subjected to IRI plus pre-treatment with thiamine HCL 
(500 mg/kg) by gavage once daily for 3 days. 
 
(iv)THIAMINE LOW DOSE GROUP: Rats subjected to IRI plus pre-treatment with 
thiamine HCL (125 mg/kg) gavaged 1 h before IRI. 
 
3.2.4: Histological evaluation 
 
Histological evaluation was done as described earlier (Kumar et al., 2009). Briefly a 
renal pathologist, who was blinded to the treatment given, performed the morphologic 
assessment. Kidney sections were stained with haematoxylin and eosin. A hundred 
intersections were examined for each kidney and a score from 0 to 3 was given for each 
tubular profile. Briefly, 0, normal histology; 1, tubular cell swelling, brush border loss, 
nuclear condensation, with up to one third of tubular profile showing nuclear loss; 2, as 
for score 1 but greater than one third and less than two thirds of tubular profile shows 
nuclear loss; and 3, greater than two thirds of tubular profile shows nuclear loss. The 
total score for each kidney was calculated by addition of all 100 scores with a maximum 
score of 300. 
 
3.2.5 Terminal deoxynucleotide transferase nick end labeling (TUNEL) 
assay 
 
Terminal deoxynucleotide transferase nick end labelling (TUNEL) assay done as 
described earlier (Kumar et al., 2009). Briefly TUNEL was employed to detect apoptosis 
on histological sections. The TUNEL method is based on direct, specific, labelling of 
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DNA breaks in nuclei, in situ. One of the characteristics of apoptosis is the degradation 
of DNA after the activation of Ca2+/Mg2+ dependent endonucleases. This DNA cleavage 
leads to strand breaks within the DNA. The method is based on the specific binding of 
terminal deoxynucleotidyl transferase (TdT) to 3’-OH ends of the strand breaks of 
cleaved DNA ensuring the synthesis of a polydeoxynucleotide polymer. After the 
exposure of nuclear DNA on histological sections by proteolytic treatment, TdT is used 
to incorporate biotinylated deoxyuridine at sites of DNA breaks. The biotin-labelled 
cleavage sites are then detected by reaction with HRP conjugated streptavidin and 
visualized by diaminobenzidine showing as a brown colour. 
 
The TUNEL assay was performed by using a TUNEL detection kit according to the 
manufacturer’s instructions (Apotag, peroxidase ISOL apoptosis detection kit). Briefly, 
sections were incubated with 15 µg/mL proteinase K for 15 min at room temperature 
and then washed with PBS. Endogenous peroxidase was inactivated by 3% H2O2 for 5 
min at room temperature and then washed with PBS. Sections were immersed in TdT 
buffer containing deoxynucleotidyl transferase and biotinylated dUTP in TdT buffer, 
incubated in a humid atmosphere at 37°C for 90 min, and then washed with PBS. The 
sections were incubated at room temperature for 30 min with anti-horseradish 
peroxidase-conjugated antibody, and the signals were visualized with diaminobenzidine. 
The number of TUNEL-positive cells/high power field was counted in 5 to 10 fields for 
each coded slide. 
 
3.2.6 Tissue extracts 
 
Cytosolic and nuclear extracts were prepared as previously described (Tripatara et al., 
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2008). Briefly, kidneys were homogenized at 10% (w/v) in a Potter Elvehjem 
homogeniser (Fisher Scientific Ltd., Loughborough, UK) using a homogenisation buffer 
containing 20 mM HEPES, pH 7.9, 1 mmol/L MgCl2, 0.5 mmol/L EDTA, 1% NP-40, 1 
mmol/L EGTA, 1 mmol/L Dithiothreitol (DTT), 0.5 mmol/L Phenylmethyl Sulphonyl 
Fluoride (PMSF), 5 g/mL aprotinin, 2.5 g/mL leupeptin. Homogenates were 
centrifuged at 4,000 g for 5 min at 4°C. Supernatants were removed and centrifuged at 
14,000 g at 4°C for 40 min to obtain the cytosolic fraction. The pelleted nuclei were 
resuspended in extraction buffer containing 20 mmol/L HEPES, pH 7.9, 1.5 mmol/L 
MgCl2, 300 mmol/L NaCl, 0.2 mmol/L EDTA, 20% glycerol, 1 mmol/L EGTA, 1 mmol/L 
DTT, 0.5 mmol/L PMSF, 5 g/mL aprotinin, 2.5 g/mL leupeptin. The suspensions were 
incubated on ice for 30 min for high-salt extraction followed by centrifugation at 15,000 g 
for 20 min at 4°C. The resulting supernatants containing nuclear proteins were carefully 
removed and protein content was determined using a BCA protein assay following the 
manufacturers’ directions. Samples were stored at -80°C until use. 
 
3.2.7 ROS detection 
 
ROS were measured in cytosolic fractions using 2',7'-dichlorofluorescein diacetate 
(DCFH-DA) as a probe. DCFH-DA is a stable, non-fluorescent molecule that readily 
crosses the cell membrane and is hydrolysed by intracellular esterases to non-
fluorescent 2',7'-dichlorofluorescein (DCFH), which is rapidly oxidised, in the presence 
of peroxides, to highly fluorescent 2',7'-dichlorofluorescein (DCF). The DCF is then 
measured fluorimetrically (Ravindranath, 1994). Results are expressed as units of 
fluorescence (UF)/mg protein. 
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3.2.8 End products of lipid peroxidation  
 
Lipid peroxidation was investigated by measuring the main end-product of peroxidation, 
hydroxynonenal (HNE), in the cytosolic fractions. HNE concentration was determined on 
fresh cytosolic fractions by Esterbauer’s method (Esterbauer et al., 1986). An aliquot of 
cytosol (100 µL) was extracted in an equal volume of a solution of acetic 
acid/acetonitrile (4/96, v/v). After centrifugation at 250 g for 20 min at 4°C, 50 L of 
supernatant were injected on to an HPLC Symmetry C18 column (5 m, 3.9x150 mm). 
The mobile phase used was acetonitrile:bi-distilled water (42%, v/v). The HNE 
concentration was calculated by comparison with a standard solution of HNE 
(Calbiochem, Merck Chemicals Ltd, Beeston, UK) of known concentration.  
 
3.2.9 Myeloperoxidase activity 
 
Myeloperoxidase (MPO) activity, an indicator of polymorphonuclear leukocyte 
accumulation, was determined at 24 h reperfusion as described previously (Mullane et 
al., 1985). At the specified reperfusion time, kidneys were obtained and weighed and 
each piece homogenized in a solution containing 0.5% (w/v) hexadecyltrimethyl-
ammonium bromide dissolved in 10 mmol/L potassium phosphate buffer (pH 7) and 
centrifuged for 30 min at 20,000 g at 4°C. An aliquot of the supernatant was then 
allowed to react with a solution of 1.6 mmol/L tetramethylbenzidine and 0.1 mmol/L 
H2O2. The rate of change in absorbance was measured spectrophotometrically at 650 
nm. MPO activity was defined as the quantity of enzyme degrading 1 µmol of peroxide 
per min at 37°C and was expressed in mU per gram of wet tissue. 
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3.2.10. Western blot analysis  
 
About 60 µg of protein was loaded. Proteins (COX-2 and ICAM-1) were separated on 
pre-cast 8% sodium dodecyl sulphate-polyacylamide gel electrophoresis (SDS-PAGE) 
and transferred to a polyvinyldenedifluride (PVDF) membrane, which was then 
incubated with blocking buffer overnight at 40C. Membranes were incubated with 
primary antibody (rabbit anti-COX-2, goat anti-ICAM-1). Blots were then incubated with 
secondary antibody conjugated with horseradish peroxidase for 30 min at room 
temperature and the immunoreactive bands were visualised by Enhance 
Chemiluminescence (ECL) reagent (GE Healthcare, Buckinghamshire, UK) and the 
density of the bands were evaluated densitometrically using NIH Image J software. The 
membranes were stripped and incubated with -actin monoclonal antibody and 
subsequently with anti-mouse antibody, both for 30 min at room temperature, in order to 
assess gel-loading homogeneity. 
 
3.2.11 Administration of benfotiamine 
Benfotiamine (Sigma-Aldrich) was dissolved in a 200 mmol/L solution of hydroxypropyl-
β-cyclodextrin (HP-β-CD, Sigma Aldrich Chemical Company) at a concentration of 25 
mg/mL as described by others (Volvert et al., 2008). The solution was homogenized at 
4°C. The rats were gavaged with a dose of 250 mg benfotiamine/kg once daily for 3 
days Control animals were gavaged HP-β-CD solution (200 mmol/L) prepared in saline 
once daily for 3 days without benfotiamine.  
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3.2.12 Experimental design 
 
The study was divided into the following groups; 
(i) SHAM OPERATED RATS: The renal pedicle was not clamped but the remaining 
protocol was the same as for the IRI group and rats were gavaged using HP-β-CD 
solution (200 mmol/L) without benfotiamine once daily for 3 days.  
 
(ii) IRI GROUP: Rats subjected to IRI of the kidney (IRI group) and were gavaged with 
HP-β-CD solution (200 mmol/L) without benfotiamine once daily for 3 days.  
 
(iii) BENFOTIAMINE GROUP: Rats subjected to IRI plus pre-treatment with 
benfotiamine (250 mg/kg) by gavage once daily for 3 days. 
 
3.2.13 In vitro IRI model  
As described in section 2.2.6 
 
3.2.14 LDH cytotoxicity assay  
As described in section 2.2.11 
 
3.2.15 Cell viability (MTS) assay 
As described in section 2.2.7. 
 
3.2.16 Serum starvation model 
As described in section 2.2.8. 
 
3.2.17 Materials and statistical analysis 
As described in section 2.2.13 and 2.2.14. 
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3.3 Results 
 
3.3.1: Thiamine attenuates apoptosis in HK-2 cultures in renal IRI (in 
vitro model) 
 
Caspase-3 activity was found to be significantly increased in the lysates derived from 
HK-2 cells treated with antimycin A 50 mol/L and 2-deoxyglucose (10 mmol/L) in 
HBSS when compared with control treated cells (HBSS only). Thiamine (10 mol/L-100 
mol/L) attenuated this increase (Figure 11). This anti-apoptotic effect of thiamine was 
also translated into preserved cell viability (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
HK-2 cells were incubated with 50 mol/L antimycin A plus 10 mmol/L 2-deoxyglucose 
with HBSS for 1 h (AA) to induce ischaemic injury in vitro. The in vitro reperfusion was 
achieved by incubating cells in DMEM with FCS 10% and antibiotic 1%. Cells were 
allowed to grow for 24 h in an incubator. Caspase-3 activity was significantly increased 
in the AA model group compared to control treated cells, P <0.05, which was largely 
prevented by thiamine 10-100 µmol/L if given with in vitro ischaemia P <0.01. There 
was no protection seen if thiamine was given after AA treatment, n=3, *= P<0.05,**= 
P<0.01, ***= P<0.001. 
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Figure 11. Thiamine protects HK-2 cells against cellular IRI induced apoptosis. 
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Cell viability was significantly attenuated by 24 h of serum starvation (SS) compared to 
control cells (P <0.001). Thiamine (100 mol/L) significantly preserved viability of HK-2 
cells upon serum starvation (SS) for 24 h P <0.001. Cell viability was determined by 
MTS assay and the absorbance, proportional to the number of viable cells was 
measured at 490 nm, n=3, ***= P<0.001.  
 
 
3.3.2: Effects of thiamine on necrosis caused by in vitro reperfusion 
model 
 
LDH assay shows significant increases in cytotoxicity in H2O2 (500 mol/L) treated 
group when compared to control HK-2 cells, P <0.001 (Figure 13). However, this 
increase could not be attenuated by the addition of thiamine (100 mol/L). 
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Figure 12.  Thiamine preserves viability of HK-2 cells in a serum starvation model. 
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HK-2 cells were given H2O2 (500 mol/L) for 2 h with or without thiamine (100 mol/L) 
and then the LDH assay was performed to assess necrosis. There was significant 
necrosis in the H2O2 group when compared to control HK-2 cells P <0.001. However, 
thiamine was unable to protect against H2O2 induced cytotoxicity, NS = not significant, 
***= P<0.001. 
 
 
3.3.3 Thiamine ameliorates renal dysfunction and attenuates the 
histological damage of rat renal IRI  
 
An initial pilot study with thiamine at 125 mg/kg was performed to assess whether 
thiamine treatment can prevent renal IRI at that dose given 1 h prior to renal IRI. It 
showed a trend indicating that thiamine might be able to prevent renal IRI at a higher 
dose (data not shown). From this we chose to use a higher dose of thiamine (500 
mg/kg). 
 
In the study presented here, in comparison with sham treated animals, control animals 
that were subjected to renal IRI (IRI+V) had significant renal dysfunction at 24 h as 
shown by a significant increase in serum creatinine (Figure 14). However, the rats that 
were orally gavaged thiamine (500 mg/kg) for 3 days prior to ischaemia (IRI+THI) had a 
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Figure 13. Thiamine does not protect HK-2 cells against necrosis caused by 
hydrogen peroxide. 
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marked reduction in serum creatinine by comparison (224 mol/L  64 to 119 mol/L  
55; IRI+V versus IRI+THI, P< 0.012, respectively (Figure 14). Histology data indicated 
that the kidneys from the IRI+V group (Figure 15 A) had signs of severe tubular damage 
in the outer medulla, as evidenced by widespread tubular necrosis when compared with 
sham group (Figure 15 C). In contrast, all renal sections obtained from animals that 
were treated with thiamine showed significantly less tubular damage at the same time 
point of 24 h (Figure 15 B). Quantification of the tubular damage revealed a markedly 
lower mean tubular injury score from the kidneys of rats treated with thiamine (Figure 15 
D).  
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Figure 14 Thiamine attenuates the increase in serum creatinine caused by renal 
IRI. 
There was significant increase in the serum creatinine concentrations of the IRI+V 
group when compared to sham rats. This increase in serum creatinine at 24 h post-
reperfusion after renal IRI is abrogated by the gavaging of thiamine (500 mg/kg, orally) 
for 3 days prior to ischaemia, n =6, ** = P<0.01, ***= P<0.001. 
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Figure 15 (A-D). Thiamine ameliorates renal dysfunction and attenuates the 
histological damage caused by renal IRI. 
Panels A, B) Renal histopathology of hematoxylin and eosin stained sections are from 
kidney (representative images of at least three experiments). (D) Quantitative scores of 
tubular injury in the outer medulla, ***= P<0.001, n=6.  
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3.3.4 Thiamine attenuates apoptosis post renal IRI in rat kidney 
 
Kidneys from control animals (IRI+V) showed extensive nuclear changes consistent with 
apoptotic cell death as demonstrated by intense and widespread TUNEL positive 
staining cells (mean±SD=2.41±0.88) (16 A). Thiamine oral administration (500 mg/kg) 
for 3 days before ischaemia led to significant reduction in the percentage of TUNEL 
positive cells (mean±SD=0.31±0.7) when compared to IRI+V (mean±SD=2.41±0.88) 
suggesting a profound anti-apoptotic effect in vivo (Figure 16 B). 
A                                                                     B 
                            
       IRI+V                                                                      IRI+THIAMINE 500 mg/kg.                                        
                             C 
 
 
           Kit positive control 
 
Figure 16 (A-C). Thiamine has anti-apoptotic effects against renal IRI. 
Apoptosis was investigated by TUNEL staining. TUNEL staining revealed strikingly 
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fewer apoptotic nuclei in rats treated with thiamine (IRI + thiamine, 500 mg/kg) (B) when 
compared to control (IRI+V) group (A). The number of TUNEL positive cells/high-power 
field were counted in 5 to 10 fields for each coded slide. There was significant apoptosis 
seen in IRI+ V and this was significantly reduced by thiamine supplementation, **= 
P<0.01, n=6 
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3.3.5 Thiamine Attenuates ICAM-1 and COX-2 expression after renal 
IRI: 
 
Western blots were performed on kidney homogenate to examine the expression of 
ICAM-1 and COX-2. There was a significant increase in the expression of ICAM-1 and 
COX-2 in the IRI+V group when compared to the sham group in kidney homogenate 
and this increase was significantly attenuated in thiamine treated animals (Figure 17, 
panels A and B). 
A                                                                                      B 
ICAM-1                     COX-2     
β-actin                                     β-actin                                      
                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                        
 
 
 
Each immunoblot is from a single experiment and is representative of three separate 
experiments. Densitometry analysis of the bands is expressed as relative optical density 
(O.D.), corrected for the corresponding -actin and normalised using the related sham-
operated band. Data are means  SD. of three separate experiments, n=6, *= P<0.05, 
***= P<0.001. 
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Figure 17. Thiamine has anti-inflammatory effects in renal IRi as it causes 
significant reduction in expression of (A) ICAM-1 and (B) COX-2. 
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3.3.6: Thiamine attenuates oxidative stress and inflammation in renal 
IRI 
 
DCF assay demonstrated a significant increase in ROS generation in the IRI +V group 
when compared to sham, and this increase was significantly attenuated by treatment 
with thiamine (500 mg/kg) for 3 days prior to ischaemia (Figure 18A). End product of 
lipid peroxidation was assessed by measuring hydroxynonenal (HNE). There was a 
significant increase in HNE levels in IRI+V group when compared to sham group and 
this increase was significantly attenuated by treatment with thiamine (500 mg/kg) 
gavage for 3 days prior to ischaemia (Figure 18B). Furthermore the MPO assay showed 
an increase in levels in the IRI+V group and this increase was also attenuated by 
thiamine (500 mg/kg) gavaged for 3 days prior to ischaemia (Figure 18C). 
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                                                   C 
 
 
 
 
Panel (A) shows a significant reduction of ROS in thiamine treated animals when 
compared to IRI+V group. Panel (B) shows a significant reduction in HNE-4 levels in 
thiamine treated animals when compared to IRI+V group. Panel (C) shows a significant 
reduction in MPO activity in thiamine treated animals compared to IRI+ V group, n=6, *= 
P<0.05, ***= P<0.001. 
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Figure 18. Thiamine has anti-oxidant and anti-inflammatory effects in renal IRI. 
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3.3.7 Benfotiamine role in renal IRI 
 
Benfotiamine was given to rats by gavaging once daily for 3 days prior to renal IRI at a 
dose of 250 mg/kg. Sham and IRI+V were gavaged with saline once daily for 3 days 
prior to renal IRI. At day 3 renal IRI was performed. The results demonstrate that there 
was a significant increase in serum creatinine in the IRI+V group when compared to 
sham rats (Figure 19). However, benfotiamine was not able to reduce this increase 
(Figure 19).  
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Figure 19. Benfotiamine does not prevent damage and dysfunction casued by 
renal IRI. 
Sham rats and IRI animals received normal water and standard diet for 7 days and were 
gavaged saline once daily for 3 days prior to ischaemia. The IRI+ benfotiamine (250 
mg/kg) group received normal standard diet and were gavaged with benfotiamine once 
daily for 3 days prior to ischaemia. IRI was performed on all rats except sham in which 
renal pedicle was not clamped. Blood was collected at 24 h after ischaemia and serum 
was sent for biochemical analysis. The results provide evidence that pre-treatment with 
benfotiamine did not attenuate the increase in serum creatinine concentration when 
compared to IRI group, ***= P <0.001, n=6, NS = not significant. 
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3.4: Discussion 
 
The main findings of these experiments are that (a) thiamine is reno-protective against 
renal IRI and (b) the direct cytoprotective effect of thiamine on human renal PTECs 
might contributes to this observed protection and (c) thiamine ameliorates renal IRI by 
its anti-oxidant and anti-inflammatory properties (d) benfotimaine cannot attenuate the 
damage and dysfunction associated with renal IRI. Taken together, these observations 
suggest that thiamine therapy is protective against renal IRI. In comparison to thiamine, 
benfotiamine was not able to attenuate the damage and dysfunction associated with 
renal IRI. 
 
Several observations led us to evaluate thiamine in the setting of renal IRI. Firstly, 
thiamine treatment significantly increased cardiomyocyte survival after a hypoxic insult, 
and did so by protecting the cells from hypoxia-induced apoptosis associated with 
caspase-3 activation, PARP cleavage and DNA fragmentation (Larrieu et al., 1987, Shin 
et al., 2004). The studies described here are the first to provide evidence that thiamine 
can prevent renal IRI by an anti-apoptotic effect both in vivo shown by reduction in 
TUNEL positive staining and in vitro by preventing apoptosis in HK-2 cells caused by a 
renal IRI model.  
 
Much data exists to indicate that thiamine can prevent IRI in the brain and heart (Larrieu 
et al., 1987, Sheline and Wei, 2006, Klooster et al., 2007). These studies suggest the 
possibility that thiamine can have a potential role in the IRI settings. However, a further 
study conducted by Klooster et al. indicated that in the renal IRI setting severe thiamine 
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deficiency and weight loss is beneficial (Klooster et al., 2009), but they believed that the 
beneficial effects were likely due to fasting rather than due to thiamine deficiency. 
Furthermore, there is evidence that fasting protects the heart against IRI (Schaefer and 
Ramasamy, 1997). Our study provides evidence that thiamine can reduce renal IRI that 
mimics the previous studies that have established the role of thiamine in IRI models of 
heart and brain(Larrieu et al., 1987, Sheline and Wei, 2006). It is notable that the dose 
of thiamine used in the work of Klooster et al (Klooster et al., 2009) was very low (400 
g/daily), both in the control rats and thiamine deficient rats as they received only 0.16 
g/kg of body weight. The renal IRI model was also different to the one presented here 
as they performed unilateral left kidney ischaemia for 45 min with partial nephrectomy of 
the right kidney (Klooster et al., 2009), whereas our model consisted of a bilateral 
ischaemia on both kidneys for 45 min. This might be the explanation for the differences 
in outcome of these studies. The profound reno-protective effects of thiamine that we 
found were reflected in the histological evaluation of renal sections, as marked 
preservation of tubular architecture and a concomitant striking reduction in the tubular 
injury score. Furthermore the work described here has revealed that the kidneys 
harvested from thiamine treated rats were noted as showing a huge reduction in the 
TUNEL positive staining and that this anti-apoptotic effect was also seen in an in vitro 
IRI model by the reduction in caspase-3 and preserved cell viability. 
 
Studies demonstrate that thiamine deficiency leads to oxidative stress and that thiamine 
itself is purported to have anti-oxidant properties (Depeint et al., 2007). During 
ischaemia there is significant oxidative stress which upon reperfusion leads to the 
formation of ROS and causes lipid peroxidation (Locatelli et al., 2003). This led us to 
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investigate the role of thiamine in preventing renal IRI through anti-oxidant effects. This 
hypothesis was proven correct as indicated by the reduction in ROS levels after 24 h of 
reperfusion in the cytosolic fractions of renal IRI kidneys treated with thiamine (500 
mg/kg). An end product of lipid peroxidation, HNE-4 was also reduced in thiamine 
treated renal IRI kidneys, confirming that thiamine protect through an anti-oxidant 
mechanism.  
 
Finally some studies have shown that thiamine deficiency is associated with 
inflammation and that there is an increase in COX-2 and ICAM-1 in the thiamine 
deficient rat brain (Calingasan et al., 2000). The administration of both anti–ICAM-1 
antibodies and the creation of ICAM-1–deficient mice have both been shown to be 
protective strategies against renal IRI (Kelly et al., 1994, Kelly et al., 1996). However, no 
study has demonstrated that thiamine can ameliorate renal IRI by anti-inflammatory 
mechanisms. We therefore investigated whether thiamine can reduce inflammatory 
markers such as MPO, COX-2 and ICAM-1 and found that it could attenuate the 
increase in these inflammatory markers in a renal IRI setting. As far as we are aware, 
this study is the first to establish that thiamine can ameliorate injury and dysfunction 
caused by renal IRI in rats by anti-oxidant, anti-inflammatory and anti-apoptotic 
mechanisms. This study is also the first to show that thiamine reduces tubular injury ( in 
vivo) and tubular apoptosis (both in vivo and in vitro) thereby providing evidence that 
thiamine has anti-apoptotic properties. We therefore believe we are the first group to 
demonstrate that thiamine can ameliorate AKI. 
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The second part of the study was to evaluate the possible role of benfotiamine in the 
renal IRI setting. S-acyl thiamine derivatives and lipid-soluble thiamine disulphide 
derivatives have been developed because they have a 5-10 fold higher bioavailability 
than thiamine (Volvert et al., 2008). Benfotiamine has been able to prevent diabetic 
nephropathy (Babaei-Jadidi et al., 2003) and play a crucial role in ischaemic conditions 
(Gadau et al., 2006).This led us to investigate the role of benfotiamine in renal IRI at a 
lower dose compared to thiamine to see if we could prove that lipid soluble benfotiamine 
has a better bioavailability and could reduce the renal IRI at a much lower dose 
compared to thiamine. The result of renal IRI study performed on rats shows a 
significant rise of serum creatinine in the renal IRI group when compared to the sham 
rats but this increase was not abolished by the supplementation of 250 mg/kg of 
benfotiamine. This suggests that benfotiamine cannot reduce the degree of renal IRI at 
a lower dose when compared to thiamine.  
 
There is a debate that whether these S-acyl thiamine derivatives and lipid-soluble 
thiamine disulphide derivatives are needed when thiamine is available. One of the 
reason is that tissue uptake of these is highly variable across different tissues and 
organs (Volvert et al., 2008). Secondly, oral thiamine when given over a 1-week period 
was able to produce blood levels that approach those obtained by intramuscular and 
intravenous administration (Baines et al., 1988, Royer-Morrot et al., 1992). Thirdly, in 
vitro studies that have compared thiamine to thiamine derivatives have generally found 
them to have similar effects (Babaei-Jadidi et al., 2003, Beltramo et al., 2004, Beltramo 
et al., 2009, Berrone et al., 2006, Karachalias et al., 2005, Karachalias et al., 2010).  
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Another study shows that benfotiamine has a different mechanism of action and has a 
different pharmacological profile than lipid soluble thiamine disulphide derivatives. The 
study showed that whilst levels of thiamine in blood and liver are increased when 
supplemented with benfotiamine or sulbutiamine but were low in the brain in the 
benfotiamine group when compared to sulbutiamine group (Volvert et al., 2008). 
Furthermore, the same study also suggested that benfotiamine penetrates the cells only 
after dephophorylation by intestinal alkaline phosphatases. It then enters the blood 
stream as S-benzoylthiamine before being converted to thiamine in erythrocytes and 
liver. Moreover, it has been claimed that benfotiamine should not be treated as a true 
lipid soluble drug (Volvert et al., 2008). Although our study with benfotiamine suggests 
that it can not reduce renal IRI at lower dose than thiamine it still leaves open a window 
for future research using the newly found thiamine derivatives such as sulbutiamine and 
allithiamine which have better bioavailability at the tissue level when compared to 
thiamine and benfotiamine (Volvert et al., 2008). 
 
In summary, this is the first study to identify that thiamine can prevent renal IRI and its 
analog benfotiamine appears ineffective in the same experimental model. It identifies a 
potential role for thiamine in the prevention of AKI in multiple clinical settings and calls 
for use of large scale randomized control trials so that this potential therapeutic could 
eventually be realized. 
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CHAPTER 4 
 
GENE THERAPY OF HUMAN BMP-7 IN 
RENAL IRI 
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4.1 Introduction 
 
BMP-7 belongs to the TGF-superfamily and is associated with organ development as 
shown in the eye, bone and kidney nephron formation (Dudley et al., 1995). In adults, 
BMP-7 is only expressed in a few tissues and its maximum expression is seen in the 
kidneys. BMP-7 is expressed in the tubules of the outer medulla and glomerular parietal 
epithelial cells, in podocytes and in renal artery adventitial cells (Vukicevic et al., 1998, 
Simon et al., 1999). During renal IRI there is a massive downregulation of BMP-7 
mRNA in the outer medulla and glomeruli (Gould et al., 2002). Studies have 
demonstrated that rhBMP-7 protein can ameliorate the injury and the dysfunction 
caused by renal IRI at a given dose of 250 µg/kg (Vukicevic et al., 1998). Furthermore, 
BMP-7 plays an important role in renal repair and regeneration of the tubules during 
ischaemia (Vukicevic et al., 1998). Data suggest that BMP-7 has anti-inflammatory and 
cytoprotective effects on renal PTECs by suppressing TNF-stimulated pro-
inflammatory cytokines such as IL-6, IL-8 and MCP-1. It also suppresses proximal 
tubular expression of endothelin-2 and adenosine A1 but increases the expression of 
endothelin-1 (Gould et al., 2002) which leads to increase blood flow to the peritubular 
capillaries. Conversely, the loss of endogenous BMP-7 may lead to profibrotic effects 
following IRI in the kidney. 
 
BMP-7 has also been shown to reduce interstitial inflammation, fibrogenesis, apoptosis 
and tubular atrophy in a renal unilateral uretheral obstruction model (Hruska et al., 
2000). In addition, BMP-7 has been shown to reverse chronic renal injury by 
counteracting the TGF-1 mediated epithelial to mesenchymal transition (Zeisberg et 
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al., 2003). In a streptozotocin-induced type 1 diabetic nephropathy model, BMP-7 levels 
were found to be decreased and that the use of exogenous administration of BMP-7 
was able to attenuate the severity of diabetic nephropathy by reducing tubulointerestitial 
fibrosis and glomerular pathology and restore GFR back to normal levels and decrease 
proteinuria (Wang et al., 2003).  
 
Gene therapy is the use of DNA as a pharmaceutical agent to treat inherited and 
acquired disease (Jobs, 2011). It can also be defined as a technique to correct defective 
genes responsible for a disease. The technique uses DNA to supplement or alter genes 
within an individual's cells as a therapy to manage and treat disease (Patil P.M, 2012). 
Gene therapy can be performed by using DNA encoded with a functional gene to 
replace a mutated gene and this is the most common used form. 
 
Gene therapy can be also be conducted by either directly correcting a mutation or using 
DNA encoding a therapeutic protein drug rather than a gene to provide treatment. A 
vector is used to carry the DNA encoding the therapeutic protein and takes the DNA 
inside cells. When inside the cell the DNA becomes part of the host chromosome and 
starts producing the desired protein which ultimately treats the disease. Gene therapy 
can be classified as somatic and germ line gene therapy. Furthermore, the gene 
delivery systems in vivo can be further categorised as viral and non-viral approaches 
(Liu et al., 1999, Crystal, 1995). Evidence suggests that virus gene therapy is an 
efficient form of transferring foreign genes in vivo but it has several major limitations. 
Construction and preparation of viral vectors is time consuming and some viral vectors 
are unable to infect non-proliferating cells, making it impossible for substantial 
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expression of the transgene in most normal and diseased tissues where cell turnover is 
relatively low. Furthermore, many other viral vectors have shown to induce severe host 
immune responses that not only result in a short duration of transgene expression but 
also make the repeated administration extremely difficult or even impossible (Yang et 
al., 2001). Safety in the usage of viral vectors for clinical gene therapy is not yet 
optimum, (Liu et al., 1999) whereas plasmid DNA (pDNA), which is a typical non-viral 
vector, has advantages in terms of safety compared with a viral vector (Hirayama et al., 
2004). 
 
Currently naked DNA gene therapy has been gaining increased interest in gene therapy 
applications as it has the advantages of simplicity of use, lack of immunogenicity and 
ease of DNA preparation (Walther et al., 2005). Many methods have been developed to 
deliver naked DNA into the desired cells or tissues in vivo and in vitro, such as in vivo 
electroporation (EP), jet injections, needle and syringe injections, ultrasound and 
hydrodynamics pressure, particle bombardment (gene gun), intraportal injection and 
hydrodynamic gene delivery (Lawrie et al., 2000, Zhang et al., 2000, Sikes et al., 1994, 
Yang et al., 1990, Lin et al., 2000, Aihara and Miyazaki, 1998, Walther et al., 2005). 
 
Research indicates that the direct administration of plasmid vector with the desired 
genes can be a potential approach to deliver and express foreign genes in vivo (Liu et 
al., 1999, Li et al., 1997, Yang et al., 2001). This method has benefits such as the ease 
in the preparation of the plasmids and its established safety in vivo (Yang et al., 2001). 
A study has shown effective exogenous human EPO gene therapy with an in vivo gene 
transfection procedure by rapid injection of a large volume of naked plasmid DNA 
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solution via the tail vein (Wang et al., 2004). It has been proposed that the injected DNA 
solution is forced into the liver by hydrostatic pressure as the liver may tolerate large 
volume of solution. The hydrostatic pressure results in the crushing of endothelial 
barrier and it is by this mechanism by which highly efficient gene expression is seen in 
the liver (Wang et al., 2004). This study further identified that the PCMV-EPO plasmid 
injection into the tail vein of rats when diluted in 3 mL of saline results in a high level of 
expression of EPO protein in the circulation and can help prevent hypoxic ischaemic 
encephalopathy (Wang et al., 2004). With this background in mind we decided to 
investigate the effects of BMP-7 gene therapy by injecting naked BMP-7 plasmid DNA 
in a renal IRI setting. 
In rodents, nucleus acid gene delivery by hydrodynamic tail vein injection is a highly 
competent procedure(Jobs, 2011). Hydrodynamic gene delivery is commonly used due 
to its simplicity and high efficiency and the nucleic acid gene delivery with this technique 
has been successful in all major organs with the best results are found in the liver (Jobs, 
2011). Research shows that this method of gene delivery in the liver is well tolerated 
and shows no biochemical evidence of liver injury after eight accumulative doses 15 day 
apart, whereas efficacy of transgene expression was increased accordingly (Crespo et 
al., 2005, Alino et al., 2007, Dicks et al., 2009, Jobs, 2011). However, data suggest that 
there is liver injury seen at 24 to 48 h after hydrodynamic gene delivery but it is 
temporary and non-damaging event. Furthermore it is a method with many clinical 
applications but adverse effects of its injection could cause circulatory collapse and 
death. These hazards of hydrodynamic gene therapy are those that are limiting the 
translation of this procedure to the clinical practice. With enhanced knowledge of the 
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mechanisms involved in high gene delivery efficiency it may help in developing a clinical 
procedure with mild hemodynamic effects (Jobs, 2011, Suda and Liu, 2007).  Recent 
studies on the mechanisms involved in gene therapy via hydrodynamic gene delivery to 
the liver, provide evidence that improvement s in the technique and to conduct it in large 
animals by a catheterization procedure (Alino et al., 2007, Dicks et al. 2010) is a safe 
and non-invasive method for regional in vivo gene delivery under mild condition and 
may have potential clinical applications.  
However clinically, hydrodynamic gene delivery is not considered feasible in humans 
because of heavy overload of fluid which can cause abnormality in cardiac function and 
can lead to heart failure. Furthermore, cardiac congestion may be well tolerated by 
rodents but it will be not considered safe for patients (Suda and Liu, 2007). Although at 
the experimental level hydrodynamic gene delivery shows promising results, clinically its 
utility is still unclear. 
‘Electroporation (EP) is another gene therapy technique available to introduce 
macromolecules such as nucleic acids into cells, either in vivo or in vitro, by brief 
electric pulses to induce transient and reversible permeabilization of the cell 
membrane’(Sardesai and Weiner, 2011). This method is now been used in clinical trials 
to deliver nucleic acid and drugs.to many target tissues and organs within the last 
decade (draghia-akli, 2009, Sardesai and Weiner, 2011). Multiple studies have 
indicated transient pores are generated due to transmembrane voltage function during 
EP (Cukjati et al., 2007, Trollet et al., 2006). Researchers have shown that 
macromolecules present in the extracellular medium surrounding the target cells gain 
access to the intracellular environment during the period of membrane destabilisation 
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within nano to milli seconds (Becker and Kuznetsov, 2007). Furthermore there is then a 
slow resealing of the membrane (on the s to min time scale) after the EP pulses. 
Although the exact mechanism of translocation of DNA across the membrane pores is 
debatable (electrophoretic facilitation versus passive diffusion) the end result of this 
process is upwards of 100–1000 fold enhancement of plasmid delivery and gene 
expression can be achieved relative to delivery of DNA alone without EP (Sardesai and 
Weiner, 2011). EP is an easy to perform non-viral gene therapy technique that requires 
only a plasmid and a device to perform EP (Kawai et al., 2006). The technique of EP 
can play an important role in the development for gene therapeutic approaches with the 
potential to treat many conditions with a single low dose of plasmid resulting in long-
term benefits (Bodles-Brakhop et al., 2009).  
 
A pilot study was conducted on large animals with plasmid growth hormone releasing 
hormone (GHRH) with EP to treat renal failure and to investigate its possible side 
effects. This study had shown that malignant melanoma can be treated by DNA delivery 
of xenogenic human tyrosinase DNA by EP successfully in a Phase I veterinary trial 
conducted on dogs (Bergman et al., 2003, Brown et al., 2009). A more recent study 
showed that this gene therapeutic approach by EP can attenuate the complications of 
CKD by increasing the life expectancy, wellbeing, and quality of life of animals with 
experimentally induced renal failure (Brown et al., 2009). Earlier studies using GHRH 
showed that plasmid therapy with EP can be a promising technique to produce and 
regulate the secretion of proteins in both experimental animal models and in humans 
(Tone et al., 2004, Brown et al., 2004, Brown et al., 2008, Bodles-Brakhop et al., 2008). 
Furthermore, it does not require viral vectors, expensive proteins and carrier matrices. 
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The technique appears to be of particular utility to our study because the direct BMP-7 
protein administration has been shown to cause ectopic bone formation at the site of 
injection (Ripamonti et al., 2001a, Ripamonti et al., 2001b) Indeed data show that non-
viral gene therapy with the EP of BMP-7 simultaneously with BMP-2 has been 
successful in gastrocnemius muscle and was not associated with ectopic bone 
formation (Kawai et al., 2006). As mentioned earlier, the exogenous administration of 
BMP-7 protein has been shown to be beneficial in renal IRI (Vukicevic et al., 1998) and 
as gene therapy with EP has been shown to be previously successful we hypothesise 
that gene therapy of BMP-7 with EP might have an important therapeutic value in 
preventing the injury and the dysfunction caused by renal IRI in mice. 
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4.2 Materials and methods 
 
4.2.1. Naked DNA gene delivery 
 
Control and BMP-7 plasmid DNA were delivered by direct injection. The injections were 
prepared by diluting DNA in 2.5 mL of 0.9% NaCl solution. Endotoxin-free plasmid for 
injection was prepared in 0.9% NaCl as a vehicle control 5-50 g of naked DNA was 
injected into the tail vein. An ELISA for BMP-7 was performed on serum and kidney 
homogenate to assess the success of gene delivery. 
 
4.2.2 Rat model of renal IRI 
 
The protocol was the same as described in chapter 2.2.1. Briefly, the procedure 
requires the renal pedicles bilaterally clamped for 45 min with microaneurysm clamps 
followed by reperfusion for 24 h with the time of ischaemia chosen to obtain a reversible 
model of ischaemic AKI and to avoid animal mortality. Sham surgery consisted of the 
same surgical procedure without the clamps being applied.  
 
4.2.3 Assessment of renal function 
 
The protocol was as described in section chapter 2.2.2. Briefly, centrifugation of the 
collected blood for 3 min at 9000 g yielded the serum. The veterinary clinical 
pathologists, IDEXX Laboratories, Sussex, UK; blinded to the treatment given, 
performed serum creatinine measurements. 
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4.2.4 Experimental design 
 
A total of 40 rats were used in this study and they were divided into the following 3 
groups. Control rats were directly injected with control PCMV SPORT6 DNA (PCMV 
SPORT6 is the backbone vector) 3 days before ischaemia. IRI BMP-7 group were 
directly injected with human BMP-7 DNA 3days before ischaemia. The sham group 
were directly injected with control PCMV SPORT 6 DNA, again 3 days before 
ischaemia. All rats received normal water and standard diet and the same surgical 
procedures were performed for all animals except in the sham group where the arterial 
clamps were not applied.  
 
4.2.5 Mice IRI model 
 
Male mice C57/BL6 wild-type mice (WT, 25–30 g; Charles River Laboratories, Margate, 
UK) received a standard diet and water ad libitum, and were cared for in accordance 
with both the UK Home Office Guidance in the Operation of the Animals (Scientific 
Procedures) Act 1986, published by Her Majesty’s Stationery Office, London, UK. Mice 
were subjected to renal IRI as previously detailed (Chatterjee and Thiemermann, 2003). 
First the mice were anaesthetised with ketamine (100 mg/mL) and xylazine (20 mg/mL) 
(2:1) at a dose of 1.5 mL/kg, i.p. and their abdominal hair was shaved and the skin 
cleaned with 70% alcohol (v/v). The mice were then placed upon a heated blanket set to 
a temperature of 37°C and a mid-line laparotomy was performed and their renal 
pedicles (consisting of the renal artery, vein and nerve) were isolated and clamped 
using non-traumatic microvascular clamps at time 0 as described before (Chatterjee 
and Thiemermann, 2003). After 30 min of acute bilateral ischaemia, the clamps were 
removed, the skin was then sutured following administration of buprenorphine (0.1 
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mg/kg, s.c.) for pain control, and the mice were allowed to recover from anaesthesia 
and returned to cages. At 24 h the animals were sacrificed, blood samples were 
collected via cardiac puncture and the kidneys harvested. The kidneys were cut 
longitudinally into two halves and each half from respective kidneys were stored in 10% 
formalin for histological analysis or were immediately snap frozen in liquid N2 for further 
experiments. Mice subjected to IRI were electroporated with control PCMV-SPORT 6 
DNA or human BMP-7 DNA (both at 25-50 g/mL) 2 days before renal IRI. Sham 
operated mice underwent the same surgical procedures except ligation of renal pedicle 
and the experiments were performed in parallel. 
 
4.2.6 Assessment of renal function in mice 
 
Serum creatinine was measured as mentioned before (see chapter 2.2.2). 
 
4.2.7 Plasmid purification 
 
PCMV SPORT 6 control plasmid and human BMP-7 plasmid were purchased from 
I.M.A.G.E Clone, Source Bioscience, Nottingham, UK). Liquid culture of E.coli 
containing control or BMP-7 plasmids were grown in 12 mL tubes containing 5 mL of 
sterile autoclaved L-broth (Sigma) at a concentration of 20 g/L, with ampicillin 100 g 
/mL and were left  on an orbital shaker at 200 rpm at 37°C overnight. Next day, glycerol 
stocks were made with glycerol concentrations of 15% and 50% in control and BMP-7 
plasmid containing culture and were stored at -80°C. The same procedure was 
performed onto a larger scale using a large sterile 1 L flask. The next day the large 
cultures were poured in to sterile autoclaved 500 mL tubes and were spun at 5000 g for 
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30 min and the resulting pellet was used for plasmid purification. Plasmid DNA was 
purified using the Plasmid Mega Kit (Qiagen Ltd, Crawley, UK), or when required for 
injection into mice using the EndoFree™ Plasmid Mega Kit (Qiagen Ltd). Plasmid DNA 
concentration was quantified using a Nanodrop spectrophotometer (Thermo Scientific, 
Loughborough, UK). 
 
4.2.8 Experimental design 
 
A total of 24 mice were used in this study and they were divided into the following 
groups. Control mice were electroporated with control PCMV SPORT 6 DNA 2 days 
before ischaemia. IRI BMP-7 group was electroporated with human BMP-7 DNA. The 
sham group was electroporated with control PCMV SPORT 6 DNA, again two days 
before ischaemia.  All mice received normal water and standard diet and the same 
surgical procedures were performed for all animals except in the sham group where the 
arterial clamps were not applied.  
 
4.2.9 Transfections  
 
Transfections were performed using the OPTIFECT™ reagent (Invitrogen Life Science, 
Paisley, UK) according to the manufacturer’s protocol. HK-2 and 293-T cells were 
seeded onto 6 well plates with DMEM, 10 % FCS, without antibiotics and were 
incubated for 24 h. When 30-50 % confluent, 1 g of control DNA or BMP-7 DNA was 
diluted in DMEM without FCS and incubated for 5 min in an incubator. Simultaneously, 
12 µL of OPTIFECT™ was diluted in 250 µL of DMEM and incubated for 5 min. Diluted 
DNA and diluted OPTIFECT™ were combined and incubated for 20 min. Control or 
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BMP-7 DNA lipid complexes were added to their cultured cells and incubated for 24 to 
48 h. Supernatants were collected at the end of the study period and the ELISA 
described below (4.2.10 ELISA for detecting BMP-7 in serum and transfected cells) was 
performed to determine BMP-7 expression. 
 
4.2.10 ELISA for detecting BMP-7 in serum and transfected cells 
 
A BMP-7 ELISA was performed on the serum of mice and the supernatant of 
transfected 293 T (Human Embryonic Kidney 293 cells) and HK-2 cells in order to 
assess the expression of BMP-7. Blood samples were collected at different time points 
both at day 2 after EP and at day 4. The supernatant from 293 T cells and HK-2 cells 
were collected at day 2 after transfection. The ELISA was performed according to 
manufacturer’s instructions (DuoSet for BMP-7, R&D Systems).  
 
Briefly, a 96 well microplate was coated with capture antibody at a concentration of 2 
g/mL in PBS (pH 7.3) and incubated overnight at room temperature. The plate was 
then aspirated, washed 4 times with washing buffer (0.05% Tween 20 in PBS, pH 7.2 - 
7.4) and was blocked by adding blocking buffer 300 L (1% BSA in PBS, pH 7.2 - 7.4, 
0.2 m filtered) and incubated at room temperature for 1 h. The plate was again washed 
4 times with washing buffer and standards and sample were added at 50 L per well 
and were incubated for 3 h at room temperature. The plate was then washed 4 times 
and a detection antibody was added at a concentration of 0.5 g/mL and left to incubate 
at room temperature for a further 2 h. The plate was again washed 4 times and 
streptavidin-HRP was added at a concentration of 1:200 in reagent diluent to each well 
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and incubated for 30 min in the dark. Washing was repeated as mentioned above and 
substrate solution (100 L) was added to the wells and left in the dark for 30 min. After 
30 min, H2SO4 (2.5 mmol/L stop solution) 50 L was added to prevent further colour 
change. The plate was then read at 450 nm with a reference reading at 650 nm in a 
microplate reader (Dynex Jencons PLS Technologies).  
 
4.2.11 In vivo electroporation (EP) 
 
Mice were treated in according to the UK Home Office Guidance in the Operation of the 
Animals (Scientific Procedures) Act 1986. Mice were anaesthetized with isoflurane 
(Concord Pharmaceuticals Ltd, Dunmow, UK) using Boyle’s apparatus (BOC Ltd, 
London, UK). The fur covering the right and left anterior tibialis muscle of the leg was 
shaved and the exposed skin sprayed with disinfectant. Endotoxin-free plasmid for 
injection was prepared in a solution of 0.9% NaCl. DNA (25-50 μg) was injected into the 
anterior tibialis muscle, and Camcare ECG gel (Camcare Gels, Mepal, Cambridgeshire, 
was then applied to the surface of the skin. Caliper electrodes 384L (BTX Instrument 
Division, Harvard Apparatus Inc., Ltd, Kent, UK) were applied transversely across the 
anterior tibialis muscle was electroporated with four pulses at 200 V/cm and 20 ms 
duration at a frequency of 2 Hz using a BTX Electro Square Porator ECM 830 (Harvard 
Apparatus Ltd) (Gould et al., 2004). The polarity of the electrodes was then reversed 
and the procedure repeated. 
 
4.2.12 In vitro renal IRI model 
As described in chapter 2.2.6. 
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4.2.13 Cell viability (MTS) assay  
As described in chapter 2.2.7. 
 
4.2.14 Caspase-3 assay  
As described in chapter 2.2.9. 
 
4.2.15 Materials & statistical analysis 
As described in chapter 2.2.13 and 2.2.14 unless specified. 
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4.3. Results 
 
4.3.1 Naked BMP-7 DNA does not protect against apoptosis caused by 
in vitro renal IRI model in PTECs 
 
Caspase-3 activity was significantly increased in the lysates derived from HK-2 cells 
treated with antimycin A (50 mol/L) and 2-deoxyglucose (10 mmol/L) in HBSS (AA) 
when compared with lysates derived from control treated cells (HBSS only). Naked 
BMP-7 DNA (1-50 g/mL in 2.5 mL DMEM) treatment did not attenuate this increase 
(Figure 20). 
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Figure 20. BMP-7 DNA does not protect against apoptosis in HK-2 cells in an in 
vitro renal IRI model. 
HK-2 cells were incubated with 50 mol/L of antimycin A plus 10 mmol/L 2-
deoxyglucose with HBSS for 1 h (AA) to induce ischaemic injury in vitro. The in vitro 
reperfusion was achieved by incubating cells in DMEM with FCS 10% and antibiotic 1%. 
Cells were allowed to grow for 24 h in an incubator. HK-2 cell apoptosis was 
significantly increased in the AA model group compared to control group P <0.001, 
which was not attenuated by naked BMP-7 DNA 1-50 g/mL in 2.5 mL DMEM if given at 
time of ischaemia, ***= P<0.001, n= 3. 
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4.3.2 Naked BMP-7 DNA does not cause upregulation of BMP-7 
protein in PTECs 
 
PTECs (HK-2) were cultured in 6 well plates for 24 h. When around 50-60 % confluent 
the cell culture media was replaced with or without different concentrations of BMP-7 
DNA. After 24 h the cells were scraped from the wells, centrifuged at 3000 g for 5 min 
and the media was collected for BMP-7 quantification. ELISA was performed on 
supernatants to access the expression of BMP-7 protein. The results demonstrate that 
there was no upregulation of BMP-7 protein in the BMP-7 group (data not shown). 
 
4.3.3 Expression of human BMP-7 in transfected 293-T and HK-2 cells 
 
Supernatants from transfected 293 T and HK-2 cells with control DNA or human BMP-7 
were collected after 24 h and the ELISA was performed to quantify BMP-7 protein. The 
results showed that the transfection of 293 T cells was much more efficient than for HK-
2 cells (Table 3). 
 
Table 3: Transfected 293 T cells show expression of human BMP-7 protein after 
24 h. 
 Control DNA transfection BMP-7 DNA transfection 
293 T cell Not detectable 598 ± 49 pg/mL 
HK-2 cell Not detectable Not detectable 
 
Table 3: 293 T cells were found to be more suited to transfection than HK-2 cells. BMP-
7 expression was detected by ELISA as mentioned above. 
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4.3.4: Injected naked BMP-7 DNA causes upregulation of BMP-7 in 
kidney homogenate 
 
Rats were injected with control PCMV SPORT 6 DNA and human BMP-7 DNA. DNA 5-
and 50 g was diluted with 2.5 mL of saline. Kidneys were harvested after 24 h after of 
renal IRI and were homogenised with RIPA buffer (see chapter 2.2.9.1). The ELISA was 
performed to quantify BMP-7 in the kidney homogenate The results of adding 5 g 
BMP-7 DNA demonstrated that there was an upregulation of BMP-7 in the BMP-7 
group, when compared to controls in a few of rats but was not statistically significant 
(Figure 21). For the higher dose the ELISA results of adding 50 g BMP-7 DNA showed 
that there was significant upregulation of BMP-7 in kidney homogenate compared to the 
controls (Figure 22). 
0
10
20
30
40
50
control DNA 5 g
BMP-7 DNA 5 g
NS
B
M
P
-7
 l
e
v
e
ls
 i
n
k
id
n
e
y
 h
o
m
o
g
e
n
a
te
 p
g
/m
l
 
Figure 21. Expression of BMP-7 in the rat kidney homogenate after renal IRI at 
day 4. 
Control and BMP-7 DNA (5 g diluted in 2.5 mL of saline and injected into the tail vein 3 
days prior to renal IRI was performed on rats as recorded in the method. Kidneys were 
collected on day 4 after renal IRI. An ELISA was performed on kidney homogenate to 
assess human BMP-7 concentrations. There was an increase in human BMP-7 
concentrations on day 4 after renal IRI in rat kidneys of BMP-7 group, when compared 
to the control group but was not statistically significant. **= P<0.01, n=3, NS = not 
significant. 
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Figure 22. Figure shows that there is significant expression of BMP-7 in the rat 
kidney homogenate after renal IRI at day 4. 
BMP-7 DNA (50 g) and control DNA (50 g) was diluted in 2.5 mL of saline and 
injected into the tail vein 3 days prior to renal IRI was performed on rats as recorded in 
the method. Kidneys were collected on day 4 after renal IRI. An ELISA was performed 
on kidney homogenate to assess human BMP-7 concentrations. There was a significant 
increase in human BMP-7 levels on day 4 after renal IRI in rat kidneys of BMP-7 group, 
when compared to the control group. **= P<0.01, n=3, NS = not significant. 
 
 
4.3.5 Expression of BMP-7 levels in serum after naked BMP-7 DNA 
injection: 
 
Rats were injected with control PCMV SPORT 6 DNA and human BMP-7 DNA. DNA 5-
50 g was diluted with 2.5 mL saline. Blood was collected at day 4 after renal IRI and 
the serum was separated by centrifuging at 9000 g for 3 min. The ELISA was performed 
to quantify the BMP-7 concentration in serum. The results of both the 5 and 50 g BMP-
7 DNA treatments demonstrated there was no upregulation of BMP-7 in the BMP-7 
group when compared to controls (data not shown). 
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4.3.6 Injected naked BMP-7 DNA therapy failed to attenuate the 
increase in serum creatinine after 24 h of renal IRI: 
 
In comparison with sham rats, IRI+ Control DNA 5-50 g injected into rats 3 days prior 
to renal IRI (IRI + control DNA) had significant renal dysfunction at 24 h as suggested 
by a significant increase in serum creatinine concentration (Figure 23). Rats injected 
with BMP-7 5-50 g 3 days before ischaemia in IRI+BMP-7 group did not show any 
significantly attenuation of this increase in serum creatinine (Figure 23). 
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Figure 23. BMP-7 DNA injected by tail vein does not reduce injury and 
dysfunction caused by renal IRI in rats. 
All rats received normal water and standard diet for 7 days. IRI was performed on all 
rats except sham in which renal pedicle was not clamped. Blood was collected at 24 h 
after ischaemia. The results provide evidence that pre-treatment with injecting BMP-7 
DNA did not attenuate the increase in serum creatinine concentration when compared 
to IRI+ control group, **= P <0.01, n=9, NS = not significant. 
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4.3.7 BMP-7 ameliorates apoptosis in HK-2 cells caused by an in vitro IRI model: 
 
Caspase-3 activity was significantly increased in the lysates derived from HK-2 cells 
treated with antimycin A (50 mol/L) with 2-deoxyglucose (10 mmol/L) in HBSS (AA) 
when compared with controls (HBSS only). rhBMP7 (10-100 ng/mL) attenuated this 
increase (Figure 24). This anti-apoptotic effect of rhBMP-7 was translated into 
preserved cell viability as assessed by MTS assay (Figure 25). 
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Figure 24. BMP-7 protects HK-2 cells against cellular IRI induced apoptosis. 
HK-2 cells were incubated with 50 mol/L antimycin A plus 10 mmol/L 2-deoxyglucose 
with HBSS for 1 h (AA) to induce ischaemic injury in vitro. The in vitro reperfusion was 
achieved by incubating cells in DMEM with 10% FCS and 1% antibiotic solution. Cells 
were allowed to incubate for a further 24 h. Caspase-3 activity was significantly 
increased in AA model group compared to the control group, P <0.01, which was 
attenuated by rhBMP-7 10-100 ng/mL if given with in vitro ischaemia, *= P<0.05, **= 
P<0.01, ***= P<0.001, n= 4. 
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Figure 25. BMP-7 preserves viability of HK-2 cells in the in vitro renal IRI model. 
HK-2 cells were incubated with 50 mol/L of antimycin A plus 10 mmol/L 2-
deoxyglucose with HBSS for 1 h (AA) to induce ischaemic injury in vitro. The in vitro 
reperfusion was achieved by incubating cells in DMEM with 10% FCS and 1% antibiotic 
solution. Cells were allowed to incubate for a further 24 h. Cell viability was significantly 
decreased in the AA model group compared to control group P <0.001, which was 
preserved by rhBMP-7 10-100 ng/mL if given with in vitro ischaemia, ***= P<0.001, n= 
8. 
 
 
4.3.8 BMP-7 expression in mice serum after EP on anterior tibialis 
muscle: 
 
Mice were electroporated (EP) with control PCMV SPORT 6 DNA and human BMP-7 
DNA. Blood was collected at day 2 and 4. The ELISA was performed to quantify BMP-7 
in the serum. There was significant upregulation of BMP-7 in the BMP-7 group on day 2 
when compared to controls. BMP-7 expression remained high on day 4 but this 
increase was found not to be statistically significant (Figure 26).  
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Figure 26. BMP-7 DNA with EP significant increased expression of human BMP-7 
on day 2. 
EP was performed on mice as recorded in the method. Blood was collected on day 2 
and 4. ELISA was performed to assess human BMP-7 concentrations in the mice 
serum. There was a significant increase in human BMP-7 levels on day 2, when 
compared to the control group.at day 2 and 4 *= P<0.05, n=5, NS = not significant. 
 
4.3.9 Effects of EP of BMP7 in renal IRI in mice: 
 
In comparison with the sham mice, IRI+Control EP mice had significant renal 
dysfunction at 24 h as illustrated by a significant increase in serum creatinine 
concentrations (Figure 27). However, EP of BMP-7 3 days before ischaemia (IRI+BMP-
7 EP) did not significantly attenuate this increase (Figure 27). 
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Figure 27. EP of BMP-7 DNA did not attenuate the increase in serum creatinine 
caused by renal IRI in mice. 
There was significant increase in the serum creatinine concentrations in the IRI+Control 
EP group when compared to sham mice. This increase in serum creatinine at 24 h post-
reperfusion was not significantly abrogated by the EP of BMP-7 3 days prior to 
ischaemia, n=6, ** = P<0.01, NS= not significant. 
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4.4 Discussion 
 
The main findings of the naked DNA gene therapy study were that (a) naked DNA 
cannot reduce apoptosis in PTECs, (b) naked DNA without transfection in PTECs 
cannot up regulate BMP-7 protein levels, (c) naked DNA injection in rats causes the up 
regulation of BMP-7 protein in the kidney when compared to control DNA but no serum 
BMP-7 was detected (d) and although,BMP-7 levels were elevated on day 2 after renal 
IRI, it was not found to attenuate the damage and dysfunction caused by renal IRI. 
 
Previous work conducted on the proximal tubules of rats indicates that gene therapy 
can be done successfully with retroviral vectors with transfer of the LacZ gene into the 
proximal tubules of rats after injuring the kidney with a nephrotoxic dose of folic acid 
(Bosch et al., 1993). This injury leads to regeneration of tubular cells that are necessary 
for infection with the retrovirus; otherwise, the majority of the adult PTECs would be in 
an inactive state and would not be infected (Bosch et al., 1993). Other work shows that 
the systemic injection of liposome-DNA complexes with mainly transfected endothelial 
cells (Wissing et al., 1997) and that gene expression mostly resides in the tubular 
epithelial cells following intravenous injection of naked DNA (Wu et al., 2005).This study 
further identifies that specific transient gene expression in the renal tubular epithelial 
cells can be demonstrated following injection of exogenous, naked DNA via systemic 
injection. Furthermore, the level of kidney-specific gene expression was concentrated in 
the corticomedullary region and predominantly in the proximal tubular cells. There was 
little or no expression of the exogenous gene detected in the distal convoluted tubules 
and it provides evidence that naked DNA delivery can be a successfully used in 
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targeting the kidney for gene therapy (Wu et al., 2005). This suggests that there can be 
a potential role of naked DNA gene delivery in the setting of renal IRI and this led us to 
investigate whether naked DNA injection of BMP-7 can enhance the levels of BMP-7 in 
serum and kidney and whether it can protect renal IRI.  
 
The results from our study show that there was no upregulation of BMP-7 in the serum 
after renal IRI but that the renal level of BMP-7 was significantly higher in the group 
injected with naked BMP-7 DNA 50 g when compared to the control DNA group. One 
of the likely explanations for the upregulation of BMP-7 can be that the kidneys have 
membrane-bound, specific, high-affinity BMP-7 receptors able to mediate BMP-7 
actions. The major BMP-7 binding component of kidney may be a long form of BMP 
type II receptor with a molecular weight of 100 kDa (Bosukonda et al., 2000).  
 
Our findings are in accordance with others who have demonstrated that naked DNA can 
cause upregulation of gene expression in the kidney (Wu et al., 2005). Furthermore, 
previous research shows that the in vivo cellular targets for BMP-7 are the convoluted 
tubule epithelium, the glomeruli in the cortex and the collecting ducts in the medulla 
region (Bosukonda et al., 2000). An alternative reason for the non-detection of BMP-7 
protein in serum could be due to the presence of large amount of endonuclease in the 
circulation and as a result, the plasmid DNA is rapidly degraded following delivery into 
the blood circulation and therefore no gene expression could be detected (Wang et al., 
2004). A likely reason for naked plasmid DNA therapy not attenuating renal IRI can be 
that the gene transduction is very low and expression of transgene is temporary when 
naked plasmid DNA is injected in animals (Hara et al., 1997, Kanemura et al., 2008) 
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which is seen in our study with low levels of BMP-7 expression in the kidney. Research 
indicates that this problem can be overcome by hydrodynamic gene delivery as it is 
considered to provide better expression of gene/protein expression after gene therapy 
(Crystal, 1995, Zhang et al., 1997, Liu et al., 1999) but this method of gene delivery has 
its own severe limitations clinically as it can cause heart failure and hepatic injury. 
Studies have shown that this problem of volume overload caused by hydrodynamic 
delivery can be overcome by delivering the gene via the inferior vena cava and this 
study provides hopes for future work (Wu et al., 2005). 
 
Although previous research shows that BMP-7 protein can prevent apoptosis (Mitu et 
al., 2007), there have been no other reports showing that using naked DNA BMP-7 
gene therapy in the setting of in vitro renal IRI model is anti-apoptotic. The results 
described here show that human naked DNA for BMP-7 cannot protect PTECs from 
apoptosis caused by an in vitro renal IRI model. We further investigated the role of 
naked BMP-7 DNA on PTECs to assess whether PTECs can take up BMP-7 DNA 
without transfection and be able to secrete BMP-7 protein. The results demonstrated 
that PTECs were unable to produce BMP-7 protein.  
 
The main findings of second part of this study suggest that (a) BMP-7 protein can 
reduce apoptosis and preserve cell viability in HK-2 cells (b) that the transfection of 
BMP-7 DNA into 293-T cells shows that BMP-7 expression is increased when 
compared to control transfection. However (c), transfection of HK-2 cells was not able to 
produce the same effect and (d) the EP of BMP-7 DNA into the anterior tibialis muscle 
of mice increases its expression in serum which is maximal observed on day 2. Lastly, 
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EP of BMP-7 cannot prevent the damage and dysfunction caused by renal IRI in vivo. 
 
Previous studies have demonstrated that BMP-7 protein can reduce TGF- induced 
caspase-3 activity in podocytes through Smad-5 activation and improve cell survival 
(Mitu et al., 2007). Data show that the intravenous administration of recombinant human 
BMP-7 protein reduced the number of apoptotic tubular cells, suggesting that BMP-7 
may play an important role in promoting renal repair and regeneration after an 
ischaemic insult in renal PTECs (Hruska et al., 2000). In a renal IRI model, BMP-7 
protein has been shown to ameliorate the injury at a dose of 250 g/kg (Vukicevic et al., 
1998). Research indicate that BMP-7 reduces apoptosis in the cortex and medulla, 
suppresses inflammation by reducing levels of ICAM-1, MPO significantly and reduced 
the rise in serum creatinine (Hruska et al., 2000). In a model of aristochololic acid 
nephropathy (a progressive fibrosis model), BMP-7 at a dose of 500 ng/mL was found 
to reduce apoptosis, necrosis and enhances cell viability in PTECs (HK-2) cells (Wang 
et al., 2010). This led us to examine the effects of BMP-7 on HK-2 cells and to see 
whether it can reduce the apoptosis in the setting of an in vitro IRI model. Our results 
demonstrated that BMP-7 can reduce apoptosis when given at a concentration of 10-
100 ng/mL. Furthermore, it also enhanced the cell viability in HK-2 cells in the same 
model when given at the same treatment dose. Our findings provide evidence that 
BMP-7 can protect HK-2 cells from in vitro renal IRI induced apoptosis thus preserving 
cell viability. Our results can be considered as being in tandem with others (Mitu et al., 
2007, Wang et al., 2010, Hruska et al., 2000).  
 
The transfection of human BMP-7 plasmid DNA into renal epithelial cells (HK-2) with a 
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liposome method leads to increased expression of BMP-7 protein (Li et al., 2006). This 
led us to investigate whether transfection of HK-2 cells and 293-T cells with 
OPTIFECT™ transfection reagent and BMP-7 plasmid DNA would work in the same 
manner. Transfection was performed using the same method following the 
manufacturer’s instructions for both cell lines. Interestingly, our findings are in contrast 
to the previous study (Li et al., 2006). The expression of BMP-7 was not detectable in 
HK-2 cells but was very high in 293-T cell. One of the explanation for this might be that 
the 293-T cell are embryonic kidney epithelial cells and are easily transfected as they 
contain SV40 large T-antigen that allows for episomal replication of transfected 
plasmids containing the SV40 origin of replication and extended temporal 
expression of the desired gene products (Harvey et al., 1997) and BMP-7 expression 
is also higher during the embryonic stage.  
 
More recent studies have shown that EP of human BMP-7 DNA into skeletal muscle 
increases it expression and that EP is considered a useful technique for clinical 
application (Sardesai and Weiner, 2011). Furthermore, another study has demonstrated 
that EP on gastrocnemius muscle with BMP-7 also increases BMP-7 expression as 
detected by PCR (Kawai et al., 2006). To examine whether EP of the skeletal muscle 
can enhance BMP-7 expression in serum, we performed EP on mouse anterior tibialis 
muscle. The ELISA data showed that there was a significant increase in the expression 
of BMP-7 protein in serum at day 2 after EP and that BMP-7 levels were higher on day 
4 but not significantly different from the control EP group (Figure 26). Renal IRI was 
performed on mice on day 3 after EP with control and BMP-7 DNA. Blood was collected 
on day 2 and 4 to determine the concentration of BMP-7 in serum. The results 
  
136 
 
demonstrate that gene therapy of BMP-7 cannot protect against the damage and 
dysfunction caused by renal IRI even though serum concentrations of BMP-7 were 
significantly higher, when compared to control mice at day 2. A possible explanation for 
this can be that whilst BMP-7 was able to attenuate PTECs apoptosis at nmol/L doses 
in vitro, the amount of BMP-7 seen after in vivo EP at day 2 was in the range of pg/L, 
which is 1000 fold less. Furthermore, previous studies have also demonstrated that a 
much higher level of BMP-7 protein is required to prevent renal IRI (Vukicevic et al., 
1998). One the likely reasons for less BMP-7 protein generation can be that EP has 
been associated with cell death at site of injection which might affect the overall gene 
therapy procedure and result in less expression of desired gene or protein (Patil P.M, 
2012) but further research is needed to confirm whether this was a contributing factor. 
 
In summary, the study presented here is the first one to analyse the possible putative 
role of gene therapy with BMP-7 in the settings of renal IRI. Two different modes of 
administration were studied using naked DNA and EP in mice and rats in vivo. Initially, 
in vitro experiments were performed and these suggested that BMP-7 protein can 
prevent apoptosis and preserve cell viability in PTECs. Naked BMP-7 DNA treatment of 
PTECs was not able to attenuate apoptosis caused by an in vitro IRI mode. PTECs 
were incubated with naked BMP-7 DNA for 24 h to assess whether PTECs can induce 
protein expression without transfection but ELISA results showed no detectable 
evidence of BMP-7 protein. Transfections of 293-T cells with BMP-7 DNA showed 
upregulation of BMP-7 protein at 24 h. 
 
With the in vivo study, the positive finding were that naked BMP-7 DNA was able to 
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upregulate the levels of BMP-7 in kidney in rats at day 4 after injection but was unable 
to attenuate the degree of injury caused by renal IRI. The results of EP of BMP-7 
demonstrate that there was upregulation of BMP-7 in serum at day 2 but again it was 
not able to prevent the damage resulting from renal IRI. In conclusion, although 
attempts with gene therapy of BMP-7 were not successful in attenuating renal IRI it 
does provide evidence that gene therapy could play a crucial role in the future treatment 
of renal IRI. 
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CHAPTER 5 
 
GENERAL DISCUSSION 
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5.1: General discussion 
 
AKI ranges from reversible early mild forms to the most severe requiring RRT (Molitoris 
et al., 2007). It is associated with significant patient morbidity and mortality that is 
frequently associated following complex surgery, transplantation, sepsis and cardiac 
surgery (Chertow et al., 1998, Uchino et al., 2005). Current therapy is limited to 
supportive measures and preventive strategies, but none have been definitively shown 
to alter mortality (Bonventre and Weinberg, 2003). One of the main causes of AKI is 
renal IRI which is largely considered a reversible phenomenon, an observation 
supported by an excess of pre-clinical data (Bonventre and Weinberg, 2003). However, 
the translation of these findings into the clinical setting has remained elusive with the 
failure of several novel therapies tested in clinical trials (Lameire et al., 2008). 
Therefore, treatments to improve the outcome post renal IRI currently represent an 
unmet therapeutic need, and additional research investigating novel therapies and 
improving understanding of the mechanisms of disease progression are required. 
Despite advances in the understanding of pathophysiology of AKI, the available option 
for treatment has not improved and indeed the mortality associated with AKI has not 
fallen (Hoste et al., 2006). IRI contributes to acute and delayed graft failure after renal 
transplantation (Powell et al., 2013). Thus, in the thesis presented here an attempt to 
investigate new strategies to prevent AKI has been undertaken.  
 
Chapter 2 explored the role of NO2
- during apoptosis in PTECs and its role in the setting 
of renal IRI. Several studies led us to investigate the role of oral NO2
- in renal IRI. 
Firstly, topical NO2
- application on kidneys has been previously shown to be protective 
  
140 
 
in renal IRI setting (Tripatara et al., 2007). These beneficial effects are dependent on 
the generation on NO by XOR, acidic disproportion and haem proteins (Tripatara et al., 
2007). Another study has demonstrated that i.v or i.p administration of NO2
- is 
detrimental in AKI or renal IRI (Basireddy et al., 2006) whilst other work shows that oral 
NO2
- given at a dose of 50 mg/kg in drinking water to rats can significantly protect 
against myocardial infarction (Bryan et al., 2007). It therefore seems likely that NO2
- can 
be protective or detrimental depending on its mode of delivery as mentioned previously.  
 
Until now, no research that we are aware has assessed the role of oral NO2
- in the 
setting of renal IRI. As MI is associated with ischaemia and oral NO2
- has been shown 
to be protective against it (Bryan et al., 2007), we decided to investigate the effects of 
oral NO2
- in a model of renal IRI. However, surprisingly, the results of our study were in 
contrast to the finding shown earlier in our laboratory (Tripatara et al., 2007). One of the 
likely explanations for this difference can be that the mode of administration of NO2
- was 
topical upon the kidneys once, just before reperfusion in Tripatara study whereas in my 
study the mode of administration was oral for 7 days prior to ischaemia. Secondly, the 
dosage used by Tripatara was lower (60 mol/L) whilst in my study it was high around 
50 mg/L which is equal to 724 mol/L (although it was dependent on how much the 
animals were drinking). Finally the ischaemia duration was different, 60 min in Tripatara 
study and 45 min in my study (Tripatara et al., 2007).   
 
I initially examined the role of NO2
- on PTECs in vitro. As there were no well-
differentiated PTECs derived from adult human kidney commercially available at the 
time of the study so we used immortalized HK-2 cells. HK-2 cells are epidermal growth 
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factor dependent and the cells retain a phenotype indicative of being well-differentiated 
on the basis of its histochemical, immune cytochemical, and functional characteristics, 
and it can reproduce experimental results obtained with freshly isolated PTECs (Ryan et 
al., 1994).  
 
As mentioned earlier apoptosis is the leading cause of cell death during renal IRI. I 
initially chose the serum starvation/deprivation (SS) model for studying apoptosis in 
PTECs. Research has shown that the elimination of serum from culture medium 
reduces analytical interference, reduces basal cell activity and provides more 
reproducible experimental conditions (Sergej Pirkmajer, 2011). Furthermore, SS is used 
in research to study molecular mechanisms involving protein degradation, cellular stress 
response, autophagy, apoptosis, and to simulate particular pathological conditions. 
Researchers have combined SS with hypoxia and/or lowered glucose content in 
experimental models to mimic clinical conditions such as myocardial infarction and 
stroke (Sergej Pirkmajer, 2011). We have a well-established SS model which has been 
used previously to mimic renal ischaemia in PTECs (Kumar et al., 2009, Sergej 
Pirkmajer, 2011). In the research presented here I firstly explored the role of NO2
- in 
PTECs apoptosis at multiple doses of NO2
- in nmol/L doses with SS. The reason for 
choosing the nmol/L dose for my research was that previous work with NO2
- did indicate 
that NO2
- given in nmol/L amounts (1.2 nmol/L – 48 nmol/L) was able to reduce infarct 
size, infarct volume and apoptosis in heart and liver by 50% (Duranski et al., 2005, 
Webb et al., 2004). Furthermore a study conducted using a model of stroke in rat shows 
that NO2
- supplementation at a dose of 48 nmol/L to 480 nmol/L may reduce cerebral 
infarcts size by 75% and did attenuate neurological damage (Jung et al., 2006). My 
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results indicated that NO2
- is able to prevent caspase 3 activity in HK-2 cells caused by 
SS at multiple doses if given at time of SS injury. This shows the potential of NO2
- as a 
potential treatment therapy in renal ischaemia. As mentioned earlier to our knowledge 
this is the first study to explore the role of NO2
- in HK-2 cells apoptosis. These positive 
finding were strengthened by the results of cell viability assay (MTS) assay which 
showed that the reduction caused by SS in HK-2 cell viability was preserved by NO2
- 
supplementation in vitro. My findings are in tandem with previous research that shows 
that the supplementation of L-arginine increases NO production in epithelial cells and is 
protective against damage in post-ischemic injury (Jerkic et al., 1999). The next step 
was to evaluate that whether the protection of apoptosis seen in PTECs by NO2
- is 
intrinsic or extrinsic. In order to answer this caspase activity assays for caspase 8 & 9 
were performed on the lysis from samples derived from HK-2 cells that had injury 
induced by 24 h of SS. There was found to be an increase of caspase-9 activity (but no 
caspase-8 activity) after 24 h of SS in HK-2 cells and this increase was abolished by 
NO2
- supplementation. The result showed that the apoptosis in PTECs (HK-2 cell) is 
through the intrinsic pathway indicating mitochondrial involvement.  
 
Our results are in accordance with previous work that shows that NO2
- is cytoprotective 
after IRI of the mammalian heart and liver at the mitochondrial level through the 
transient inhibition of complex I and subsequent limitation of oxidative damage (Shiva et 
al., 2007). NO is a well-characterized regulator of mitochondrial function, with nmol/L 
concentrations reversibly inhibiting cytochrome c oxidase , regulating ROS formation, 
initiating biogenesis, and limiting apoptotic cytochrome c release (Shiva et al., 2007). 
This may be one of the possible mechanism by which NO2
- is attenuating apoptosis in 
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PTECs. Previous work shows that NO2
- beneficial effects are because of its conversion 
to NO via XOR (Tripatara et al., 2007), therefore it will be worthwhile for future studies 
to explore the involvement of anti-apoptotic proteins such as Bcl and IAP and the role of 
eNOS, XOR and iNOS. Although the results presented here are promising, further 
research is needed to explore the possible mechanisms behind this protection.  
 
After examining the role of NO2
- in PTECs apoptosis caused by SS, I further 
investigated NO2
- role in necrosis of PTECs by using in vitro reperfusion model to elicit 
injury. Research shows that this is a very good model to study necrosis in vitro (Saito et 
al., 2006). Furthermore, a recently conducted study shows that NO2
- prevents necrosis 
in a model of diabetic ischaemic injury (Bir et al., 2014). However, my results show that 
NO2
- was unable to prevent necrosis in PTECs.  
 
Studies have shown that there is a viable in vitro model that can mimic renal ischaemia 
(Lee and Emala, 2002). This model uses antimycin A, which is produced by 
streptomyces bacteria and is used as an antibiotic commercially. It inhibits ATP 
production by binding to the cytochrome bc1 complex III of the electron transport chain 
thus interfering with the oxidation of coenzyme Q and causing irreversible defects in 
aerobic respiration in the mitochondria (Dagher, 2000, Breggia and Himmelfarb, 2008). 
Furthermore, inhibition of oxidative phosphorylation caused by antimycin A has been 
shown in vivo to produce large quantities of O2
•−
, a toxic free radical implicated in kidney 
injury (Jones, 1986, Breggia and Himmelfarb, 2008) and exposure to high levels of 
antimycin A for longer period leads to necrosis (Lieberthal et al., 1998b). My results 
provide evidence that NO2
- at lower doses (nmol/L) can prevent apoptosis in an in vitro 
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IRI model if given with ischaemia or post-ischaemia. Furthermore, NO2
- was able to 
preserve cell viability of PTECs in the SS model and attenuated the rise in caspase-9 
activity in the NO2
- treated group when compared to the controls suggesting that the 
apoptosis in PTECs is mediated via the intrinsic mitochondrial pathway.  
 
Previous research has shown that the benefits of NO2
- are mediated through the 
modulation of mitochondrial function by involving the post-translational S- nitrosylation 
of complex I to attenuate reperfusion oxygen radical generation and prevent 
cytochrome-C release (Shiva and Gladwin, 2009, Shiva, 2013). Other investigations into 
the effects of pre-treatment with NO2
- at several doses showed that this pre-treatment 
was unable to attenuate apoptosis in PTECs in an in vitro IRI model. I believe that this is 
the first evaluation of the role of NO2
- on PTECs apoptosis but more work is needed 
before we can understand the underlying mechanism. My findings are in parallel with a 
study that has shown that NO can inhibit caspase proteases via S-nitrosylation, thereby 
inhibiting apoptosis (Dimmeler et al., 1997). This effect may be concentration 
dependent. Evidence suggests that NO at lower concentrations may inhibit apoptosis 
whilst higher concentrations may lead to the formation of toxic products such as ONOO - 
or other ROS which lead to cell necrosis and apoptosis (Dimmeler et al., 1997, 
Siriussawakul et al., 2010).  
 
Studies have shown that NO2
- at low levels can attenuate apoptosis and has 
cytoprotective effects (Sugimoto et al., 2012, Gonzalez et al., 2008). Our findings also 
indicate that NO2
- in nmol/L doses during ischaemic or reperfusion phase have anti-
apoptotic properties and can be cytoprotective. Furthermore, previous studies show that 
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NO can also induce apoptosis when there are high levels of NO donors (Messmer and 
Brune, 1996) such as NO2
-/NO3
-and increased expression of iNOS (Lysiak et al., 1995) 
in macrophages (Messmer and Brune, 1996, Albina et al., 1993), neurons (Dawson et 
al., 1996) and thermocytes (Fehsel et al., 1995). The results of my pretreatment of NO2
- 
group indicating apoptosis are consistant with above studies.  
 
One of the likely explanations for this NO dual nature can be that NO or its reaction 
product induces apoptosis by a mechanism independent of caspase-3 in some cell 
types (Kim et al., 1997). Secondly, NO reacts rapidly with O2
•−
 to form the highly toxic 
ONOO-, which can induce apoptosis (Lin et al., 1995). This interaction of NO with O2
•−
 
leads to the formation of more toxic radicals and can also remove NO from the system. 
So, NO may protect cells from apoptosis or may induces cell death and this mostly 
depends on the rate of NO formation and the prominence of caspase-3-like protease 
activation in the apoptotic process as well as other factors such as the presence of 
other radicals and antioxidants (Kim et al., 1997). I believe that the work presented here 
is the first study to identify the anti-apoptotic role of NO2
- in PTECs. Whilst I have shown 
that NO2
- supplementation protects PTECs from apoptosis mediated through intrinsic 
pathway the mechanism behind this protection is still unknown.  
 
The in vivo NO2
- study was conducted using a rat model of renal IRI in which rats 
subjected to renal IRI demonstrated the characteristic signs of renal dysfunction and 
injury by the development of increased serum creatinine concentrations. Previous 
research has shown that NO2
- can prevent IRI by the conversion to NO during 
ischaemia by XOR (Tripatara et al., 2007). Another study has demonstrated that the 
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beneficial effects of topical NO2
- on kidneys in a renal IRI setting but the systemic 
administration of NO2
- has been shown to be detrimental (Basireddy et al., 2006). One 
of the likely explanations of this is thought to be that the topical route provides a higher 
local concentration of NO2
- to the kidney than systemic administration (Tripatara et al., 
2007). When NO2
- is administered by a systemic route, it is probable that substantial 
amounts of NO2
- are metabolized to NO by deoxyhaemoglobin in the circulation before 
it reaches the kidney (Tripatara et al., 2007). Others have demonstrated that very high 
levels of NO derived from iNOS is detrimental in renal IRI (Basireddy et al., 2006). In 
chapter 2, the in vivo results demonstrated that systemic application of NO2
- via oral 
route was able to increase the levels of plasma NO2
-/ NO3
- but it was not able to prevent 
the damage and dysfunction caused by renal IRI. Similar results were seen with low 
NO2
- diet group. One of the likely explanation is that insufficient NO2
− might have 
reached the kidney, as it gets blood supply only from renal artery, which, if clamped, 
may prevent the achievement of sufficient tissue levels of NO2
−(Basireddy et al., 2006). 
Research suggests that in the liver and the heart the direct exposure of NO2
−to the 
organ surface was protective and resulted in elevations in NO2
− in the plasma (Duranski 
et al., 2005). Secondly, excess of NO can lead to the formation of O2
•−
 and ONOO- 
which is very toxic at cellular levels and can worsen injury (Basireddy et al., 2006). 
Another study demonstrate that signiﬁcant NO production may be induced by the single 
cytokines IL-1 and TNF- or their combination in the presence or absence of LPS and 
that this NO production is associated with damage of PTECs (Sugimoto et al., 2012). 
Furthermore, NO can be generated by two different pathways: one is NOS dependent 
NO synthesis is the main pathway of NO generation and it requires physiological pH 
and oxygen (Giraldez et al., 1997). Contrary to this, the second NOS-independent 
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pathway generates NO (reduction of NO2
- by XOR) under ischaemic conditions. NOS 
and XOR are both important enzyme for NO synthesis and they can be either protective 
or damaging to cells, depending on the conditions. These contradictory functions can be 
explained by the dual roles of these enzymes; both NOS and XOR can generate either 
NO or ROS (Lundberg and Weitzberg, 2005, Sugimoto et al., 2012). Evidence exists 
suggesting that NOS generates ONOO- and O2
•−
 whilst in shortage of L-arginine or 
cofactors resulting in cellular injury (Xia and Zweier, 1997). Similarly, XOR reduces 
oxygen to O2
•−
 and generates other damaging ROS during the reperfusion phase 
contributing to oxidative tissue injuries (Berry and Hare, 2004). Although Tripatara’s 
study (Tripatara et al., 2007) did demonstrate that NO generation via XOR can protect 
renal IRI via topical route studies have shown that inhibition of XOR can also protect 
kidney from the damage associated with it (Rhoden et al., 2000). Although, in our 
studies NO2
- was given to rats for 7 days prior to ischaemia in drinking water and it led 
to significant increase in levels of NO2
-/ NO3
- compared to the control animals before 
renal IRI, it still remains unclear what level of NO2
- there was present in the kidney at 
time of ischaemia and at the 24 h reperfusion phase. It would be of some importance to 
investigate whether the pretreatment of NO2
- leads to the generation of NO or to the 
generation of ONOO- or ROS before ischaemia. Although one study in a cardiac MI 
model shows that when NO2
- is given in the drinking water it is able to prevent MI in rats 
and that there is NO generation in NO2
- treated group compared to the control treated 
animals (Bryan et al., 2007), it is still not justified to assume that the same is happening 
in the kidneys.  
 
A recent study with NO2
- shows that it can reduce liver cold IRI in rats at a dose of 250 
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mol/L (Li et al., 2012) which is lower when compared to the dose used in my study. 
Although previous work indicates that NO2
- at low levels can protect against IRI, the 
mode of administration was different for each study (Tripatara et al., 2007). For future 
research I think the key line of investigation would be study the levels of NO before and 
after ishaemia and to assess whether pretreatment through oral administration prior to 
ischaemia leads to the generation of ONOO- or ROS. 
 
In summary the results shows that NO2
- treatment can prevent apoptosis and preserve 
cell viability in PTECs if given at time of SS or ischaemia but cannot reverse damage 
caused by necrosis in the same conditions. Furthermore, apoptosis in PTECs is 
mediated through the intrinsic pathway as shown by caspase-9 activation in these same 
models. Furthermore, pretreatment with NO2
- did not attenuate the degree of apoptosis 
caused by the in vitro IRI model at multiple doses when compared to the control treated 
cultures. 
 
My findings suggest that high and low NO2
- doses when given through an oral route 
cannot attenuate renal IRI even though the plasma levels of NO2
-/NO3
- were 
significantly higher in the high NO2
- group when compared to the controls. Further 
research is needed to understand the mechanism of NO2
- and NO when given orally 
with renal IRI. 
  
In chapter 3 I investigated the role of thiamine and its lipid soluble analog benfotiamine 
in the renal IRI setting. Previous research shows that thiamine can protect 
cardiomyocytes from hypoxic stress by causing a sustained expression of Hsp70 and 
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inhibiting apoptosis (Shin et al., 2004). Thiamine has been shown to have protective 
effects on several disorders of the heart (Larrieu et al., 1987, Vinogradov et al., 1991) 
and the brain (Naito et al., 1999, Tanaka et al., 1997). Hypoxic/ischaemic insult can 
disturb metabolic homeostasis, leading to protein instability and loss of anti-apoptotic 
signals, and can cause necrosis and apoptosis (Shin et al., 2004). Thiamine deprivation 
causes focal necrosis and apoptosis, and reduces myocyte contractility ultimately 
leading to myocardial dysfunction (Cappelli et al., 1990). Although research show that 
thiamine can prevent apoptosis in cardiomyocyte (Shin et al., 2004), nothing as yet is 
known regarding its role in the proximal tubular epithelial cells (PTECs). This led us to 
investigate the role of thiamine in PTECS that whether it can prevent apoptosis in in 
vitro renal IRI model and necrosis in in vitro reperfusion model. Our results demonstrate 
that thiamine can prevent apoptosis and preserve cell viability in PTECs but it is unable 
to reverse the progression to necrosis in PTECs. Our findings are in tandem with an 
earlier study that showed that thiamine treatment significantly increased cardiomyocyte 
survival after a hypoxic insult by protecting the cells from hypoxia-induced apoptosis 
associated with caspase-3 activation, PARP cleavage and DNA fragmentation (Shin et 
al., 2004). 
 
Earlier work (Larrieu et al., 1987) suggested that thiamine is protective against 
experimental MI. It has been argued that many organs, including the kidneys are 
deficient in thiamine at the moment of transplantation (Klooster et al., 2007). Another 
study has shown that cardiac oxidative stress is involved in heart failure induced by 
thiamine deprivation (Gioda et al., 2010). This study further identifies that there is lower 
oxygen consumption, increased ROS generation and increased apoptosis in thiamine 
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deficient rats compared to normally fed rats (Gioda et al., 2010). 
 
Initially a pilot study was performed by gavaging with 125 mg/kg of thiamine and this 
showed a possible trend that thiamine can play a crucial role in renal IRI settings in rats. 
Further experiments were performed at a higher dose of 500 mg/kg of thiamine by 
gavaging once daily for 3 days prior to renal IRI. The results provide evidence that 
thiamine can protect renal IRI at a dose of 500 mg/kg. This is the first study to identify 
that thiamine can prevent renal IRI. As our in vitro results provided proof that thiamine 
can prevent apoptosis in PTECs in renal IRI model and preserve cell viability we further 
investigated the role of thiamine in the setting of renal IRI in rats. Our results suggests 
that thiamine can protect against damage and dysfunction caused by renal IRI and 
apoptosis post renal IRI. Thiamine also attenuated the histological kidney damage 
caused by renal IRI. 
 
These results led us to investigate further the mechanism behind this protection caused 
by thiamine. Previous research indicates that thiamine deficiency in the brain leads to 
the upregulation of inflammatory COX-2 which leads to synthesis of prostaglandins from 
arachidonic acid (Gu et al., 2008). COX-2 can play an important role in multiple 
conditions such as inﬂammation, fever, cancer, vascularization, anaphylactic shock, 
childbirth, bone metabolism, and apoptosis (Matsuyama et al., 2005). Furthermore, 
under normal conditions COX-2 is rarely expressed, but it is upregulated in 
macrophages, ﬁbroblasts, synovial cells, endothelial cells and neurons in response to 
cytokine (e.g., IL-1) stimuli as well as carcinogenesis promoters, endotoxins, and 
hormones (Matsuyama et al., 2005, Yamada et al., 2008) . Studies show that there is 
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upregulation of COX-2 after renal IRI that is maximal at around 3 to 5 h and remains 
significantly higher at 24 h compared to controls and that this increase plays an 
important role in causing the tissue damage after renal IRI (Matsuyama et al., 2005). 
Other work shows that in contrast to this study that COX-2 levels after 24 h of renal IRI 
were not significantly higher when compared to the controls but they did not evaluate 
COX-2 at the earlier time points (Villanueva et al., 2007). As there is upregulation of 
COX-2 due to thiamine deprivation in the brain (Gu et al., 2008) our hypothesis was that 
thiamine supplementation might prevent COX-2 upregulation caused by renal IRI. Our 
western blotting data provided evidence that there is upregulation of COX-2 expression 
in the kidney after renal IRI and that thiamine supplementation significantly reduces the 
expression compared to renal IRI group. These results are in accordance with an earlier 
study that showed that COX-1 and COX-2 blockade ameliorates the renal tissue 
damage triggered by IRI (Feitoza et al., 2005).  
 
Inflammation plays a pivotal role in renal IRI and research shows that cytokines such as 
TNF- and IL-1 upregulate the adhesion receptors such as ICAM-1 on endothelia and 
that these in turn localise white blood cells to the site of inflammation/injury (Kelly, 
2003). ICAM-1 on endothelial cells interacts with its counter receptors on leucocytes 
and immobilizes leucocytes on the endothelium. Furthermore, during heart ischaemia 
there is increase of TNF- , IL-1 and an increase of mRNA for ICAM-1.These increases 
were accompanied by increases of MPO activity, increased leucocyte infiltration and 
activation in the heart (Kelly, 2003). There is a possibility that anti-ICAM-1 antibody 
might prevent leucocyte infiltration in heart ischaemia. Furthermore, anti-ICAM-1 has 
been shown to prevent damage and dysfunction caused by renal IRI (Kelly et al., 1994). 
  
152 
 
MPO is a 140 kDa protein which is stored in the lysozymes of monocytes and in the 
azurpophilic granules of PMN and it is released abundantly upon neutrophil activation. 
MPO has the capacity to catalyse the formation of hypocholrous acid HOCL from H2O2 
and chloride ion and makes it a powerful tool in the bactericidal armament of these cells 
(Klebanoff, 2005, Matthijsen et al., 2007). However, clinical research shows harmful 
effects of MPO in the immune mediated inflammatory syndromes, such as multiple 
sclerosis, acute coronary syndrome, and renal disease (Matthijsen et al., 2007). 
Furthermore, studies have shown that MPO and MPO derived oxidants play an 
important part in causing atherosclerosis and organ damage after MI. A study with 
MPO-/- mice shows that these mice are protected from renal IRI (Matthijsen et al., 2007).  
This protection is mediated by reducing PMNs infiltration in MPO deficient mice. As 
there is an increase in ICAM-1 and MPO during renal ischaemia and that thiamine 
deficiency further contributes to their increase (Calingasan et al., 2000), in this work we 
therefore attempted to assess whether supplementation of thiamine can reduce the 
levels of ICAM-1 and MPO activity during renal IRI.  
 
The results show that there is significant upregulation of ICAM-1 and MPO activity in 
renal IRI rats when compared to controls and this increase was significantly attenuated 
in the thiamine treated rats. Furthermore, we can presume that the reduction in MPO 
levels could have reduced the levels of PMN activation and adhesion, thereby reducing 
the infiltrating neutrophils at the site of injury and have prevented damage. NIMP-R14 is 
a neutrophil infiltration marker which is not influenced by MPO reduction (Matthijsen et 
al., 2007) and by studying it might be possible to demonstrate the lack of neutrophil 
infiltration in the renal IRI+ thiamine group. Another possible mechanism can be that 
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MPO generated products such as HOCL and chloramines can inactivite  ketoglurate 
dehydrogenase complex and cause ATP depletion (Jeitner et al., 2005). Although all 
these mechanisms could be involved further work is needed to establish a correlation. 
Due to limited time I was unable investigate these mechanisms but it is an area of great 
interest for future study. 
 
To summarise, our findings provide evidence that thiamine has anti-inflammatory 
properties as demonstrated by the significant reductions of COX-2, ICAM-1 and MPO in 
renal IRI group compared to vehicle group and it is one of the mechanisms by which it 
attenuates the damage and dysfunction caused by renal IRI. During IRI there is 
significant amount of ROS generation beyond the scavenging capacity of organs (Ye et 
al., 2010). Furthermore, thiamine deficiency can cause impairment of chronic oxidative 
metabolism and it is associated with generation of lipid peroxidation product, 4-HNE 
(Calingasan et al., 1999). Research shows that lipid peroxidation and ROS both plays a 
major role in renal IRI and antioxidant therapy can protect the damage associated with 
renal IRI (Zou et al., 2013).  
 
Another study shows that treatment with an antioxidant can prevent against oxidative 
stress caused by ischaemia (Yuan et al., 2011). Studies with anti-oxidant treatment 
have been shown to prevent AKI in clinical and experimental models (Lloberas et al., 
2002). Furthermore, lipid peroxidation plays one of the most pivotal roles during 
oxidative stress, and research provides evidence indicating its implication in renal IRI 
(McCord, 1985, Eschwege et al., 1999). It can cause oxidative destruction of cellular 
membranes associated with the production of toxic, reactive aldehydic metabolites and 
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cell death (Niki et al., 2005). Malondialdehyde (MDA) and 4-hydroxynonenal (HNE) are 
the most important aldehydic metabolites. Evidence exists suggesting that excessive 
production of these highly cytotoxic metabolites may cause their diffusion from the site 
of origin to attack distant targets, through which they form covalent links with various 
molecules (adducts) to mediate the inactivation of enzymes and inhibition of DNA, RNA 
and protein synthesis (Yuan et al., 2011). As thiamine has anti-oxidant properties we 
further investigated whether thiamine supplementation can reduce oxidative stress and 
attenuate ROS generation as shown by others (Yuan et al., 2011).  
 
Our results provided evidence that thiamine can attenuate the ROS generation and 
oxidative stress (HNE-4).and this is one of the mechanism by which it reduces damage 
and dysfunction caused by renal IRI. Although researchers have used different models 
and experiments to assess oxidative stress such as levels of MDA (Yuan et al., 2011). 
We chose to assess lipid peroxidation by measuring the levels of 4-HNE due to its 
correlation with thiamine deficiency (de Andrade et al., 2014). Our results are in tandem 
with previous work showing that oxidative stress reduction can protect damage 
associated with renal IRI (Zou et al., 2013, Yuan et al., 2011). Furthermore the findings 
are also in parallel with recently published data which shows that thiamine 
pyrophosphate can reduce oxidative stress caused by renal IRI (Altuner et al., 
2013).This can be one of the possible mechanisms by which thiamine affords protection 
in renal IRI. Another important factor concerns the thiamine-HCl dose of 500 mg/kg 
chosen for our study. Research conducted on mice indicates that this dose is lower than 
the maximum tolerated dose of thiamine used previously with no toxic effects seen 
(Leuschner, 1992). In comparison to this study we have additionally used a low dose of 
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thiamine. Clinical data suggests that thiamine toxicity is very low but in some cases side 
effects are seen at doses above 7000 mg/day. Research conducted on Alzeimer’s 
patients indicates that thiamine is well tolerated at a dose of 6000-8000 mg/day for 6 
months with no adverse effects reported (Meador et al., 1993). Collectively these 
studies justify our approach and there appears to be an urgent need to conduct a 
clinical trial in humans with thiamine in AKI patients to see if our findings in rodents are 
translatable to the clinical environment. For future work it will be good to assess the 
concentrations of thiamine or its derivatives in blood if possible and search for a 
technique or method that is easy to perform, inexpensive and accurate. 
 
In summary this is the first study to show that thiamine can attenuate apoptosis and 
preserve cell viability in the PTECs in SS and in vitro IRI model. Furthermore our in vivo 
data shows that thiamine prevents damage and dysfunction caused by renal IRI by anti-
apoptotic, anti-inflammatory and anti-oxidant mechanisms.  
 
As we had already investigated the role of thiamine in renal IRI we thought next to 
evaluate the role of benfotiamine, which is considered as a lipid soluble analog of 
thiamine and has been shown to have better bioavailability than water soluble thiamine 
(Bitsch et al., 1991). Previous research shows that benfotiamine supplementation can 
improve the post-ischaemic healing of diabetic mice by attenuating apoptosis and 
stimulating reparative angiogenesis and both these effects are mediated via activation 
of PKT/Akt (Gadau et al., 2006). However, most of the research conducted with 
benfotiamine does not mention the carrier for it (Hammes et al., 2003). Researchers 
have either used a special benfotiamine diet or they have solubilized it and force fed it.  
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A paper by Volvert (Volvert et al., 2008) shows that benfotiamine is sparingly soluble in 
water and they tried many different approaches to dissolve it. They found that 
benfotiamine at 100 mg/kg can be dissolved in HP--CD to a concentration of 200 
mmol/L and its derivatives ThDP reaches a peak plasma level after 2 h after 
administration and decreases slowly afterwards. As this study identified a new method 
to dissolve benfotiamine we herein tried to mimic what the Volvert group has shown 
(Volvert et al., 2008). We dissolved benfotiamine in HP--CD and rats were gavage with 
100 mg/kg to 250 mg/kg of benfotiamine for 3 days prior to renal IRI. The renal 
ischaemia was performed exactly 2 h after garaging so to achieve maximal thiamine 
concentrations (Volvert et al., 2008). The target of this was to explore whether 
benfotiamine can protect renal IRI at a lower dose than thiamine. The results showed 
that benfotiamine at a dose of 250 mg/kg cannot prevent injury and dysfunction caused 
by renal IRI. One of the likely explanation for this inability to prevent renal IRI at a lower 
dose than thiamine can be that benfotiamine according to some workers should not be 
considered as a lipid soluble thiamine (Volvert et al., 2008). This study indicates that 
benfotiamine cannot diffuse through cell members unassisted (Volvert et al., 2008) 
despite previous research having shown that benfotiamine can attenuate the injury 
caused by glucose toxicity (Hammes et al., 2003) but still there is no proof that it can 
cross the cell membrane on its own (Volvert et al., 2008). Further research is needed to 
understand the mechanism behind this dual nature of benfotiamine. I believe future 
work should investigate other lipid soluble thiamine derivatives such as sulbutiamine, 
allithiamine and frusultiamine as research has shown that they can have better 
bioavailability than benfotiamine and might prevent renal IRI at much lower dose than 
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thiamine (Volvert et al., 2008). 
 
In my final results chapter I investigated the role of gene therapy of BMP-7 in the setting 
of renal IRI and the investigated the direct effects of DNA or BMP-7 protein on 
apoptosis and cell viability in PTECs. I firstly investigated the effect of naked BMP-7 
DNA on apoptosis in PTECs. Research shows that proximal tubular cells can take up 
and express foreign naked DNA (Bosch et al., 1993). Another study shows that BMP-7 
reduces tubular apoptosis and necrosis (Wang et al., 2010). Research to assess the 
gene therapy in the kidney has met with success (Bosch et al., 1993) but the role of 
direct naked BMP-7 DNA on apoptosis in PTECs in unknown. So, I investigated the 
effects of BMP-7 naked DNA on PTECs. The results shows that direct naked BMP-7 
cannot protect PTECs against the apoptosis caused by in vitro renal IRI model. To 
assess whether PTECs can directly or by transfection take up BMP-7 DNA and 
upregulate BMP-7 protein in vitro I performed an ELISA which showed that PTECs 
cannot upregulate BMP-7 protein in vitro with or without transfection. One of the likely 
explanations for this is that foreign DNA has been shown to be detrimental and causes 
DNA dependent cell death. Other research shows that introduction of single stranded 
DNA into the cell induces DNA damage and upregulation of apoptotic factors. The 
uptake of DNA at cellular level is restricted by cell defence enzymes such as DNA 
endonucleases (Wu et al., 2005). Although transfection using lipofectamine has 
identified that PTECs can be transfected (Li et al., 2006) I was unable to detect any 
BMP-7 protein formation in my study. To test further whether this was due to any 
technical issues I transfected PTECs simultaneously with the 293 T cells, which are 
kidney embryonic cells and are considered as the ideal cells for transfection under 
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similar conditions. The results of that experiment showed the upregulation of BMP-7 in 
293 T cells but no upregulation of BMP-7 protein in PTECs. My findings are in tandem 
with previously published data that also shows that there is no expression of BMP-7/Lac 
z transgene in PTECs and it is higher in the medullary region than in the cortical region 
of the kidney (Gould et al., 2002). Although there was no expression of BMP-7 seen this 
study identifies that PTECs do possess a BMP-7 receptor which can respond to 
exogenously delivered BMP-7 (Gould et al., 2002). Others have also demonstrated that 
there is less or no BMP-7 expression in PTECs (HK-2) (Kitten et al., 1999, Bramlage et 
al., 2010). Although in contrary there is some published data which suggest that there is 
high BMP-7 mRNA expression in PTECs (Rudnicki et al., 2007). 
 
One of the likely explanation of BMP-7 expression not seen in PTECs can be that 
DNase I and Endo G are endonucleases found in PTECs and research indicate that 
plasmid DNA in host cells can be subject to endonucleolytic attacks both outside and 
inside the cell leading to the destruction of plasmid DNA by the endonuclease (Buzder 
et al., 2009). Although we think these might be the possible reasons further research is 
needed to understand the exact cause of PTECs not showing protein expression of 
BMP-7 after transfection. Previous research indicate that exogenous administration of 
naked DNA leads to gene expression at cellular levels (Bosch et al., 1993). Although, I 
could have investigated further the gene expression of BMP-7 by PCR methods on 
transfected PTECs but due to time constraints it was not feasible. For future work it will 
be important to investigate the gene expression by all of the possible delivery methods. 
Although, the results of direct naked DNA are not as yet promising it is still of 
significance as it is the first study to investigate naked BMP-7 DNA transfection and its 
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role in PTECs apoptosis. 
 
Lastly I investigated the role of naked BMP-7 DNA in the setting of renal IRI in vivo. The 
rats were injected with naked BMP-7 DNA 3 days before renal IRI and blood was 
collected after renal IRI. The results confirm the in vitro data in that naked BMP-7 DNA 
cannot reduce damage and dysfunction caused by renal IRI. To assess whether there 
was any upregulation of BMP-7 protein in the kidney or in serum an ELISA was 
performed on kidney homogenates and serum. The result show that there was a 
significant upregulation of BMP-7 protein in the kidney but no upregulation was seen in 
the serum. Although there was upregulation of BMP-7 protein in the kidney, it was still 
not able to prevent the damage and dysfunction associated with renal IRI. One of the 
likely explanation for this upregulation of BMP-7 in the kidneys can be that the kidneys 
have a membrane bound, specific, high affinity BMP-7 receptors which may help in 
mediating its action (Bosukonda et al., 2000). Secondly, previous work does indicate 
that there is expression of BMP-7 in the kidney and PTECs do possess BMP-7 receptor 
which may respond to exogenously relieved BMP-7(Gould et al., 2002). Further work is 
needed to investigate the possible mechanism behind this finding. However, previous 
research shows that BMP-7 protein in the setting renal IRI can protect against damage 
and dysfunction caused by renal IRI (Vukicevic et al., 1998). My findings are in contrast 
to it. One possible reason might be that I used naked BMP-7 DNA whilst previously it 
was given i.v directly in protein form (Vukicevic et al., 1998) and renal IRI was 
performed straight immediately whereas in my study renal IRI was performed after 3 
days of injecting BMP-7 DNA. Although unsuccessful, it still shows some promise as 
there was direct uptake of BMP-7 DNA by the kidney. Secondly the amount of BMP-7 
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protein injected was 250 g/kg in the Vukicevic study (Vukicevic et al., 1998), and they 
were able to detect 1.4 g/ml of BMP-7 in the circulation which is very high compared to 
the 100 pg/mL which I achieved in the kidney homogenates after BMP-7 DNA injection. 
Thirdly the time point is also very critical, I have injected BMP-7 DNA 3 days prior to 
ischaemia whilst Vukicevic injected BMP-7 protein 10 min before ischaemia (Vukicevic 
et al., 1998). Overall, both studies are very different from each other. Although for future 
work it will be of great interest to assess the role of BMP-7 DNA delivery and the 
amount of protein present in kidney homogenate at earlier time points. If it shows a 
significant amount of BMP-7 upregulation at earlier time points than renal IRI should be 
performed at that time point. 
 
In summary this is the first study to my knowledge to investigate the role of BMP-7 DNA 
on apoptosis in PTECs and renal IRI. Although, there was no protection against 
apoptosis and renal IRI with BMP-7 DNA still there was upregulation of BMP-7 protein 
seen in the kidney homogenate. For future work it will be of great importance to 
investigate BMP-7 DNA and its effect of BMP-7 protein formation at earlier time points 
and then to target it for renal IRI. Furthermore, with new techniques of gene delivery 
available such as electroporation, hydrodynamic gene delivery and gun needle it would 
have been helpful to investigate BMP-7 gene delivery with these alternative methods.  
 
As I had already investigated the effects of direct BMP-7 DNA on apoptosis and renal 
IRI I next investigated the role BMP-7 protein on PTECs and cell viability. As mentioned 
before earlier studies have shown that BMP-7 can attenuate the apoptosis and necrosis 
in the PTECs (Hruska et al., 2000). Our results demonstrate that BMP-7 protein can 
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reduce apoptosis in PTECs at a dose of 100 ng/mL and this finding is in tandem with 
the studies mentioned previously (Wang et al., 2010). Furthermore, BMP-7 protein was 
also able to preserve the PTECs cell viability at 24 h after ischaemia.  
 
Previous research on the effect of BMP-7 on human renal artery SMC primary cultures 
showed that BMP-7 maintains the expression of markers specific for SMC phenotype 
and protects against cytotoxicity induced by the ATP-depleting agent, antimycin A 
(Dorai et al., 2000). This led us to investigate the role of BMP-7 in this antimycin A 
model and the findings show that the degree of apoptosis was attenuated by 10-100 
ng/ml of BMP-7 protein which is in accordance with above mentioned study (Dorai et al., 
2000). Furthermore, I also demonstrated that there was PTECs viability was lost with 
this antimycin A model and that the BMP-7 supplementation during that ischaemic 
phase preserved the cell viability. Past studies have shown that BMP-7 counteracts 
TNF-α-induced apoptosis in human PTECs (Hruska et al., 2000). My in vitro results are 
in the same vein as those reported by Vukicevic and co-workers, who demonstrated 
decreases in apoptotic cells in BMP-7 rodents with acute renal failure (Vukicevic et al., 
1998). However, high concentrations of BMP-7 were necessary to achieve significant 
changes. Furthermore, previous studies have shown protection at higher dose of BMP-7 
protein 500 ng/ml (Wang et al., 2010) but I have found that BMP-7 can attenuate 
apoptosis in PTECs at a lower dose of 10-100 ng/ml.  
 
In summary BMP-7 attenuates apoptosis in PTECs and preserve cell viability. Although, 
I have shown protection of apoptosis by BMP-7 protein, further research is needed to 
investigate the mechanism behind this protection. After proving that BMP-7 can reduce 
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apoptosis in PTECs and can preserve cell viability, I next investigated whether gene 
therapy of BMP-7 with EP technique can upregulate BMP-7 at serum level and protect 
against the damage and dysfunction caused by renal IRI. Previous research shows that 
non-viral gene delivery systems are potentially useful in gene therapies for tissue 
regeneration or repair (Nishikawa and Huang, 2001). In particular, EP is attractive, 
because it is an easy and inexpensive method that requires only a plasmid and a device 
for performing electroporation (Brown et al., 2009, Ferber, 2001). In addition, this 
method does not require viral vectors, expensive proteins, or carrier matrices (Kawai et 
al., 2006). Recent study shows that simultaneous gene transfer of BMP-7 with BMP-2 in 
the gastrocnemius muscle by EP is successful and induces bone formation (Kawai et 
al., 2006). So, I investigated the role of BMP-7 by EP in mice. Initially the mice were EP 
with control or BMP-7 DNA and blood was collected at different time points to assess 
whether EP was successful or not. ELISA was performed in order to detect any BMP-7 
upregulation.  
 
The results showed that there was significant upregulation of BMP-7 on day 2 
compared to the controls. The renal IRI was performed on day 3. Blood and organs 
were collected on day 4 as end-points and serum was used to assess the degree of 
renal IRI injury. The results demonstrated that there was significant rise in serum 
creatinine in renal IRI group when compared to sham mice but this upregulation was not 
attenuated by the EP of BMP-7 DNA. Although, ELISA on serum showed that there was 
upregulation of BMP-7 protein in serum at pg/mL doses but it was unable to protect 
against the damage and dysfunction causes by the renal IRI. There are many factors 
that could account for the difference in the results obtained such as the amount of BMP-
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7 protein detected in the Vukicevic study (Vukicevic et al., 1998) was very high in g/ml 
range than that achieved in our study after EP. Secondly, the gene delivery with EP is 
an entirely different protocol that is still developing as more research is undertaken. 
Thirdly, the lower amount of BMP-7 protein expressed can be due to the difference in 
the choice of muscle that I used in my study. I performed the gene therapy on the 
anterior tibia muscle which is a small muscle when compared to the gastrocnemius 
muscle. Fourthly, it could be due to lack of BMP-7 at the time of renal IRI as I measured 
it on day 2 and renal IRI procedure ended on day 4 and the ELISA results shows that 
the BMP-7 levels were not significantly higher when compared to the controls EP mice 
on day 4.  
 
This is the first time in my knowledge someone has investigated the role of gene 
therapy with BMP-7 in the setting of renal IRI. Although EP of BMP-7 in renal IRI did not 
show significant protection from injury it was still successful at increasing BMP-7 
expression. For future work I would recommend that gene therapy of BMP-7 should be 
done with nanoparticles as recently it has emerged to be successful in inhibiting corneal 
fibrosis in rabbits (Tandon et al., 2013). Nanoparticles are defined as particulate 
dispersions or solid particles with a size in the range of 10-1000nm. The drug is 
dissolved, entrapped, encapsulated or attached to a nanoparticle matrix. Nanoparticles 
are prepared mostly by three methods: (1) dispersion of preformed polymers; (2) 
polymerization of monomers; and (3) ionic gelation or coacervation of hydrophilic 
polymers. Furthermore research indicates that nanoparticles can be loaded with 
plasmid DNA and they can serve as an efficient gene delivery system due to their ability 
to escape from the degradative endo-lysosomal compartment to the cytoplasmic 
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compartment. Furtermore, after their intracellular uptake and escape from 
endolysosomal degradation, nanoparticles could release DNA at a sustained rate 
resulting in sustained gene expression (Mohanraj, 2006). Nanoparticles have the 
potential be used as gene delivery vectors because to their ability to carry therapeutic 
molecules with high efficiency and low toxicity into targeted cells/tissues. A variety of 
nanoparticles have recently been tested for their potential as a gene therapy vectors for 
various cell types and BMP-7 gene delivery via nanoparticles may provide a potential 
way for successful future research (Tandon et al., 2013).  
In conclusion the main focus of my research was on apoptosis and necrosis in PTECs 
and renal IRI induced AKI using novel therapeutics strategies. All the treatments were 
able to attenuate apoptosis and preserve cell viability in PTECs but were unable to 
protect against necrosis in vitro. Thiamine was able to attenuate the damage and 
dysfunction caused by renal IRI in vivo but other therapeutic drugs such as NO2
-, 
benfotimine and BMP-7 were unable to protect renal IRI. It would be necessary to 
mention here that one of the main draw back of this study can be the fluctuations seen 
in serum creatinine levels in IRI group of rats, which were higher in NO2
- study and were 
getting lower as my technique was getting better with time. However, every experiment 
was conducted in parallel with their untreated controls to circumvent this issue. 
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5.2: Further studies 
 
To progress my work in chapter 2 regarding the oral administration of NO2
- in renal IRI I 
would make use of stored tissue samples from this study to analyse the degree of 
nitrotyrosine staining (as a marker of ONOO-) histologically. Furthermore, I would also 
like to investigate the mechanism involved by performing western blot to look at eNOS, 
iNOS and XOR levels in the kidney homogenate after renal IRI. In the thiamine study I 
would like to assess the circulating concentrations of thiamine in the blood pre and post 
renal IRI via an HPLC method. From the study presented in chapter 4 I would like to 
perform PCR on the anterior tibialis muscle in order to confirm BMP-7 expression after 
EP. Furthermore, histological analysis and TUNEL staining would be performed on 
stored mice kidneys with western blot analysis performed to assess for the expression 
of SMAD-5 and SMAD-1 in the kidney.  
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Poster Communications: 
 
 
 
Shoab Memon, Thiemermann C, Muhammad Yaqoob.Sodium nitrite inhibits apoptosis in 
PTECs and protects against renal Ischaemia/ reperfusion (I/R) injury in the rats. The 
Renal Association meeting; 2009 Liverpool, UK 
 
Shoab Memon, J E kieswich, Thiemermann C, Muhammad yaqoob. Thiamine protects 
the kidney against the injury and dysfunction caused by ischaemia reperfusion by 
multiple mechanisms. ASN Oct 2009 San Diego, USA 
 
Shoab Memon, J E kieswich, Thiemermann C, Muhammad yaqoob. Thiamine protects 
the kidney against the injury and dysfunction caused by ischaemia reperfusion by 
multiple mechanisms. The Renal Association meeting; 2010 Manchester, UK 
 
 
Oral administration of sodium nitrite protects against Ishaemia/Reperfusion (I/R) 
injury in the rat kidney. 
SA Memon, JE Kieswich, DA Allen, SM Harwood, NSA Patel, I Khan, MJ Raftery, C 
Thiemermann and MM Yaqoob. Centre for Translational Medicine and Therapeutics, 
William Harvey Research Institute Charterhouse Square London. 
 
 
Our previous study showed that topical application of sodium nitrite directly to the 
kidney prevents ischaemia/reperfusion injury in the rat by conversion to nitric oxide by 
xanthine oxidoreductase. Intravenous injection of sodium nitrite also ameliorates cardiac 
injury following myocardial infarction. In the present study we examined the role of 
sodium nitrite on apoptosis in renal proximal tubular epithelial cells (HK-2) as well as I/R 
injury in the rat kidney after dietary administration sodium nitrite.  PTECs were cultured 
for 24 h in growth medium with or without foetal calf serum (serum deprived) in the 
presence or absence of sodium nitrite (50 – 500 nM). The cells were scraped and whole 
cell lysates prepared using modified RIPA buffer. Caspase-3 activity was measured on 
lysates using a fluorescent peptide substrate (DEVD-AMC). Results are expressed as 
nmol AMC/mg/min and are mean±SD. Caspase-3 activity was significantly increased in 
cells that were serum deprived when compared with controls (serum deprived = 
208.5±65.3; control = 30.2±20.3, n=3, P<0.05) whereas sodium nitrite (100 nM) 
attenuated this increase (serum deprived plus nitrite = 95.1±33.4, n=3, P<0.05). 
Although 100 nM sodium nitrite was optimal for this effect there was significant 
reduction in caspase activity at 50 nM. To further test this hypothesis in vivo, we carried 
out a pilot study in which male Wistar rats were divided into three groups; sham 
operated rats, rats subjected to ischaemia/reperfusion of the kidney (I/R group) and I/R 
plus pre-treatment with sodium nitrite (50 mg/L in drinking water for 7 days). There was 
a significant reduction in renal injury in rats given sodium nitrite prior to I/R when 
226±70 compared with I/R plus nitrite = 88±29; n=4, P<0.05). Taken together, our data 
show that sodium nitrite attenuates the increase in apoptosis in serum deprived PTECs 
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and can prevent renal I/R injury in the rat. These interesting findings may have 
important clinical implications.  
 
 
 
Thiamine attenuates apoptosis and injury caused by I/R of Kidney 
 
Shoab A Memon, *1, J E Kieswich1, M Collino2, S Cuzzocrea3, M Aragno2, R Fantozzi2, 
S Castiglia2, E Mazzon3, D A Allen1, A James1, N Patel1, M J Raftery1, C Thiemermann1 
and M M Yaqoob1. 1Centre for Translational Medicine and Therapeutics, William Harvey 
Research Institute, London, United Kingdom; 2Department of Anatomy, Pharmacology 
and Forensic Medicine, University of Turin, Turin, Italy and 3Department of Clinical and 
Experimental Medicine and Pharmacology, Institute of Pharmacology, University of 
Messina,, Messina, Italy.  
 
Renal ischemia-reperfusion (I/R.) injury is a major cause of acute kidney injury (AKI) 
and is a consequence of acute tubular injury initiated by a combination of reactive 
oxygen species (ROS) generation and ATP depletion. Thiamine has been shown to play 
an essential role in the scavenging of ROS and regeneration of ATP. It has been 
hypothesized that thiamine depletion during I/R injury is a cause of AKI and can be 
prevented by thiamine supplementation. To test this we cultured a human proximal 
tubular cell line (HK2) +/- antimycin (to induce ischemia), and +/- thiamine (10uM). 
Caspase assays showed a significant (P<0.05) reduction in caspase 3 activity in 
thiamine treated cells (n=3). An in vivo study using male Wistar rats administered 
thiamine orally for 3 days prior to induction of ischemia (45 minute clamping of both 
renal pedicles) showed a significant (P<0.05) reduction in serum creatinine and urea 
levels 24hrs post ischemia in a dose dependent manner (125-500mg/kg) compared to 
animals receiving vehicle (n=6/group). Ex vivo analysis of the kidneys showed a 
significant improvement in terms of histological scoring of the tubular injury score 
(P<0.05), TUNEL positive cells (P<0.01) and reduction of COX-2 and ICAM-1 proteins 
(P<0.05) in the thiamine treated group compared to control group. Assays for MPO 
activity, HNE and ROS demonstrated significant reductions in the thiamine treated 
group. We conclude that thiamine protects the kidney against the injury and dysfunction 
caused by I.R. by anti-apoptotic and anti-oxidant mechanisms. This study identifies a 
role of thiamine or its analogue in the prevention of AKI in multiple clinical settings and 
calls for large scale randomized control trials. 
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ABSTRACT: 
 Renal ischaemia-reperfusion (I/R.) injury is a major cause of acute kidney injury (AKI) 
and is a consequence of acute tubular injury initiated by a combination of reactive 
oxygen species (ROS) generation and ATP depletion. Thiamine has been shown to play 
an essential role in the scavenging of Reactive Oxygen Species (ROS) and 
regeneration of ATP. Thiamine deficiency causes up-regulation of COX- 2 which is 
associated with inflammation and causes cell death.  It has been hypothesized that 
thiamine depletion during I/R injury may be the cause of AKI and can be prevented by 
thiamine supplementation. To test this we cultured a human proximal tubular cell line 
(HK2) +/- antimycin (to similate ischaemia), and +/- thiamine (10uM). Caspase assays 
showed a significant (P<0.05) reduction in caspase 3 activity in thiamine treated cells 
(n=3.Fig:1). An in vivo study using male Wistar rats administered thiamine 
orally(500mg/kg) for 3 days prior to induction of ischemia (45 minute clamping of both 
renal pedicles) showed a significant (P<0.05) reduction in serum creatinine and urea 
levels 24hrs post ischaemia compared to animals receiving vehicle (n=6.Fig:2a&2b). Ex 
vivo analysis of the kidneys showed a significant improvement in terms of histological 
scoring of the tubular injury score (P<0.05), TUNEL positive cells (P<0.01) and 
reduction of COX-2 and ICAM-1 proteins (P<0.05) in the thiamine treated group 
compared to control group. Assays for MPO activity (Marker of inflammation), HNE 
(marker of lipid peroxidation.Fig:3) and ROS (Fig:4) demonstrated significant reductions 
in the thiamine treated group. We conclude that thiamine protects the kidney against the 
injury and dysfunction caused by I/R. by anti-apoptotic, anti- inflammatory and anti-
oxidant mechanisms. This study identifies a role of thiamine or its analogue in the 
prevention of AKI in multiple clinical settings and calls for large scale randomized 
control trials. 
 
 
 
 
 
